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PREFACE
It is a feature of the radiotherapist’s work that he 
finds himself compelled to delve into many different fields of 
medicine, in none of which however he would claim to he expert. 
Thus, in addition to urology, laryngology, gynaecology, and 
others, the author was drawn into the realm of haematology.
As a radiotherapist, his initial concern with leukaemia in 
1946 was the treatment of patients with x-rays. It was 
impossible, however, not to become fascinated by this strange 
disease leukaemia, a disease which has defied our understanding 
for more than a century, and against which all our modern 
therapeutic armamentarium is but groping empiricism.
In addition to a general review of the leukaemic disease 
and its taxonomic, diagnostic, aetiologic and therapeutic problems, 
it is the object of this thesis to describe and discuss eight 
years* experience in treating leukaemic patients with radio­
active phosphorus. Sections I and II of this thesis are there­
fore in the nature of a review, with the object of providing 
some perspective for what follows. Section III discusses the 
pharmacological features of radiophosphorus, and Sections IV and 
V represent original work by the author. Section VI provides 
summaries of the case histories of the sixty patients treated 
with radiophosphorus at the Christie Hospital and Holt Eadium
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Institute in Manchester, England. All of the patients 
discussed in this work were personally treated and managed by 
the author, except when they required chemotherapy. At such 
times treatment was supervised by Dr. Edith Paterson, in the 
same hospital, and close collaboration was maintained through­
out the patients' lives.
In any thesis on leukaemia, if only in the interests 
of space, the writer is faced with the primary task of select­
ively excluding vast areas of modern thought and important 
research. An effort has therefore been made here to confine 
discussion to human leukaemia, rigorously eschewing animal work, 
no matter how temptingly germane such work might seem. 
Furthermore, since the main topic in this thesis is the effect 
of radiophosphorus on chronic leukaemia, discussion of the 
acute forms of this disease is deliberately limited.
SECTION I
General Review of Leukaemia







Recently exhibited in the British Museum (1954) an 
osteogenic sarcoma has been verified involving a prehistoric 
dinosaur bone estimated at eighty million years old. It is 
probable that leukaemia is just as old a disease, indeed as old 
as life itself, but being essentially a soft-tissue lesion it 
has left no records of its lethal effects. The history of 
medicine is punctuated by discoveries that one disease, on 
closer inspection, did in fact consist of two or more syndromes, 
or that one disease process could manifest itself in diverse 
ways. Thus leukaemia seems to have concealed itself amongst 
the many mysterious ’’fevers" and "declines" of literature. It 
was not until the 19th century, when the microscope began to be 
applied to the field of medicine, that the blood and its 
abnormalities attracted attention.
According to Cecil and Loeb (1952) the disease "had been 
previously observed by Barth and others, and the initial 
examination of leukaemic blood had been made by Donne in 1839". 
Nevertheless most medical historians give credit for the first 
full description of the leukaemic syndrome to Hughes Bennett of 
Edinburgh who in 1845 described a case of "leucocythaemia". 
Bennett remarked that "unless it could be shown that
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inflammation and fever were like processes, we must conclude that 
the alteration in the blood in this case was independent of 
inflammation so called". Later in the same year Virchow, 
Professor of Pathology in Berlin, published a similar case. He 
suggested that what might have been considered pus cells were in 
fact white blood cells and he called the disease "Weissers Blut" 
or leukaemia. By 1870 Neumann and others had studied the bone 
marrow changes associated with the disease, though it was not 
until the introduction of differential staining methods by 
Ehrlich about 1890 that detailed morphological studies became 
possible, and the various forms of the disease identified.
In 1865 Lissauer had found that an acute, febrile, and 
rapidly fatal disease was in fact leukaemia, and fundamentally 
similar to the already recognised chronic form of the disease. 
Thus the existence of an acute and a chronic type of leukaemia 
became one of the earliest attempts at classification, and by the 
end of the 19th century, thanks to Ehrlich’s stains, myeloid, 
lymphatic, and monocytic types were clearly recognised, morpho­
logically and clinically.
Based on the pioneer studies of Cohnheim, Metchnikoff, 
Ribbert, and others, Aschoff (1924) introduced the concept of 
the reticulo-endothelial system, as a functional entity, and this 
was considerably extended by the work of Maximow (1930),
Pullinger (1932), and Robb-Smith (1938). The latter spoke of
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the "progressive hyperplasia of reticular tissue with differ­
entiation to one or more cell types", and he recognised their 
possible association with the leukaemias - the "haemic 
reticuloses". The relationship between the frank leukaemias 
and the various aleukaemic conditions, both myeloid and 
lymphatic, is still debatable, as also is the link between 
leukaemia and polycythaemia vera. The "lymphoid reticulosis" 
described by Israels (1953) may in some cases be the earliest 
phase of a chronic lymphatic leukaemia, though Willis (1948) 
has no doubt that lymphatic leukaemia is only the haemic 
expression of metastatic lymphosarcoma. However, Steinberg 
and Martin (1946) claim that the cells of lymphosarcoma are 
immunologically dissimilar to those of lymphatic leukaemia.
In addition to the many atypical leukaemic conditions 
there are various leukaemoid syndromes - responses to infections, 
toxins, metastases from malignant lesions, and myelosclerosis - 
all of which may be confusing. Indeed, Bussell, in her "Essay 
on the Reactions of the Mesenchyme" (1949) observed that "The 
leukaemias are no doubt a dump heap of conditions, varying from 
acute haemorrhagic diseases with haemopoietic aplasia, to 
chronic lymphadenopathies showing some degree of leukaemia which 
may run a course of years".
Damashek (l95l) suggests that all of these typical and 
atypical leukaemias are perhaps "only different reactions to the
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Showing known (------ ) and probable (------) transitions
between the reticuloses. (Custer, 1952).
Figure 1.
- 7 -
same myelo-stimulatory principle", while Menkin (1947) believes 
that inflammation and neoplasia (leukocytosis and leukaemia) 
may yet "come to be regarded as quantitative variations of a 
single or perhaps several basic physiological disturbances”.
To Custer (1952) this whole field may be described as the 
•'Borderlands Dim”, with many recorded transitions of one lympho- 
reticular disease into another (Figure l).
Witts, in his opening address to the 1954 Ciba Foundation 
Symposium on Leukaemia, observed that "most of us - I know not 
all of us, but most of us - feel that leukaemia is part of the 
total problem of cancer". Thus even the malignant nature of 
leukaemia, about which so much has been written during the past 
sixty years, calls at least for some philosophic doubt.
Classification of Leukaemia.
The classification of all blood diseases progressed 
rapidly during the first half of the 20th century, but with 
increasing knowledge, documentation, and the application of 
better techniques, the simple was seen to be complex, until at 
the present time, as Engelbreth-Holm lias put it (1954), "the 
classification of the leukaemias is rather obscure, even more 
so than ten to twenty years ago". Unfortunately the pioneer 
workers such as Ehrlich, Naegeli, Sabin, Maximow, and many 
others, produced not only brilliant researches but confusing
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terminologies. The confusion was such that a committee was 
set np, charged with the Clarification of the Nomenclature of 
Cells and Diseases of the Blood and Blood-forming Organs. This 
committee published its first report in 1949 but Whitby and 
Britton (1950) have remarked: ,fIt seems unlikely that this
proposed nomenclature will come into general use without further 
discussion". This is an understatement!
Though there are many attractive (and distracting) 
theories in the field of leukaemia research, adding daily to the 
complexity of the subject, what the clinician needs is not the 
exhaustive documentation of purist taxonomists but a simple 
working hypothesis to which he may cling in his daily work.
The following classification from Whitby and Britton seems 
adequate:-
1. Myeloid leukaemia. Acute. Chronic.
2. Lymphatic leukaemia. Acute. Chronic.
3. Monocytic leukaemia. Acute. Chronic.
4. Atypical leukaemia and allied diseases.
5. Leukaemoid blood pictures.




This may occur as a primary manifestation of leukaemia 
(commonly in children and young adults, hut possibly at any age) 
or it may occur as an acute termination of an established 
chronic leukaemia. The onset of the primary form is usually 
sudden, with pyrexia, rigors, sore throat and skeletal pains - 
a picture easily mistaken for acute rheumatic fever. In 
children, puffiness of the eyes may suggest acute nephritis, 
and large mediastinal lymph nodes may give rise to superior 
vena caval compression with its associated engorgement and 
distress. The disease is frequently aleukaemic, especially in 
children, and rapidly progressive anaemia with a generalised 
haemorrhagic tendency are characteristic. Bleeding may occur 
from swollen gums, or into the retinae, brain, spinal cord, ear, 
nose, bowel, kidney or uterus. Clearly such widespread 
bleeding must produce a great variety of symptoms and signs.
Though spontaneous remissions have often been reported 
(e.g. Birge et al., 194:9), and new methods of treatment may now 
improve the general condition of the patient for a time, the 
disease is still inevitably fatal, and usually rapidly - some­
times within a few days of its onset.
Though the commonest type of acute leukaemia in children
Acute Leukaemia - Peripheral Blood Picture
Figure 2 (a)
Acute Leukaemia - Bone Marrow Picture
Figure 2 (b)
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is lymphoblastic, it is generally agreed that if primary acute 
lymphoblastic leukaemia occurs at all in adults it must be 
rare, most diagnosed cases being in fact myeloblastic. Of 
acute leukaemia Sturgis (1952) claims that "at least five types 
of the condition have been observed: the myeloblastic,
myelomonocytic, lymphosarcoma cell, lymphoblastic, and histio- 
monocytic". He does, however, concede "that a difference of 
opinion may arise .... and in some instances it may be necessary 
to be content with a diagnosis of an acute leukaemia of undeter­
mined variety or a 'stem cell' leukaemia".
The characteristic change in the blood and bone marrow 
(Figures 2 a and b) is the presence of a large number of mono­
nuclear cells, either myeloblasts or lymphoblasts, rarely 
monoblasts. The lack or scarcity of cell-types intermediate 
between primitive and mature often makes the classification of 
the type of acute leukaemia difficult.
Chronic Leukaemia.
The chronic type of leukaemia usually has an insidious 
onset, the patient complaining of vague lassitude and anorexia 
for many months before the diagnosis is made, often after a 
chance blood examination has indicated the underlying cause of 
the malaise. Medical advice may be sought because of the 
uncomfortable splenomagaly in the myeloid type, or because of
I
Chronic Myeloid Leukaemia - Peripheral Blood Picture
Figure 3 (a)
Chronic Myeloid Leukaemia - Bone Marrow Picture
Figure 3 (b)











Subacute Monocytic Lenkaemia - Peripheral Blood Picture
Figure 5 (a)
Subacute Monocytic Leukaemia - Bone Marrow Picture
Figure 5 (b)
enlarged lymph nodes in lymphatic leukaemia. Buccal ulceration 
in monocytic leukaemia is a not infrequent first stimulus to a 
medical consultation. Once the disease is suspected its 
diagnosis does not as a rule present much difficulty, though 
there are, of course, many atypical forms of leukaemia which 
will he briefly mentioned presently. In the typical case the 
peripheral blood shows an elevation of the total white cell 
count which may reach many thousands per c.mm. The differ­
ential white cell count (Figure 3 a) shows a greater or lesser 
shift to the left, with myelocytes and myeloblasts often easily 
recognisable in the myeloid variety. Basophils are increased 
and may indeed reach high proportions of the white cell count.
In lymphatic leukaemia the total white cell count may consist 
almost entirely of lymphocytes, with once more a variable 
number of primitive cells - large lymphocytes, smear cells, and 
(in late stages) lymphoblasts (Figure 4 a). Similarly in 
monocytic leukaemia the preponderating cell is the monocyte with 
varying numbers of primitive forms of the monocytic series 
(Figure 5 a) ,
The clinical course of chronic leukaemia, with or 
without treatment, is very variable, though the average duration 
of life is about three years for the myeloid and lymphatic 
forms. Monocytic leukaemia being usually acute or sub-acute,
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the duration of life is often measured in weeks or at most a 
few months.
The hone marrow in chronic leukaemia is hyperplastic, 
with islands of erythropoietic activity. In myeloid leukaemia 
(Figure 3 b) myeloblastic areas are surrounded by large numbers 
of promyelocytes and myelocytes in all stages of development.
A common feature is the presence of numerous megakaryocytes in 
the marrow associated with a high platelet count in the 
peripheral blood. In lymphatic leukaemia (Figure 4 b) the 
bone marrow is characteristically infiltrated with lymphocytes, 
but erythropoietic activity is not disturbed by replacement until 
late in the course of the disease, so that anaemia is not an 
early feature of this type of leukaemia as it is with the myeloid 
type. Megakaryocytes are usually diminished with reduced 
platelet counts in the peripheral blood. Monocytic leukaemia, 
which is rarely chronic, usually presents a bone marrow picture 
(Figure 5 b) not unlike an acute myeloblastic leukaemia or 
invasion by reticulum-cell sarcoma. Opinions differ as to the 
origin of the monocytes, a Schilling variety of reticulo­
endothelial origin, and a Naegeli variety of myeloid origin 
are described. Whitby and Britton (1950) remark that "the 
disease is apparently related to reticulum-cell sarcoma in the 
same way as lymphatic leukaemia is to lymphsarcoma”.
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Showing area of healed herpes zoster, and wide-spread 
papular eruption (Case L 5)
Figure 6 (a)
Photomicrograph of papule showing infiltration of 
dermis with lymphocytes (Case L 5)
Figure _§ (*)
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Tire spleen in myeloid leukaemia can be a source of 
distressing symptoms. Not only does the size of the organ 
produce abdominal discomfort and an unpleasant dragging sensation 
which it is sometimes impossible to alleviate, but splenic 
infarcts may cause considerable pain, and pyrexia associated 
with prostration may suggest that an acute termination of the 
leukaemic process is imminent. The spleen in lymphatic 
leukaemia is usually somewhat smaller than in myeloid leukaemia, 
and in the monocytic type the spleen is usually scarcely if at 
all palpable.
The enlarged lymph nodes in chronic lymphatic leukaemia 
can be a source of real distress, and may be very large, florid 
and unsightly, forming a collar of nodes around the neck. On 
the other hand, there may be no palpable lymphadenopathy in 
spite of well-established lymphatic leukaemia. Eustachian 
deafness is a common finding, but unlike the acute form in 
children, the generalised lymphadenopathy causes little in the 
way of pressure symptoms, presumably because the nodes are so 
soft. The writer (1954) found no case of vena caval compression, 
phrenic or recurrent laryngeal paralysis in a study of the 
thoracic manifestations of chronic lymphatic leukaemia. Histo­
logically the gland architecture is lost, germinal centres 
cannot be seen, and the entire node is filled with a mass of 
lymphocytes.
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The skin manifestations of the leukaemias have been 
described by Forkner (1938) and more recently by Twiston-Davies
(1955). Since the skin is well supplied with the undiffer­
entiated mesenchymal cells from which all the cellular elements 
of the blood may be derived, either intra- or extra-medullary 
according to circumstances, it is clear that the leukaemic 
process might well affect the skin. The fact that Hodgkin’s 
disease, Brill-Symmers’ disease, mycosis fungoides, lympho- and 
reticulo-sarcoma may also affect the skin only serves to under­
line the basic reticulo-endothelial origin of these diseases.
The author finds it difficult, however, to believe that there is 
any skin lesion which is truly specific to any of the reticu­
loses, with the sole exception perhaps of mycosis fungoides.
It is true that monocytic leukaemia frequently presents with 
skin manifestations, but these lesions are not, in my view, 
characteristic in appearance.
That bones may be affected by leukaemia was first noted 
by Heschl only two years after Hughes Bennett and Virchow had 
first described the leukaemic disease. As Griffiths (l955) 
has remarked, it is curious that Heschl should have failed to 
observe the bone-marrow changes in leukaemia which were not 
reported until twenty years later by Neumann. Widespread 
lesions of the skeleton are frequently found in the acute
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lymphoblastic leukaemia of children, often simulating acute 
rheumatism. Chronic leukaemia affects bone much less 
frequently, and when it does it is more commonly seen in the 
lymphatic type. The bone changes produced by leukaemia may be 
destructive (translucent zones in the metaphysis, focal bone 
erosion, diffuse infiltration) or formative (subperiosteal 
ossification, or osteosclerosis) and indeed both are often seen 
in the same patient or even in the same bone. As Griffiths 
observes, it is surprising that the extensive disorder of 
haemopoietic marrow in leukaemia is so seldom associated with 
changes in its covering shell.
The neurological complications of leukaemia have been 
described in detail by Forkner (loc. cit.) and by Leidler and 
RusSell (1945). Neurological abnormalities are especially 
common in acute leukaemia, and, as already said, focal 
haemorrhage may produce protean manifestations, from retinal 
damage and nerve-deaf ness to transverse myelitis. Spinal root 
pain or complete paraplegia may occur as a result of vertebral 
collapse, even in chronic lymphatic leukaemia. It has been 
the experience of those who regularly come in contact with 
malignant disease that many cancer patients develop herpes 
zoster sooner or later. (Figure 6 a and b). The same 
experience with leukaemic patients has led some workers to
- 26 -
believe that herpes and even varicella are in some way 
associated with leukaemia, and the virus theory of leukaemo- 
genesis comes to mind with each new herpetic patient. The 
truth seems to be that herpes zoster is a most common disease 
and its incidence in the general public is quite unknown. It 
appears to be "induced” by a great variety of non-specific 
debilitating diseases and episodes in the lives of men, women 
and children of all ages.
Anaemia is perhaps the most important single abnormality 
associated with the leukaemic process, and the patient's general 
health and sense of well-being are more closely tied to his 
haemoglobin level than to any other single factor. Anaemia 
may not be obvious in the early stages of the disease, but it is 
almost invariably a terminal feature of leukaemia, both acute 
and chronic. The nature of this anaemia is still debatable, 
but as with any anaemia it is true to say that it can only be 
due (a) to an inadequate production and/or (b) to an abnormally 
rapid loss of red cells.
(a) Inadequate production of red cells in leukaemia 
(apart from possible associated intercurrent factors such as 
dietetic, infective or surgical abnormalities), has long been 
attributed to "marrow invasion" by leukaemic cells. The 
early anaemia in myeloid leukaemia is undoubtedly associated
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with large areas of myeloid hyperplasia in the hone marrow.
In lymphatic leukaemia, on the other hand, high haemoglobin 
levels are commonly maintained for long periods, and it is only 
with the advent of anaemia that the bone marrow is found to be 
populated by large numbers of lymphatic cells. That erythro- 
pcfetic tissue is thus "crowded out" by white cells is, however, 
too facile and mechanistic an explanation ef the leukaemic 
patient's anaemia, especially since other causes can be 
demonstrated which are surely more important. By studies of 
iron metabolism Huff et al. (1952) have demonstrated that the 
anaemia of leukaemia is in fact usually associated with 
increased red cell production, and not decreased as the "crowd­
ing out" theory would suggest.
(b) Abnormal loss of red cells may be due to haemorrhage, 
haemolysis, or a shortened life-span of these cells.
Haemorrhage is undoubtedly a striking feature of the acute phase 
of leukaemia, though it is of course itself a manifestation of 
the abnormal blood, including e.g. low platelet levels.
(Bleeding may in fact occur with normal platelet counts) ,
Though profuse haemorrhage may be the proximate cause of death 
in some leukaemic patients this is unusual, and gross degrees 
of anaemia are common without associated haemorrhage of any 
magnitude.
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Significant shortening of the life-span of erythrocytes 
in leukaemia has been demonstrated by many workers, both by 
Ashby's agglutination method (l92l) and by isotopic techniques 
(Berlin et al. 1951; Huff et al. 1950). As Crosby and 
Damashek have said (1955) "shortened erythrocyte survival is 
synonymous with haemolytic disease", though abnormally rapid 
haemolysis is not always evident, and indeed a patient with an 
adequately reacting marrow may conceal an "occult" or compensated 
haemolytic disease. The fact that normal erythrocytes trans­
fused into a leukaemic patient may be destroyed too rapidly, 
while leukaemic red cells transfused into normal subjects have 
a normal life-span, suggests that the erythrocytes themselves 
are not abnormal. If the erythrocytes are not abnormal why and 
how are they destroyed? Auto-antibodies can undoubtedly be 
demonstrated in some cases, especially in lymphatic leukaemia, 
associated with a progressive anaemia refractory even to massive 
transfusion of carefully matched blood. This "immunological 
heresy" which leads to haemolysis of the patient's own red cells 
may cause rapid death, but there are cases in whom a similarly 
refractory anaemia occurs and no antibodies can be demonstrated 
by existing techniques. This problem requires much further 
study, especially concerning qualitative abnormalities in the 
haemoglobin.
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The colour index during the anaemia is usually less 
than 1.0, occasionally greater than 1,0, and while the marrow 
is capable of reacting there are many signs of erythropoietic 
activity in the form of nucleated red cells, reticulocytes, 
polychromasia, poikolocytes, etc. Aplasia is a common but by 
no means constant terminal feature,
ATYPICAL FOBMS OF LEUKAEMIA.
(1) A leukaemic leukaemia is one of the commonest of the 
atypical forms of leukaemia. As its name suggests, the 
conspicuous finding is a normal or subnormal total white cell 
count, though the other signs of leukaemia are demonstrable - 
a shift to the left, with primitive cells of the myeloid or 
lymphoid series, progressive anaemia, splenomegaly and lymph­
adenopathy. The disease, with atypical symptoms, frequently 
presents difficulty in diagnosis and is often confused with 
pernicious anaemia, aplastic anaemia, or diseases of the cardiac, 
skeletal, geni to-urinary or other systems. Marrow biopsy is, 
however, often diagnostic, but it is important to examine marrow 
from several different sites because of the patchy involvement 
sometimes seen - especially in the lymphoid form.
(2) Eosinophil leukaemia may occur, in which case eosinophils 
are the preponderating cell-type. This is a rare disease, it
- 30 -
runs a more chronic course than the "typical" forms of 
leukaemia, and a curious feature is the eosinophilic infiltra­
tions of muscles. Charcot-Leyden crystals are found in the 
liver. Neutrophil, Basophil, and Megakaryocyte leukaemias 
have been described hut their existence is debated.
(3) A plasma cell leukaemia has heen described, among others 
by Reiter and Freeman (1937). The very nature of these plasma 
cells is in doubt, and Moeschlin (1940) believes them to be 
reticulum cells of the bone marrow. The relationship of 
myeloma to plasma cell leukaemia is a close one, though a 
debatable one. Damashek (1957), on the other hand, considers 
this to be simply "another name for multiple myeloma, more or 
less aleukaemic".
(4) Leukosarcoma is the name given by some to the condition 
in which an infiltrating lymphosarcoma is associated with a 
lymphatic leukaemic blood picture. In the writer’s opinion 
many frank lymphatic leukaemias display soft-tissue masses of 
"sarcoma" at some stage in the course of the disease. Further­
more, many so-called lymphosarcomas which later develop 
leukaemia can be found in retrospect to have had relatively high 
lymphocyte counts initially. The last decade has seen a 
growing demand amongst histologists and oncologists for more 
sharply defined diagnostic criteria, and "lymphosarcoma" is
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becoming an increasingly uncommon disease in some centres.
Many lymphosarcomas of the past have prohahly heen Hodgkin1 s 
disease or subleukaemic chronic lymphatic leukaemia - the type 
that runs a course of ten or more years. This is a fascinating 
subject, but cannot be pursued here,
(5) Chloroma is a haematological curiosity because, though a 
rare lesion, it attracts so much attention when seen. The 
typical chloroma is a greenish tumour mass, usually subperiosteal, 
in the skull or thorax, and associated with acute leukaemia,
It is naturally most commonly seen in children but may in fact 
be seen in adults. As well as bone, soft tissues may be 
involved - breast, muscle, brain, bone-marrow, etc. The tumours 
are sometimes not coloured. Chloroma is regarded as an atypical 
form of myeloid leukaemia, of the acute myeloblastic type.
(6) Leukaemic Erythrodermia is characterised by a generalised 
redness of the skin which French writers have named ^I’homme 
rouge”. In addition to the curious dusky erythema there is 
usually generalised enlargement of lymph nodes and spleen, (all 
rather small) and a blood picture which is not always typical 
of lymphatic leukaemia. This disease is regarded as a very 
chronic and slowly progressive form of lymphatic leukaemia with 
lymphocytic infiltration of the dermis.
(7) A Mikulicz Syndrome in lymphatic leukaemia is described
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by Whitby and Britton (loc. cit.) but though seen in one or two 
cases of acute lymphoblastic leukaemia in children, the writer 
has seen no such case in a series of some two hundred patients 
with chronic lymphatic leukaemia. It must be a distinctly 
uncommon condition.
Leukaemoid Blood Pictures
A consideration of leukaemoid blood-pictures almost 
amounts to a discussion of the differential diagnosis of 
leukaemia, at least from the purely haematological aspect. It 
is clear that a leukaemic blood picture is not sufficient 
evidence to justify the diagnosis of leukaemia, and until all 
possible causes have been excluded the blood changes alone should 
be considered only ” leukaemoid”.
A leukaemoid blood picture suggesting lymphatic leukaemia 
is not unexpected in measles, chicken pox and whooping cough - 
the latter sometimes persisting for a year or two. Glandular 
fever may cause confusion with lymphatic or monocytic leukaemia. 
Septicaemic conditions, not forgetting subacute endocarditis, 
may produce high white cell counts with myelocytes in fair 
numbers. Pneumonia and meningitis may do likewise, and similar 
changes are reported in plague, eclampsia and even malaria 
(aleukaemic) . Tuberculosis may even produce leukamoid reactions 
which are myeloid in type, as well as lymphoid.
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Poisons of various kinds have heen reported to cause 
leukamoid changes - mercury, mustard gas, sulpha drugs of 
various types - and even bee stings have been reported to 
produce a leukocytosis of 120,000 per c.mm. with 69 per cent 
myelocytes and myeloblasts. (Parrisius and Heimberger, 1924).
A leuko-erythroblastic anaemia occurs when the bone- 
marrow is ’’irritated” into excessive and disorded function 
either by the implantation in it of foreign tissue, such as 
malignant metastases, or by abnormal changes in the skeleton.
As its name implies, this type of anaemia is characterised by 
a shift to the left of both erythropoiesis and leukopoiesis, 
s0 that nucleated red cells and many primitive leukocytes are 
found in the circulating blood.
The bone-marrow changes will depend on the underlying 
cause of this dyshaemopoiesis. When neoplastic metastases are 
the source of the disorded function, the sectioned bone reveals 
deposits of tumour surrounded by hyperplastic red marrow which 
microscopically displays excessive erythroblastic and myelo­
blastic activity. A high leukocytosis in the peripheral blood 
is uncommon. The primary tumour is frequently found in the 
breast, prostate, kidney, or thyroid, though almost any 
malignant disease may occasionally invade the bone-marrow 
widely enough to upset haemopoiesis in this fashion. Even
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Hodgkin’s disease, a related reticulosis, may produce this 
’irritation anaemia”.
The skeletal changes associated with a leuko-erythro­
blastic anaemia are (x) osteopetrosis, and (2) myelofibrosis. 
The first of these, the so-called Marble-bone disease of 
Albers-Schonberg, is indeed a rare disease. A hereditary 
condition, it usually declares itself in childhood, and the 
increasing thickening of the bone progresses until it becomes 
virtually solid with no marrow cavity. Extramedullary haemo­
poiesis develops to compensate for the loss of active marrow 
mass, splenomegaly and hepatomegaly are characteristic, and 
radiographs of the skeleton are quite diagnostic. The disease 
is a primary dyscrasia of the mesenchyme resulting in excessive 
bone formation.
Myelofibrosis is perhaps a more interesting and 
important cause of leukamoid blood pictures if only because it 
is much more common than osteopetrosis. This condition is 
characterised by a fibrosis of the bone marrow which is 
progressive and leads to the usual compensatory extramedullary 
haemopoiesis in liver, spleen, kidney, etc. The syndrome has 
been recently reviewed in an excellent paper by Korst et al. 
(1956). They stress the close relationship of myelofibrosis 
to chronic myeloid leukaemia and especially to polycythaemia
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X-ray films of a normal and myelofibrotic spine 
Figure 7 (a)
Photomicrograph of bone biopsy from case of myelofibrosis
Figure 7 (b)
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vera, and they insist that "at certain stages in this disease 
their separation as distinct entities may he difficult or 
impossible". A dry tap on attempting marrow aspiration from 
the sternum or elsewhere is often the first clinical indication 
that the patient may not have myeloid leukaemia but rather 
myelofibrosis. A section of bone and bone marrow from the 
iliac crest for histological study is then a wise procedure, 
and without procrastination. Circulating fragments of mega­
karyocytes and an unusual number of nucleated red cells are 
also tell-tale diagnostic signs.
The diagnosis of the infective and drug- or toxin- 
induced leukaemoid reactions is not usually difficult, depending 
mainly on careful history-taking. Myelofibrosis is often much 
more difficult to differentiate, even when the clinician is 
conscious of the possibility of this diagnosis. Indeed, to 
be conscious of the possibility is to be more than half way 
towards establishing the diagnosis. (Figures 7 a and b).
But diagnosis is essential, since x-ray treatment of 
e.g. a spleen which is enlarged only as a compensatory effort 
at haemopoiesis would be disastrous. Such spleens have in 
fact been excised in error, though Korst (loc. cit.) describes 
two patients who benefited from splenectomy after careful 
studies had revealed a progressive haemolytic anaemia.
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The value of estimations of alkaline phosphatase in 
the leukocytes is discussed under Clinical Pathology.
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In the realm of clinical pathology many deviations 
from the normal have heen found in the leukaemias. The 
explanation for these various changes is uncertain, hut having 
regard to the studies in radiosensitivity discussed in Section 
V it is appropriate to enumerate at least the well-established 
features.
The Basal Metabolic Rate is increased during the active 
phases of leukaemia and it is said that measurements of the 
B.M.B. can in fact herald the end of a remission before the 
blood picture or other clinical symptoms and signs. This fact 
might help to explain the sweating, irritability and nervous­
ness in some leukaemic patients.
The total lipins are significantly increased in all 
leukaemias regardless of the number of circulating leukocytes, 
and purine metabolism is also known to be abnormal. Blood 
uric acid levels are elevated, frank gout may co-exist 
(Figure 8), and an acute attack of gout has been precipitated 
by irradiation therapy, presumably by the rapid liberation of 
more uric acid from disintegrated leukocytes, (e.g. Shorvon, 
1946, and Case M 2l). The effectiveness of colchicine both 
in gout and in leukaemia is noteworthy. Phosphorus and 
glutathione levels in the blood are also elevated in leukaemia
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(Whitby and Britton, loc. cit.) and in the leukocytes of acute 
leukaemia at least the content of folinic acid is some five 
times that of normal leukocytes. This high folic acid 
requirement for white cell mitosis underlies the value of 
antifolic chemotherapy, and Girdwood (1956) has suggested 
that this diversion of folic acid for leukopoiesis might 
explain the folic acid-deficient megaloblastic anaemia some­
times seen in leukaemia. Though the total plasma proteins are 
not significantly altered, there is generally an increase in 
the gamma globulin fraction, easily demonstrable by electro­
phoresis. The zinc content of leukaemic cells is also lower 
than normal while the disease is active, but returns to normal 
during remission. (Hughes and Gibson, 1947).
Though achlorhydria in the general population is much 
more common than one might guess, Meyer (1938) has demonstrated 
a histamine-fast achlorhydria in 53$ of chronic lymphatic 
leukaemia cases, in 13$ of chronic myeloid and 33$ of aleukaemic 
cases. It was also found in two out of every five acute cases. 
Meyer himself doubts the significance of these findings, except 
perhaps in lymphatic cases. Witts, however, (1956) draws 
attention to the importance of the vitamin B complex in the 
metabolism and replacement of all rapidly multiplying cells.
He points out that rapidity of replacement of cells is a factor
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common to gastro-intestinal tissues and to blood, and the 
common association of alimentary and haemat.ological symptoms 
may be due to a common denominator in a chain of enzyme 
reactions.
In 1943 Miller and Turner described substances isolated 
from the' urine of leukaemic patients (and normal ox liver) 
which influence leukopoiesis and maturation. A myeloid sub­
stance (named myelokentric acid) is responsible for myeloid 
proliferation, but myeloid maturation occurs only in the 
presence of a lymphoid substance (lymphokentric acid). Con­
versely, lymphoid proliferation is controlled by lymphokentric 
acid, and lymphoid maturation by small amounts of myelokentric 
acid. Acute myeloblastic leukaemia is thus caused by an 
excess of myelokentric acid but an absence of lymphokentric 
acid. A normal amount of lymphokentric acid in such a case 
would result in chronic myeloid leukaemia, i.e. by promoting more 
maturation. The opposite arrangement would cause acute 
lymphoblastic or chronic lymphatic leukaemia respectively.
This work has not apparenify been confirmed, nor has it excited 
the interest which it first seemed likely to do.
Wachstein (1946) and Valentine et al. (1952) demon­
strated that the alkaline phosphatase content of granulocytes 
in chronic myeloid leukaemia was distinctly lower than normal.
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Maloney -(1955) has indeed claimed that a fall in this phospha­
tase content was the earliest indication of incipient leukaemia 
in humans exposed to ionising radiations from the nuclear 
bombing of Japan in 1945. This diagnostic feature has 
attracted curiously little attention so far. Leonard (1957) 
has demonstrated that the alkaline phosphatase of leukaemic 
granulocytes is as far below the normal level as it is above 
it in infective leukocytosis. The level is also well above 
normal in leukaemoid states and polycythaemia, variable but not 
low in myelosclerosis, and normal in the granulocytes of chronic 
lymphatic leukaemia.
This is interesting also in the light of Bierman’s 
conclusions (1956) that the life span of chronic myeloid 
leukaemic granulocytes is greatly increased. Bierman's 
technique for separating white from red cells and returning the 
latter to the patient's circulation allowed the white cell mass 
to be properly depleted and the rate of replacement to be more 
accurately measured. As Osgood and colleagues showed (1954) 
"more of the body's leukocytes are located extravascularly at 
any one time than are present in the blood stream", a fact 




In the great majority of cases no cause, either immed­
iate or remote, can he discovered to explain the onset of 
leukaemia. A small minority do, however, seem to have some 
antecedent exposure to "agents” of various kinds that have come 
to he regarded as leukaemogenic. These will he discussed 
presently.
The Occurrence of Leukaemia. So far as is known no race is 
immune to leukaemia, though of course detailed statistics are 
available in only a few western countries, and even these are 
less reliable the farther back in time the enquiry goes.
Indeed, the International List of the Causes of Death reveals 
a changing concept of leukaemia, since it was only in 1920 that 
leukaemia and Hodgkin's disease were separately classified.
Not only are humans widely affected but the disease has been 
known since 1058 to occur in animals. Leukaemia has been 
reported, in one form or another, in dogs, cats, cattle, horses, 
guinea pigs and mice. An epizootic leukaemia is at present 
being studied in the Canadian pike, and a transmissible leukosis 
is well known in fowls. Leukaemia in mice and leukosis in 
fowls have been the source of much experimental work over many 
years. Jarmai (1934) has written an extensive monograph on
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the occurrence of leukaemia in domesticated animals.
Incidence. (a) Total. (h) Age. (c) Sex.
(a) Total incidence. It has recently been pointed out by
Hewitt (1955) that the past decade has seen a distressing and 
dramatic increase in the incidence of three lethal diseases, 
more than any other - lung cancer, coronary thrombosis, and 
leukaemia. The national mortality statistics for England and 
Wales (Table i) show a steady rise in annual death rates for 
leukaemia in both sexes from 17 per million living persons in 
1931 to 49 per million in 1954. The incidence in other 
countries shows a similar trend. (Table II) . Paterson E.
(1956) has shown that this increased and increasing incidence 
applies to both acute and chronic forms of the disease, i.e. 
in children as well as adults.
(b) Age Incidence. Leukaemia may occur at any age and indeed 
the disease has been reported in new born infants. Acute 
leukaemia is well known as affecting chidren more than adults, 
and the disease in children is nearly always of the acute type. 
Chronic lymphatic leukaemia is also known to be commoner in the 
older age groups whilst the myelogenous type occurs more often 
in the middle decades. These distinctions in age incidence, 
firm impressions with clinicians, are confirmed by statistical 
examination such as that shown in Table III.
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Death Hate from Leukaemia per million persons: 
England and Wales. 1931 - 54
Year
Death rate per million persons
Men Women Both Sexes
1931 19 15 17
1932 20 16 18
1933 20 17 19
1934 23 18 20
1935 23 19 21
1936 25 21 23
1937 25 20 22
1938 28 22 25
1939 28 23 25
1940 30 23 26
1941 29 22 25
1942 34 24 28
1943 38 25 30
1944 38 26 31
1945 40 29 34
1946 41 30 35
1947 38 32 35
1948 40 31 35
1949 44 35 40
1950 47 37 42
1951 47 41 41
1952 52 41 46
1953 53 44 48
1954 54 44 49
Table I
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Death Bate from Leukaemia per million persons: 
Various Countries, 1940 - 54
Year
Death rate per million persons
Canada Denmark Eire Scotland U.S.A.
1940 30 48 15 38 39
1941 31 44 16 28 39
1942 31 39 16 27 40
1943 30 52 24 32 41
1944 36 51 22 32 43
1945 33 57 16 32 45
1946 36 52 22 34 47
1947 37 57 17 32 51
1948 39 58 24 30 53
1949 45 61 20 39 55
1950 46 59 26 39 59
1951 46 62 32 43 61
1952 46 64 32 44 63
1953 53 69 38 63
1954 51 71 48
Tahle II
48 -
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.5 60 40 _ _
10 65 35 - - - -
15 69 31 75 25 60 40
20 72 28 80 20 61 39
25 71 29 83 17 55 45
30 71 29 81 19 52 48
35 70 30 76 24 52 48
40 69 31 86 14 52 48
45 68 32 75 25 53 47
50 68 32 77 23 55 45
55 67 33 75 25 54 46
60 67 33 77 23 56 44
65 - - 73 27 56 44
70 _ — 74 26 56 44
75 _ 74 26 56 44
80 - 75 25 56 44
85 — — — — 56 44
Table IV
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(c) Sex Incidence. Different authorities quote slightly 
different sex incidences, hut Table IV demonstrates not only 
that males predominate hut that the relationship varies at 
different age periods. This latter fact might, with different 
proportions of males and females, explain some of the slight 
differences of overall sex incidence in the literature.
(d) Season. Sceptical as one might he on possible seasonal 
influences on malignant disease Lambin and Gerard (1934) 
describe 54 cases of acute leukaemia, 37 of whom had their onset 
between October and May, while only 17 had their onset between 
May and October. The crux of this problem lies in the 
definition of the word ’’onset", though this is admittedly less 
difficult with acute leukaemia, the onset of which is usually 
sudden.
Relationship of Leukaemia to Other Diseases.
(a) Infection. The original concept of leukaemia by Hughes 
Bennett was that leukaemia is a pyemia following some infective 
process. In addition to an association with malaria many 
authors claimed to have isolated cocci, bacilli, diphtheroids, 
tubercle bacilli, and viruses. Sir Robert Muir once wrote 
"In the absence of knowledge regarding the agent producing the 
excessive proliferation of leukocytes, we cannot definitely
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assign the place of leukocythaemia in the category of disease.
On the whole it presents most points of analogy to the growth 
of tumours; but on the other hand, it is not absurd to suppose 
that it may yet prove to be due to a microparasiteH. Apart 
from continuing interest in the virus hypothesis, recently 
revived with considerable interest by Gross (1953), little 
enthusiasm now exists for an infectious origin of leukaemia.
The similarities between the anaemia of chronic infection and 
that of leukaemia has been noted for many years, but this fact 
alone does not prove any causal relationship.
Other Diseases of the Blood-forming Organs. The close 
relationship between the leukaemias and other reticuloses is 
well established and has already been described as "The Border­
lands Dim". Polycythaemia vera may be seen in association 
with chronic myeloid leukaemia, sometimes preceding leukaemia 
and sometimes following it. (Vide Section VI, Case M 13).
The close relationship, however, between polycythaemia and 
myelofibrosis, and the tendency of the latter of produce con­
fusing leukamoid blood-pictures has already been mentioned. 
Lymphosarcoma and lymphatic leukaemia, reticulum-cell sarcoma 
and monocytic leukaemia, and myelomatosis and plasma cell 
leukaemia are three commonly accepted transitions much discussed 
in the literature. The immunological distinction between
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lymphosarcoma cells and lymphatic leukaemia is interesting, 
hut an additional therapeutic distinction seems clear from the 
author's experience. The great radiosensitivity of lympho- 
sarcomatous nodes is well known. This cannot he said of the 
lymph nodes of chronic lymphatic leukaemia where relatively 
higher doses of x-rays are required to produce resolution which, 
in addition, is usually incomplete, the nodes becoming smaller 
but remaining palpable. Lymphosarcomatous nodes resolve 
completely and are no longer palpable after small doses of 
x-rays. The histological distinction between a lymph node 
which is the seat of lymphosarcoma and one involved in chronic 
lymphatic leukaemia is notoriously difficult, and many histolo­
gists report that both diagnoses are possible and that "the 
blood picture is necessary to distinguish". Thus a "normal"
blood picture is often considered to exclude leukaemia. The
author has followed the course of several such cases for periods 
of six or seven years and has noted (a) the relative insensi­
tivity of lymph nodes to x-ray treatment and (b) a very gradual 
inversion of the polymorph/lymphocyte ratio and increasing total 
white cell count to leukaemic levels. Such cases have clearly
been examples of very chronic lymphatic leukaemia and not
lymphosarcoma. The latter diagnosis would imply that patients 
with manifestly generalised sarcoma were capable of surviving
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many years. All other experience suggests otherwise. It is 
indeed easy to be wise after the event, but it is also wise.
The relationship of the leukaemias to abnormalities of 
the vitamin B complex has already been mentioned in the section 
on clinical pathology. Biochemical studies in the field of 
nutrition are throwing increasing light on the enzyme systems 
concerned in common with the health of e.g. the central nervous 
system, mucosal, and erythropoietic tissues. It is hard to 
resist a feeling that many lines of enquiry are gradually con­
verging, bringing to this vast field a sense of imminent 
discovery.
Relationship of Leukaemia to Noxious Extrinsic Factors.
(a) Toxins and Drugs. There must be many toxic and leukaemo- 
genic substances to which humans are exposed which are still 
unknown to us. There is no doubt that workers exposed to 
benzol (CgHg) may develop leukaemia, as well as the more common 
aplastic anaemia. Exposure to benzol may occur in such 
manufacturing processes as leather, rubber, celluloid, enamels, 
lacquers, paint-removers, silvering and bronzing liquids, dry- 
cleaning, electroplating, photography, aeroplane and sulphite 
pulp industries. Tar and indol are also suspect, and no doubt 
in many other occupations the hazards are unknown. Wilkinson 
(1955) has suggested that adulterated and contaminated food may
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play a part in explaining the increased incidence of leukaemia. 
Paterson E. (1956) has drawn attention to the social gradient 
in leukaemia incidence in Great Britain (Figure 9), and suggests 
some dietary factor may he operating here, quoting White and 
Mider who showed that a diet deficient in sulphur-containing 
amino acids clearly inhibits leukaemogenesis in mice. So far 
as drugs are concerned, Wilkinson (loc. cit.) has repeatedly 
drawn attention to the leukaemogenic propensities of the 
sulphonamide drugs, the leukaemia sometimes following an 
agranulocutic phase.
(b) Ionising Radiations - occupational, medical and military.
(i) Occupational. According to Forkner (loc. cit.) 
lymphatic leukaemia was described by Jajic and co-workers as 
early as 1911 in a patient who had been engaged for eight yeara 
in diagnostic and therapeutic work with rontgen rays. They 
had known three other similar cases. The literature on this 
subject has since become voluminous, one of the more recent 
surveys being that of Pellar and Pick (l95l). The incidence 
of leukaemia amongst radiologists is undoubtedly higher than 
with non-radiological medical workers. (But see below).
Recent enquiries by the author into the code of practice of 
physicians using diagnostic x-ray apparatus in the North-West 
of England make this occupational hazard more understandable.
For example, it seems only too clear that some physicians have
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acquired the reprehensible habit of embarking on the screening 
of patients’ chests without troubling to adapt their eyes to 
the darkness: the prolonged exposures that follow, are harmful
to the patient, the doctor, and other staff in the vicinity.
It is hoped that the recent Medical Research Council Report on 
the Hazards to Man of Nuclear and Allied Radiations (1956) will 
see the enforcement of a safer code of practice. The industrial 
problems of ionising radiations were discussed as long ago as 
1931 by Martland, who described the tragedy of luminous dial 
painters, many of whom acquired significant body burdens of 
radium and developed aplastic auaemia. It seems likely,as 
remarked in the Research Council report just mentioned, that some 
of these dyscrasias were leukaemic in type rather than simply 
aplastic. Again, one cannot but be concerned at the rapid 
employment of radioactive sources of all kinds in an ever- 
widening field of industry with little apparent concern or even 
knowledge of the potential hazards to health.
(2) Medical. The leukaemogenic effects of radiations 
used therapeutically have also been recognised for some time 
though renewed interest has been stimulated in this field by 
van Swaay1s report (1955) of aplastic anaemia and leukaemia 
following the radiation of the spine for ankylosing spondylitis. 
This problem was also mentioned by the author, (Sharp and 
Easson, 1954), and has become the subject of a nation-wide
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survey by a Medical Research Council Group for the study of 
radiation hazards, (Court-Brown and Abhatt, 1955; Court-Brown 
and Doll, 1956; Court-Brown, 1956; Abbatt and Lea, 1956).
The increased risk of leukaemia (and also cancer of the thyroid) 
as a result of the irradiation of the thymus gland in babies 
has been stressed by Simpson et al (1955), though a baby with 
a large thymic tumour presents such an emergency that a risk 
of leukaemia could scarcely justify the witholding of the only 
known approach to treatment. Leukaemia has also been reported 
following therapeutic doses of radioactive iodine (lAOX) for 
thyroid disease (Pochin et al., 1956). Diagnostic x-ray 
exposures have also been recently impugned, and the evidence of 
leukaemogenesis due to pre-natal obstetric radiography seems 
almost beyond question. (Stewart et al., 1956). A similar 
general conclusion was reached (though by statistically less 
acceptable methods) by Faber (1956) and no doubt further data 
will be sought and found in the near future.
(3) Military. The leukaemogenic properties of ionising 
radiations received further confirmation by the increased 
incidence of leukaemia in survivors of the atom-bombing of 
Hiroshima and Nagasaki in 1945. This has been described by 
Maloney (1955) and Maloney and Kastenbaum (1955) and their 
study demonstrates the important effect of dosage of radiation,
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in that incidence bore a direct relationship to the distance 
of the patient from the epicentre. It is interesting also to 
note that the lymphatic type of leukaemia did not show an 
increased incidence. This is curious, in some ways, and would 
certainly tend to reduce the degree of risk which is claimed, 
e.g. amongst radiologists, since the removal of lymphatic cases 
from the total number of instances of leukaemia in such workers 
would significantly reduce this risk.. It would not, however, 
remove it.
A study of the aetiology of leukaemia, indeed of all 
malignant disease, involves a study in human ecology. Though 
many environmental factors are known for cancers of various 
Sites, few are well established so far as leukaemia is 
concerned. It has been said of Darwin that his work caused 
zoologists to flock indoors where they stayed for fifty years 
instead of doing essential field-work. With leukaemia, the 
same might be said of Ehrlich from whom so much of our morpho­
logical preoccupations stem. One major problem, however, lies 
in the relative rarity of leukaemia, so that statistical studies 
of large populations at risk are quite indispensable. This 
matter has been recently reviewed by Witts (1957) who points 
also to the need for higher standards of diagnosis.
SECTION II
General Therapeutic Background
(i) Aim in Management.
(ii) Evolution of Treatment Methods,
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THERAPY IN GENERAL
Aim in management of the lenkaemic patient
In spite of recent advances in chemotherapy and radio­
active isotope therapy leukaemia remains an incurable disease. 
Much can he done, however, to keep the patient comfortable by 
controlling the symptoms associated with high white cell counts, 
anaemia, splenomegaly and lymphadenopathy. The criteria of 
good palliative radiotherapy were outlined by Tod (1952), and 
the management of the leukaemic patient fulfills these require­
ments in typical fashion. Palliative treatment should aim to 
relieve symptoms without creating new symptoms due to the 
treatment itself. The treatment should be relatively simple and 
of short duration - especially in relation to the overall period 
of symptomatic improvement. The period spent in hospital should 
also be short, and an out-patient method of treatment is ideal 
in this connection. Palliative treatment aims at the improve­
ment in the general well-being of the patient, and the duration 
of this improved health is of less importance than its quality. 
The final criterion of good palliation is that the terminal 
illness should be short.
Acute leukaemia remains a desperately difficult disease 
to treat with any hope of worthwhile palliation, though some
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temporary improvement can be looked for since the introduction 
of antifolic and antipurine drugs, as well as ACTH and 
cortisoneo The antimetabolites in fact provide helpful tools 
for the study of the leukaemic disease and it is in that sense, 
rather than their true therapeutic value, that I see their main 
importance.
Chronic leukaemia can be usefully palliated over several, 
and in some cases over many years. Many methods can be 
employed to induce a remission, both clinically and haematologi- 
cally, though some may be considered better than others because 
they involve less hospitalisation, some cause less toxic side 
effects than others, some induce their beneficial effects 
quickly, some more slowly - all factors to be carefully considered 
with each individual patient, and in the light of the criteria 
described above.
The Evolution of Treatment Methods.
The evolution of treatment methods for leukaemia, as 
indeed with many other diseases, is inseparably linked with our 
understanding of the disease itself, its pathology and symptom­
atology, as well as to the growth of pharmacology. The 
confusion, for example, between the clinical pictures of malaria 
and leukaemia during the 19th century was perhaps the main if not 
the sole reason for the use of quinine as a therapeutic agent.
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Apparently it was seldom used alone, and "authentic" cases of 
improvement may be ascribed to the concomitant use of arsenic. 
Efforts to produce splenic contraction by cold douching, or by 
painting the overlying skin with iodine seem no more curious 
than treatment by prolonged inhalation of oxygen or hypodermic 
injections of ergotine. Some rationale was advanced for all 
the treatment methods adopted, though empiricism, combined with 
an optimism bora of despair, ruled the day. It is a chastening 
thought that we are still no nearer curing this disease, and 
though we believe we understand it better than a hundred years 
ago, a historian may well smile a hundred years hence at our 
confident empiricism.
Chemical Methods
Lissauer, in 1865, is credited with the first obser­
vations on the value of arsenic for leukaemic patients. Since 
this was in the days before blood counting he regarded the 
improvement as due to the general tonic effect of Fowler's 
Solution. Cutler and Bradford (1878) were among the first to 
carry out a detailed haematological study of the effects of 
arsenic on the blood of normal as well as leukaemic patients.
A mixture of iron and arsenic rapidly became a popular approach 
to the treatment and care of chronic leukaemia.
In his exhaustive monograph on leukaemia Forkner (1938)
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quotes the claims of many authors for Successful treatment with 
such widely diverse agents as antimony, silver and lead, Coley's 
toxin, tuberculin, naphtholene tetrachloride, cinnamic acid, 
and amidopyrine. Most of these chemotherapeutic agents were 
in fact found to be valueless in the hands of careful and 
critical workers. Colchicine was tried many years ago but 
its toxic effects led to its being abandoned. However 
Moeschlin (1954), and Leonard and Wilkinson (1955), have 
described their experience with a new alkaloid of colchicine 
(desacetylmethylcolchicine) which promises to have some value 
in chronic myeloid leukaemia. Benzol (CgHg) was found to have 
a depressent effect on bone marrow as long ago as 1900 and was 
used as an anti-leukaemic agent from time to time from about 
1912 onwards. Its serious toxic side-effects, however, 
including aplastic anaemia and widespread fatty degeneration, 
finally led to its gradual abandonment.
ArSenic remained the most effective chemo-therapeutic 
agent until the discovery of a series of nucleo-toxic anti­
mitotic drugs during and just after the Second World War.
Haddow and Sexton (1946) discovered the anti-tumour effects of 
urethane (ethyl carbamate), and Paterson et al. (1946) followed 
this up by demonstrating the value of "this tantalisingly 
simple radio-mimetic drug" in chronic leukaemia. Wilkinson and
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Fletcher (1947) described the value of nitrogen mustard in 
chronic leukaemia and other reticuloses and Gardikas, Leonard 
and Wilkinson (1955) have discussed in detail the place of many 
nitrogen mustard derivatives which have been tested during the 
past ten years. Another group of radio-mimetic "cross-linking" 
chemicals is the ethylene imine drugs such as T.E.M., T.E.P.A. , 
and Thio-T.E.P.A. (Paterson and Boland, 195l). These chemicals 
had been used in Germany and the U.S.S.R. long before the War 
in the textile industry for binding textile fibres together.
It has been thought that their capacity to bind amino acid 
chains leads to chromosomal cross-linkage and break-down in 
mitosis, though Bacq and Alexander (1955) suggest that change 
of shape of the D.N.A. molecule is the initial reaction. In 
addition to the epoxide B.E.P. (bisethyleneiminosulphyl propane), 
yet another cross-linkage agent was discovered by Haddow and 
Timmis (1953) and described in clinical practice by Galton (1953). 
This was the sulphone Myeleran (l: 4-Dime thane sulphonyl oxybutane) . 
Now called Busulphan, it has a selective action on cells of the 
myeloid series, though it also depresses platelet formation. 
Another of the recent products of the Chester Beatty Laboratories 
is p-bis(2 chloroethyl) aminophenylbutyric acid. This drug, 
known as C.B. 1348, and more recently as chlorambucil, seems 
to be more effective against lymphatic leukaemia than myeloid,
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though some workers have been unduly enthusiastic about it.
An international conference on the subject of alkylating 
agents was recently sponsored by the New York Academy of 
Sciences (March, 1957) and in conclusion Professor A. Haddow 
"doubted whether they (alkylating agents) would have any 
ultimate or permanent place in the chemotherapy of malignant 
disease." (Haddow, 1957).
A different approach to the chemotherapy of the leuk­
aemias is by the anti-metabolic drugs. Farber and his 
co-workers (1948) found that folic acid made acute leukaemia 
worse, and on testing folic acid antagonists (the pterins) they 
succeeded in controlling acute leukaemic cases for significantly 
longer periods than hitherto. Not only did these drugs increase 
the duration of life of acute leukaemic patients, they provided 
a new tool for the study of the disease. A second attack on 
the metabolic processes of leukaemic cells was that of the purine 
antagonists. The synthesis of 6-mercaptopurine was the result 
of a ten-year study of possible antagonists of precursors of 
nucleic acid by Clarke et al. (1953). The effect of this 
agent on leukaemia was quickly established, and yet another new 
weapon was provided, of especial value in acute leukaemia. It 
can also be effective even after resistance has been established 
to other antileukaemic drugs, and even in chronic leukaemia 
in an acute terminal phase.
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Resistance is acquired to all of these chemotherapeutic 
agents, presumably by enzymic adaptation, and it is also to be 
noted that they are by no means free from toxic side-effects 
Such as buccal ulceration, diarrhoea, nausea and vomiting, 
purpura, aplastic anaemia, etc. Dosage control is of great 
importance and idiosyncrasy has to be anticipated.
The steroid hormones A.C.T.H., cortisone, and its newer 
derivatives, also have a real place in the treatment of the 
leukaemias, but almost entirely in the acute lymphoblastic type. 
They seem to be valueless in acute myeloblastic and monocytic 
leukaemia, and in chronic leukaemia too they have no effect 
except occasionally in the control of the haemolytic features 
sometimes seen in chronic lymphatic leukaemia.
Ionising Radiations and Radio-mimetic Chemicals.
The voluminous literature on this physico-chemical 
borderland has been recently reviewed by Bacq and Alexander 
(l955). There is no doubt that the biological effects of 
ionising radiations can be closely simulated by certain radio- 
mimetic chemicals such as those just described - especially 
the nitrogen mustards, T.E.M., Myeleran, etc. They all produce 
chromosomal breaks, and can kill both dividing and resting cells. 
They are both mutagenic and carcinogenic. They can suppress
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anti-body formation, cause acute or chronic degenerative 
changes in bone-marrow, intestinal mucosa and testis, and can 
inhibit the growth of certain tumours. Many of these super­
ficial similarities, however, have differences in detail. For 
example, the period of maximum sensitivity for the production of 
chromosome aberrations is during early interphase with chemicals, 
but just before propbase with x-rays. There are also differences 
in the site of action of these agents on the chromosomes. 
Furthermore, nitrogen mustards produce much more frequent 
mosaics in Drosophila than do x-rays. It is interesting to 
note also that though cysteine and cysteamine protect animals 
against the lethal effects of both x-rays and nitrogen mustard 
(Peczenik, 1953), this is not true for T.E.M. (Nadkarni, 1954).
So far as leukaemia is concerned Elson et al. (1955) 
claim that chlorambucil produces the same effect as x-radiation 
on lymphoid tissues, while myeleran produces similar effects 
on myeloid tissue. Both chemicals together are claimed to 
induce a total effect which is identical to x-radiation, in 
animals at least.
Radiation Methods.
Heliotherapy was at one time claimed to be useful in 
leukaemia, but probably did little more than help general 
supportive measures, so necessary with any course of treatment.
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It is quite remarkable, however, how quickly after the discovery 
of roentgen rays, and the radioactivity of radium, the biological 
effects of ionising radiations were appreciated. The effects 
on the blood were noted within a year, skin erythema and 
necrosis were soon recognised as hazards of fluoroscopy, and by 
1902 Pusey described the use of x-rays in the treatment of 
various diseases including leukaemia. This was only seven 
years after the discovery of x-rays, and by 1905 the literature 
on this subject was already becoming voluminous.
Mode of action. It would be out of place to discuss here the 
detailed theories of radiobiology, though some consideration 
must be given to a few of the more commonly advanced hypotheses 
concerning the antileukaemic effects of ionising radiations.
One of the earliest observations of the effects of 
ionising radiations was their power to depress the leukocyte 
count, and if the exposure to the rays was long enough a 
depression of all the blood elements took place, and death 
followed from aplastic anaemia. Heinecke was one of the first 
to carry out careful studies of the different sensitivities of 
tissues and blood cells to radiations, and it was soon generally 
realised that though all living cells were vulnerable, those in 
active mitosis were especially so. Thus the bone marrow was 
more sensitive to radiations than muscle tissue, even though the
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latter could also be damaged "by larger doses. However, that 
this is not the whole answer is clear from the radioresistance 
of some tumours, and indeed some types of leukaemia, in which 
active mitosis is taking place. Thus the old ’Law1 of 
Bergonie and Trihondeau is no longer accepted as an adequate 
explanation of the fact that the stem cells in the marrow are 
more sensitive than fully differentiated cells of other tissues. 
Becent work by Hevesy (1956) on the existence of different 
soluble fractions of D.N.A. possessing different radio­
sensitivity in radioresistant tumours might throw new light on 
this old problem. The fact that the lymphocytes disappear from 
the blood after irradiation more quickly than neutrophils, and 
the latter more quickly than red cells, has been explained as due 
to the differing life spans of these three types of cell. Once 
again, this explanation is not quite so simple and authorities 
are still sceptical. The facts remain.
There is much evidence, from in vivo as well as in vitro 
experiments, to support the theory of a direct action of 
radiation on leukaemic white cells. There is, however, even 
more interesting and compelling evidence in favour of an indirect 
action. The production of leukopenia in animals following the 
injection of serum from irradiated leukaemic patients was 
demonstrated as early as 1905 and has been repeated on many
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occasions (Forkner, 1938). Antimitotic effects in the bone 
marrow of the sternum have been reported by Gunz (1953) following 
irradiation of the spleen, care having been taken to avoid any 
scattered irradiation of the sternum. Levitt (1948) has 
emphasised that since splenectomy does not have the same effect 
as irradiation of the spleen, the radiation effect cannot be due 
to simple depression of activities which have their seat in the 
spleen. There is thus strong opinion in favour of the produc­
tion of some leukolytic substance in the irradiated spleen of 
leukaemic patients. Presumably any such substance would act 
by inhibiting the synthesis of nucleic acid by one of many 
possible pathways. Much work on this subject is still called 
for, and may yet provide further tools in the search for a final 
cure of leukaemia, or its effective control.
Whatever its precise mode of action irradiation therapy 
leads to a depression of the excessive leukopoiesis, with a 
concomitant increase in erythropoiesis, diminution in the size 
of the spleen and lymph nodes, and an improvement in the general 
condition of the patient. Furthermore, this improvement may 
last for many months, or even for some years, a fact which argues 




The earliest attempts at irradiation therapy for 
leukaemia consisted of whole body radiation - so-called spray- 
radiation. Soon other workers tried and advocated the 
irradiation of different portions of the body - sometimeB the 
long bones only, aimed at treating the active bone marrow; 
others would treat the enlarged spleen alone, with or without 
the lymph nodes in lymphatic leukaemia; others suggested the 
irradiation of the thorax, or of the heart to treat only the 
circulating blood; still others suggested treating the vege­
tative nervous system which was considered the seat of the 
underlying defect causing hyperactivity of leukopoietic tissue. 
There were those also who argued that irradiation of the kidneys 
was important in order to promote excretion of uric acid.
There are those who adopt a less dogmatic view and agree that 
when one method of treatment appears to be losing its effect it 
is reasonable to attempt further treatment by other means. With 
the advent of various chemotherapeutic approaches to leukaemia 
the failure of a radiation method of treatment would seem to call 
for a chemotherapeutic approach, rather than continued use of 
one antimitotic agent. If it be assumed that even radiation 
therapy acts by virtue of a chemical blocking of nucleic acid 
synthesis, then, on the analogy of bacterial resistance, it is
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undoubtedly preferable to use when necessary a new agent which 
will perhaps interfere with cell metabolism in a different way. 
Attempts at synergism have been made and x-rays have been 
combined with arsenic or with benzol. Magnin et al. have more 
recently reported favourably on the synergism of cortisone and 
antifolics in acute leukaemia. (1953).
Badium Therapy
Radium has been used in the treatment of leukaemia (e.g.
White, 1933) and its gamma radiation does of course have
biological effects similar to x-rays. The problem with radium
therapy is that in order to attain a usable beam of radiation a
substantial quantity of radium is necessary. This has been
available for many years in the form of the so-called radium
bombs. These teleradium units are now being replaced by even
60more effective bombs of radiocobalt (Co ). The penetrating 
quality of this gamma radiation is equivalent to x-rays generated 
at over a million electron volts, and so far as leukaemia is 
concerned this is needlessly high. However, there is no doubt 
that such units have been and can be used in leukaemia treatment. 
Badium in much smaller quantities has been used under emergency 
conditions when no other form of radiation has been available. 
Melville (1950) has described the use of a surface application
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of radium amounting to only a few hundred milligrammes (all that 
was available) placed over the spleen of a leukaemic patient.
The response was very satisfactory and a good remission was 
induced. Many writers have made claims for the superiority of 
radium over other methods but one rather suspects that no other 
agent was available to them.
The indications for the use of radium are clearly similar 
to those for the use of x-ray therapy. The latter is much 
simpler and is certainly safer, for the operator as well as for 
the patient.
Thorium Therapy
The radioactive decay products of the thorium family 
have been used in the treatment of leukaemia, the two members 
most commonly used being radiothorium and thorium-X. Both of 
these substances have been found to remain in the body, in liver, 
spleen and bone, for long periods, and aplasia is a dangerous 
side effect. The poor prognosis of leukaemia, however, tempted 
many workers to continue to use these thorium derivatives, 
though they have been abandoned in Britain for many years.
Radioactive Isotopes in the Treatment of Leukaemia
Since this is the main subject of this thesis it is 
appropriate to consider the matter in some detail.
Thanks to the pioneer work of Gustave de Hevesy in the
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study and development of the method of biological tracers, 
using natural stable and radioactive isotopes, the scene was 
set for the arrival of artificial radioactivity in 1934. The 
discovery of artificial radioactivity by the Joliot-Curies 
introduced a new, vast, and still expanding chapter in the 
history of radiology. Hevesy and his co-workers had already 
shown that tissues will concentrate metabolites whether they be 
radioactive or not. Tissues are unable to distinguish between 
stable and radioactive isotopes of any element, so that cells 
will absorb, metabolise, and excrete radio-isotopes depending only 
on the affinity of the cells in question for the element 
presented to them. For example, phosphorus is an ubiquitous 
cellular metabolite, the concentration of which in any tissue 
depends on metabolic activity; thus the distribution of phos­
phorous throughout the body is not uniform since the metabolic 
activity of tissues varies so widely. Strontium, being the 
biochemical analogue of calcium, is on the other hand selectively 
concentrated in the skeleton, and is thus confined largely to 
one organ system. Iodine is another example of an element which 
is selectively absorbed and concentrated in one organ system, 
namely the thyroid gland. When these elements are radioactive, 
the organ in which they are deposited, or more properly, through 
which they pass, will be irradiated continuously until the
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isotope leaves the tissue in question and/or until the isotope 
decays into an inert element.
So far as leukaemia is concerned, radioactive phosphorus 
(P ) in the form of the sodium acid phosphate, was used as early 
as 1937 hy Lawrence and his co-workers (1939). The importance 
of the chemical compound in which the isotope is incorporated 
was shown by studies in the distribution of insoluble chromic 
phosphate. This material was selectively taken up by the 
reticuloendothelial system, mainly the liver and spleen. (Low- 
Beer, 1950). The size of the particles were found to be of 
importance, and though Lawrence and Dougherty (quoted by Low-Beer, 
loc. cit.) tried treating five cases of chronic myeloid leukemia 
by chromic phosphate, they met with unfavourable responses and 
abandoned this approach.
24\Badioactive sodium (Na ) was considered on theoretical 
grounds to be an ideal source of general body radiation, since 
sodium is an extracellular metabolite with no special selective 
uptake by any tissue. Hamilton and Stone (1937) were, however, 
disappointed with their first trials on leukaemic patients and, 
though Evans et al. (1948) were somewhat more enthusiastic, 
radiosodium has nevertheless been generally superceded by 
radiophosphorus.
Though Shepperd et al. (1947) have studied radioactive
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198gold (An ) , so far as its distribution in the body is
concerned, and some workers, e.g. Hahn et al. (1956) have in
fact used this isotope enthusiastically in leukaemia, it has been
generally abandoned. The importance of the colloidal particle
198size is again seen with Au and the selective uptake by spleen 
and liver is characteristic.
Indications for Treatment
This is commonly the title to a section in most mono­
graphs on leukaemia, but a much more desirable attitude of mind 
is to consider the mode of management, and only as a distinctly 
different problem, the indications for positive anti-1eukaemic 
treatment in some form or other. It cannot be too strongly 
stressed that a mere elevation of the white cell count with some 
primitive white cells in the peripheral blood is no indication 
for dosing the patient with mustard drugs or radioactive isotopes. 
As was said at the outset to this section on therapy, the aim in 
management is to improve the quality of a patient's health and 
living by improving his blood and removing symptons associated 
with his high white cell count and low red cell count. If a 
patient is kept under observation it will generally be found 
that his white cell count slowly increases and ultimately the 
red cell count will begin to fall. The red cell count sometimes 
is found to fluctuate, and action should be delayed until there
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is no doubt that the count is falling. The errors inherent in 
blood counting are significant. (Williams, 1954).
Apart from a falling red cell count as an indication for 
positive treatment, it may be necessary to consider treating a 
leukaemic patient because the spleen is assuming unpleasant and 
uncomfortable proportions. In the writer’s experience there is 
an interesting group of subleukaemic (rather than aleukaemic) 
cases in whom a painfully large spleen occurs in association 
with only a moderately elevated white cell count. In this type 
of case it is possible to provide considerable relief of dis­
comfort, though curiously little splenic resolution, by small 
doses of x-rays to the spleen. It will be found, incidentally, 
that the white cell count in such cases falls slowly and can 
indeed be reduced to very low levels with impunity. As well as 
a large spleen, treatment may be indicated for large and 
mechanically troublesome lymph nodes in lymphatic leukaemia.
In this connection, the writer’s experience has already been 
mentioned that the lymph nodes of lymphatic leukaemia are by no 
means as sensitive to x-rays as lymphosarcomatous nodes, or 
indeed any of the other reticuloses.
Sometimes a patient whose white cell count is slowly 
increasing but whose red cell count is well maintained, may 
complain of vague malaise. Even in the absence of any 
discoverable cause for this, it is often wise to institute a
- 77 -
course of treatment. The patient himself is often able to 
indicate deterioration before any clinical or haematological 
test will do so.
Indications fqr Besoming Treatment
After the successful induction of a remission, there are
two schools of thought as to further treatment. Some believe
that frequent repeated treatment should be given by small
exposures of x-rays to the spleen or elsewhere, or by small 
32doses of P (Osgood et al., 1955), or by maintenance doses of 
one of the chemotherapeutic agents. The other school of thought 
is that the greatest improvement possible should be achieved, 
and then the patient should he allowed to live a life as free 
of hospital control as possible. The patient who lives, as it 
were, in the shadow of the hospital for the remainder of his 
life does, I believe, lose one of the greatest advantages of his 
palliative treatment.
As a member of the second school of thought, what are 
the indications for re-treatment? Once more the red cell 
count or haemoglobin level is the most important single index 
of the patient’s well-being. Provided the haemoglobin level 
is rising, or static, further treatment should be withheld, but 
as soon as the physician is quite certain that the level has 
dropped significantly further treatment should he considered.
- 78 -
As with the initial treatment, other factors such as splenic 
discomfort, large lymph nodes, or the vague hut definite 
deterioration in the patient's general condition may call for 
special consideration, even with a good and steady haemoglohin 
level.
Contra-indications for Treatment
Here again, by treatment is meant the application of 
some positive antileukaemic agent, since significant assistance 
may he given to a patient even when there exists some accepted 
contra-indication to, for example, x-ray therapy. It is agreed 
that acute leukaemia is aggravated by radiation therapy in all 
its forms, and the same applies to most of the chemical agents 
of known value in chronic leukaemia. Thus when a chronic 
leukaemic patient begins to show any signs which may herald the 
onset of an acute phase of his disease it is wise to withhold 
treatment. Such signs as pyrexia, mucosal bleeding and 
petechial haemorrhages, considerable increase of stem cells in 
the peripheral blood, sudden drop in the platelet count, 
(especially in myelogenous leukaemia), and severe splenic pain, 
are all indications for exercising the utmost caution. In the 
past, such an acute phase of a previously chronic leukaemia was 
regarded as the end of the struggle, and apart from transfusions, 
often badly tolerated, nothing could he done for these patients.
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Fortunately it is now possible to exhibit 6-mercaptopurine with 
some hope of success in the form of another remission, albeit 
a short one.
The Refractory State
Much has been written about the so-called refractory 
state of leukaemia, the condition at which a previously 
responsive chronic leukaemia fails to show much or any response 
to the same agent. Low-Beer (1950) asserts that this so-called 
radioresistance, in the sense of induced metabolic change, has 
not been proved, and he believes that since there is a gradual 
increase of primitive cells in the bone marrow and blood of 
chronic leukaemic patients, associated with a progressive 
replacement of erythropoietic and megakaryocytic elements, it 
is this increasing activity of the malignant disease and not 
radioresistance which is responsible for the lessened response 
to radiation in the later stages of chronic leukaemia. The 
complete lack of response of acute leukaemia to radiation is 
cited as substantiating this view. Variation in radiosensi­
tivity in the same patient at different phases of his disease 
is, however, a different problem from the variation in 
sensitivity seen between different patients. This matter is 
discussed in detail in Section V.
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Synergism
Much has been written on the synergistic value of 
combined methods of treatment. In a recent "Round-Table 
Discussion on Therapy1’ of leukaemia (Rebuck et al., 1957), 
many speakers claimed "undoubted" improvement from combinations 
of chemical, isotopic, steroid or x-ray therapy. Mitchell 
(1953) in discussing the potentiating effects of Synkavit has 
emphasised the importance of a planned pharmacological approach 
to this difficult subject of synergism, and the author deems it 
wise to avoid further discussion here. Suffice it to say that 
few of the many claims in this field would stand up to a critical 
examination. The subject does, nevertheless, call for most 
careful and detailed study, and is closely linked to the problems 
of acquired cell-resistance.
General Supportive Measures
It has long been appreciated that much can be done for 
the leukaemic patient in addition to specific anti-leukaomic 
treatment.
An important feature in the management of the leukaemic 
patient is the avoidance of fuss over such matters as diet, work 
and rest. A common-sense attitude should prevail, and provided 
the diet is well-balanced, and work is not such as to tax the 
strength of the patient, some occupational activity should be 
pursued as long as possible. Though acute differences of
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opinion exist, the author believes firmly that it is rarely in 
the patient’s interests to know the nature of his disease, 
since he can so readily discover the hopelessness of his 
prognosis. Snch a realisation greatly undermines the quality 
of a clinical remission, and rare indeed is the patient who can 
adjust well to the knowledge of his approaching death. The 
avoidance of undue fussing is an essential part of reassurance.
Iron tonics for leukaemic patients have been in vogue 
for at least a century. However, in a haemolytic phase of 
leukaemia the patient may take up iron which he can neither use 
nor excrete, and further iron supplies can only increase the 
embarrassment of his siderotic organs. Crosby and Damashek 
(1955) condemn iron therapy in haemolytic anaemias, and caution 
is clearly required with the leukaemic patient.
The theoretical value of the vitamin B complex has 
already been mentioned, and the author feels that this vitamin, 
combined with vitamins A, B and C, (as well as liver in the 
diet) are wise if still empiric adjuvants.
Infection is often a great problem, especially in the 
acute forms of the disease, and also commonly in chronic 
lymphatic leukaemia. Antibiotics are of inestimable value, 
and many patients who would otherwise have succumbed to advancing 
pulmonary infections have been kept alive and well for several 
years longer. It is true to say that antibiotics have
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significantly extended the life-expectancy of chronic lymphatic 
leukaemia apart altogether from specific anti—leukaemic agents.
Bone marrow injections have been tried and found 
wanting, but blood transfusions have an undoubted place in the 
general care of leukaemic patients. Most clinicians have had 
experience of remissions of leukaemia following blood trans­
fusion, remissions which were qualitatively better than could 
have been expected from the quantity of blood transfused.
Sabin et al. (1924) have in fact reported maturation of myelo­
blasts in a case of subacute myeloblastic leukaemia following 
blood transfusion, and Schwind (1947) had the same experience 
following transfusion of fresh plasma. In acute leukaemia in 
children the author has seen remarkable though temporary 
improvement after exchange transfusion. It should be mentioned, 
however, that though blood transfusion can be helpful, it is 
often open to doubt whether the clinician is justified in using 
precious blood for the temporary support of a patient whose 
very need for blood is usually an indication of approaching and 
inevitable death. Rarely does transfusion of the grossly 
anaemic patient permit subsequent useful specific treatment with 
radiation or radio-mimetic drugs.
Splenectomy in Leukaemia
It was natural that the size and discomfort of the 
spleen in leukaemia should tempt surgeons to remove the organ,
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and Forkner (loc. cit.) quotes Bryant as haying done so as 
long ago as 1866. The results were disastrous, though a few 
of the many subsequent reports were more favourable. With all 
the present-day excellence of surgical technique the removal of 
a large and adherent leukaemic spleen may still prove extremely 
difficult, and since palliation is the sole intent of such an 
operation few surgeons are willing to embark on splenectomy 
even with the most favourable case. Though splenectomy may be
valuable in certain haemolytic anaemias, such a phase in the 
course of leukaemia is usually a terminal one, and the patient 
would not be considered suitable for operation.
The author has yet to see a leukaemic patient for whom 
splenectomy has at any time seemed worth contemplating.
Heterologous Marrow
Though discussion of animal research has been deliber­
ately avoided in this thesis, it would be unwise not to mention 
the recent and fascinating work of Loutit and his colleagues, 
(Barnes et al., 1956). By whole-body irradiation of leukaemic 
mice to lethal dosage levels Loutit aimed to kill off all 
leukaemia cells and stem cells, and at the same time to inhibit 
antibody-formation in the irradiated mice. Then he injected 
heterologous marrow from non-leukaemic mice, or even from rats, 
and the implanted marrow did successfully repopulate the
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haemopoietic system of the irradiated mice with non-1 eukaemic 
hlood cells. This entirely new and hold approach to leukaemia, 
therapy has rightly earned for Loutit the Leukaemia Society’s 
Award for 1956. The possibilities of applying this principle 
to human leukaemia are being considered, though confirmation in 
other laboratories is still awaited.
Causes of Death in Leukaemic Patients
Life has been defined as the ensemble of functions that 
resist death, and this is particularly apt when consideration 
is given to the causes of death in leukaemic patients. It is 
of course often difficult at autopsy to understand how any 
patient has survived so long with so much obvious anatomical 
derangement.
It is not an uncommon experience at autopsy to find an 
unsuspected chronic lymphatic leukaemia, clearly asymptomatic 
before death, and not significantly related to the sequence of 
events which culminated in death. This must be rare with 
chronic myeloid leukaemia.
Infection is a frequent terminal feature of acute 
leukaemias and chronic lymphatic leukaemia, and may well be an 
important contributory cause of death. The value of antibiotics 
in this connection has already been mentioned.
The author has seen substantial haemorrhage from the
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nasopharynx and from the intestine resulting in death, hut 
this is a distinctly uncommon event with chronic leukaemia.
Small mucosal bleedings and petechial haemorrhages are not a 
significant cause of the anaemia of leukaemia. That very low 
levels of haemoglobin are compatible with a moderately active 
life is common experience in tropical countries where nutritional 
anaemias are almost endemic. It may also be seen in children 
with congenital hypoplastic marrows, where death may be delayed 
until adolescence or early twenties, and is in any case largely 
due to extensive haemosiderosis. Thus it seems that anaemia 
alone is not a necessary cause of death in leukaemia though it 
may well be a contributory cause in many cases.
That aplasia is not a constant terminal finding in 
leukaemia is well established. Even in the presence of a gross 
anaemia the erythropoietic activity of the marrow can be seen 
microscopically, and can also be demonstrated by radioactive 
iron studies. The author has found this latter feature in 
several patients whose iron turn-over was measured. Some have 
proved quite aplastic and have died within a few weeks: others
have had active erythropoiesis suggesting haemolysis though this 
was not confirmed by serological studies. The latter group of 
patients also died rapidly with a gross and refractory anaemia 
which did appear to be the main cause of death. (This work has 
not been published, but accords well with the experience of
other workers, such as Huff et al., 1952).
"Iatrogenic death" is a more common jibe than a fact.
That myelofibrosis and marrow exhaustion may be induced, e.g. 
by irradiation of the bone marrow has often been suggested, 
but many writers (e.g. Korst et al., 1956) have equally 
emphasised that myelofibrosis may occur at any stage of treated 
or untreated leukaemia or polycythaemia vera. That a chronic 
leukaemia may become acute as a result of treatment has been 
described from time to time, but though the association in time 
is sometimes interesting it is no proof of a causal relationship.
That any organ may be infiltrated with leukaemic cells, 
and that haemorrhage may occur into any tissue has already been 
mentioned, and such anatomical derangements might lead to a 
breakdown in function incompatible with continued life.
Whatever its cause, it is unfortunately still true that 
death is inevitable for the leukaemic patient.
SECTION III 
Pharmacology of Radiophosphorns.
(1) Physical and Chemical, 
(ii) Radiation Effects.
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THE PHARMACOLOGY OF RADIOACTIVE PHOSPHORUS (32P15)
Forkner (1938) draws attention to the report of Roger 
and Josue (1899) of the leukaemogenic properties of stable 
phosphorus, but also discusses several studies of the results 
of treatment of the leukaemias by oral phosphorus. The 
pharmacological similarities of arsenic and phosphorus are noted 
as a possible explanation of this antileukaemic effect, but no 
study of stable phosphorus seems to have been published during 
the past fifty years.
We are concerned here, however, with radioactive 
phosphorus, the biological effectiveness of which depends on its 
radioactivity. It is relevant, therefore, to discuss its 
pharmacology from the physical as well as the biochemical point 
of view.
Characteristics of therapeutic usefulness. Radioactive iso­
topes may emit alpha or beta particles and/or gamma rays.
Alpha particles are in fact emitted by only a few artificial 
isotopes and consist of helium nuclei ejected with great 
velocity from the nucleus of the isotope. They are rapidly 
stopped in tissues, and even in air^ liberating all their energy 
in the former within a fraction of a millimetre. Beta rtrays"
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are high speed electrons, with greater penetrating power, hut 
still a range limited to a few millimetres in tissues. Gamma 
rays are truly penetrating electromagnetic radiations capable 
of passing through several feet of concrete.
Clearly, the gamma rays released in a given gram of 
tissue will produce only a small amount of ionisation locally, 
most of their energy being expended elsewhere along their paths. 
Beta rays, on the other hand, expend all their energy in the 
immediate vicinity of their site of emanation. The ideal 
therapeutic isotope, therefore, is one which emits beta rays 
and which will be selectively absorbed into a particular tissue. 
Radio-phosphorus is one of the few isotopes possessing these 
requirements in some measure.
A further therapeutically important characteristic is 
the effective half-life of the isotope in question. It is 
biologically and posologically undesirable to employ a compound 
which disintegrates very slowly over several years, and which is 
also retained in the body during that time - whether in the 
diseased tissues or elsewhere. The contrary is also true, in 
that an isotope may decay so rapidly as to be useless by the 
time it reaches the physician from the distributor.
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Physical characteristics of radioactive phosphorus
The element phosphorus occurs in nature in only one
form - Five isotopes can he produced by nuclearX5
excitation - ^ ^ 15» 30j>i5> 32pi5’ 33^15 aiu* 34pi5* Sine:e all
six isotopes of phosphorus have the same number of protons in
29 30their nuclei (l5), they are chemically identical. P and P
are positron emitters, but with a half-life of 4.6 .seconds and
2.3 minutes respectively, they are of no value in biological
work. ^^P has a half-life of 25 days, and though this could
be a useful feature, the beta particles emitted have a very low
maximum energy of only 0.27 Mev. has a good high energy
beta emission (5.1 Mev.) but has a therapeutically useless half-
life of only 12.4 seconds. 32p on the other hand, emits
energetic beta particles of 1.70 Mev maximum energy, and with a
disintegration rate of 4.8$ per day has a half-life of 14.3 days.
This isotope has therefore physical characteristics of obvious
biological value and has been put to considerable use. It is
with this particular isotope that this thesis is concerned.
32p.5 can be produced either in the cyclotron or in the
nuclear reactor. The cyclotron method requires the bombardment
of stable phosphorus with deuterons of relatively low energy,
only the neutron entering the phosphorus atom to produce ^^P1K.Xo
When the ultimately regains stability by emitting a beta
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particle the nucleus consists of 16 protons and 16 neutrons,
32that is stable sulphur, The cyclotron was the source
of 32P1S used by Lawrence and his co-workers (1939) in the first 15
clinical studies of this isotope in medicine.
The explosion of the atom bombs over Hiroshima and 
Nagasaki in 1945 ushered in a new epoch of medical science, 
however, and isotopes of many different kinds have now become 
available in large quantities, and considerably cheaper than 
the cyclotron-produced isotopes. ^^*15 *s now Pr°dnced in the 
nuclear reactor, stable sulphur being bombarded by neutrons, 
so that becomes
thus: -
The cyclotron method of production may be symbolised 
\  + 31P15 -----» 32P15 + \
32pi5 ---- » 32S10 + f
The reactor method of production may be symbolised
1 . 32 _____v 32p 1
“0 + 16 * 15 + H1
32p ____ v 32g
15 f 16 + P
The specific activity of the radioactive phosphorus
(i.e. the ratio of 3V .  to admixed 81p,. "carrier”) is much15 15 '
higher with the reactor-prepared isotope than with the cyclotron
thus: -
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isotope. This fact is at least as important as its cheapness 
and ready availability.
Finally, the radioactivity on which the usefulness of 
this isotope depends consists of a negatively charged electron 
emitted with a maximum kinetic energy of 1.70 million electron 
volts, the average energy being approximately 0.6 Mev. The 
maximum range of these beta particles in air is about 7.05 
metres, while in tissues of unit density their average range is 
2 mms. with a maximum of 7 mms. Thus most of the ionising 
action is localised to the tissue which takes up the isotope.
Biochemical Characteristics of Radioactive Phosphorus
The metabolism of stable phosphorus was of course studied
chemically long before its radioactive isotopes were discovered.
Nevertheless, since *8 fci°ckem;i-cally indistinguishable
from all the subtleties of radioactive tracer studies15
have added greatly to our understanding of the dynamics of this 
ubiquitous element in living tissues. The literature is already 
voluminous and continues to expand.
Radiophosphorus has been used clinically both externally 
(to irradiate skin and eye lesions) and internally. The latter 
only concerns us here. Colloidal suspensions of chromic 
phosphate have been injected intravenously in leukaemic patients, 
as well as into the peritoneum and pleura. It has now been
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abandoned. Sodium and magnesium phosphate was prepared by 
Scheer (1952) as a compound for interstitial use, depending on 
its capacity to remain localised in tissues at the site of 
injection. It has no place in leukaemia therapy.
The compound with which this thesis is concerned is the 
inorganic soluble sodium phosphate, and the biochemical charac­
teristics of this compound alone will be discussed.
32Absorption and excretion. For therapeutic use the P 
is oxydised to phosphoric acid, neutralised with sodium 
hydroxide to a pH of 7.0, and administered as a mixture of 
sodium acid and basic phosphates. This may be given orally or 
intravenously. After oral administration in the normal subject 
about 75^ of the given dose is absorbed, the remainder appearing 
in the faeces. Renal excretion is rapid, being the main route 
of elimination, and up to 50J& of an absorbed oral or intra­
venous dose is excreted in the urine during the first 4 to 6 
days. Thereafter excretion falls to less than Yfo of the 
administered dose per day (Goodman and Gilman, 1955), In 
leukaemic patients urinary excretion may be reduced, as it is 
also in polycythaemia vera,
The combination of radioactive decay and excretion 
results in a radiobiological half life of about eleven days, 
according to measurements made by Easson, Mackenzie and Jones
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(1952, unpublished). This is in agreement with the findings 
of Mitchell (l95l), though Osgood (1956) would disagree in some 
details.
Distribution. Phosphorus is a constituent of all cells and 
tissues, and its metabolic pathways are consequently extremely 
complex. A phosphate radical taken up from the food may 
participate in the phosphorylation of glucose in the intestinal 
mucosa; it may instead enter the circulation as free phosphate 
where it may then enter a red cell and become incorporated into 
an adenosine phosphoric acid molecule and participate in 
glycolytic processes within the cell, later appearing in the 
plasma. From the plasma it may return to the liver to take 
part there in the formation of a phospholipid molecule which in 
turn may be carried in the circulation to the spleen or other 
organs to be incorporated into a leukocyte. Alternatively, 
the phosphate radical may pass directly into the skeleton from 
the plasma. Such are the dynamics of metabolic processes that 
the phosphate radical may return again to the circulation, 
after following any of its possible paths, and participate in 
the formation of nucleoproteins, desoxyribose nucleic acid, or 
other products of intermediate metabolism.
The above outline of possible metabolic pathways was 




























The differential uptake of phosphorus by cells depends 
on at least three factors: (i) the total amount of phosphorus
in exchangeable form in the tissue being studied, (2) the rate 
of turnover of phosphorus by that tissue, and (3) the rate at 
which new tissue is being formed.
For example, the total amount of inorganic phosphorus in 
bone is high, so that eventually a large proportion of an 
administered dose of phosphorus will find its way there. The 
effect of the rate of turnover of phosphorus is exemplified by 
liver and brain tissues. Both organs have approximately the 
same phosphorus content, but the higher rate of turnover by liver 
leads to a much greater uptake of radiophosphorus by the liver 
than by the brain. The third factor is exemplified by the 
higher rate of uptake of radioactive phosphorus by neoplastic 
tissue as compared with the same tissue when growing normally. 
This fact is so marked in the case of certain brain tumours that 
localisation of a tumour is possible because of the relatively 
high differential uptake of radiophosphorus. (Morley and 
Jefferson, 1952; Selverstone et al., 1949).
A vast literature now exists on the subject of phosphorus
uptake by various tissues, both human and animal, and the
accumulated findings clearly indicate the preferential uptake 




















RATE OF ABSORPTION FROM BLOOD INTO ASCITIC FLUID OF 
RADIOACTIVE PHOSPHORUS
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RATE OF ABSORPTION FROM PERITONEAL ASCITIC FLUID OF 
RADIOACTIVE PHOSPHORUS
32Rate of transfer of P from ascitic fluid into blood
Figure 12.
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as leukaemia Is concerned, it has been shown by Kenny at al.
(l94l), Reinhard et al. (1946), Warren (1943), and many others,
32that P is absorbed most actively into the liver, Spleen, 
lymph nodes, bone marrow and kidney. Low-Beer (loc. cit.)
points out that the longer the interval between administration
32 32of P and death the greater is the concentration of P in
bone, though Osgood (1956) emphasises that in human adults this
deposition is so slow relative to radioactive decay "that
progressive accumulation does not occur even in patients who have
been treated for years".
In leukaemic patients, during the first 48 hours after
32 32administration of P , the red cells contain more P than the
leukocytes. Within nine or ten days, however, the leukocytes
32contain four or five times the amount of P in erythrocytes,
32and this is even higher if the P is given intravenously.
Low-Beer has also shown (Figures 11 and 12) that though
32phosphorus is mainly a cellular metabolite, P administered
intravenously can be detected in ascitic fluid as soon as five
minutes after injection, and equilibrium between blood and
ascitic fluid is reached within 30 minutes. Diffusion in the
32opposite direction has also been demonstrated, and P injected 
intraperitoneally appears in the blood within five minutes, 
though equilibrium in this case takes about 60 minutes. The
same author reports similar diffusion of rad i o phos phorus 
between blood and pleural effusions. The absence of selective 
concentration in tissue fluids is important, and demonstrates 
the futility of treating metastatic carcinoma in these regions 
with soluble P^.
The Biological Effects of Radioactive Phosphorus
32The histological changes produced by P are due to its 
beta radiation. These changes would not be expected to differ 
significantly from those observed after irradiation with x- or 
gamma rays. Platt (1947) has described in detail the histo­
logical appearances in 43 patients suffering from various reticu-
32loses, all of whom were treated with P before death. The
tissues of patients dying of similar diseases but not treated 
32with P were used as controls.
The histological changes described by Platt may be 
summarised as showing:- varying degrees of cellular disinte­
gration; abnormal mitoses producing giant irregular nuclei; 
generalised tissue fibrosis; hyalinisation of collagen; 
vascular changes characterised by thickening and hyalinisation 
of small blood vessels. The most extensive changes were noted 
in bone marrow, spleen and lymph nodes, as would be expected 
from the high selective uptake of phosphorus by these tissues - 
a fact which explains the striking effect of therapeutic dosage
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onof P in leukaemia. Changes of a lesser degree were also
observed, however, in kidneys, longs, gastro-intestinal tract,
ovaries and testes.
A hitherto nnreported finding, which may well be an 
32important effect of P on the bone marrow, has been described
by Dr. Helen Bussell. This is a curious bright red colour of
the marrow throughout the length of the femur, instead of the 
usual fatty yellow-grey colour seen in untreated leukaemia. 
Microscopically it resembles the naked eye picture of the 
megaloblastic marrow of pernicious anaemia, but histological 
examination shows that the colour is due to wide vascular 
spaces with haemorrhagic degeneration and capillary stasis.
This picture is reminiscent of the effects of lethal whole-body 
irradiation as seen for example in the bone marrow of monkeys 
irradiated to LD 50 levels with x-rays. The similarity between 
these two marrow pictures is sufficiently striking to call for 
more detailed study. It is of interest that such a dis­
organised marrow has been seen as soon as three weeks after a 
32dose of V (C ase E ll), and as long as 160 weeks after the 
32start of P therapy (Case M 14). In the latter case a total
32quantity of 40 mcs« of P had been given, while in the former 
only 6.0 mcs. had been given. It is not easy, therefore, to
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see any immediate explanation for this marrow effect, though 
it has not been observed in patients treated by other methods 
at this hospital.
SECTION IV
Author's Experience with Badiophosphorus
(i) Evolution of a Dosage System
(ii) Prediction Method of Dosimetry
- 102 -
Evolution of a Dosage System for Radioactive Phosphorus
Therapy
Before discussing dosage of radiation or techniques of 
treatment it must he re-emphasised that, short of actual cure, 
the object of any therapeutic regimen is to improve the well­
being of the patient. This general improvement of the patient 
(as will be shown later) is closely concerned with the improve- 
ment in his anaemia, though the reduction in size of an uncom­
fortably large spleen or of lymph nodes must also contribute to 
the general subjective improvement. Nevertheless, during a 
course of anti-leukaemic treatment, whether by chemotherapeutic 
or radiotherapeutic means, what the clinician requires is some 
guide to the patient’s response. Shrinkage of the spleen is 
too slow and coarse a criterion for control of dosage, and in 
practice the white cell count has become the usual index of 
effectiveness of treatment - at least in the earlier phases of 
a course of treatment. As the treatment progresses, the 
response of the red blood count and platelets, splenic resolution, 
and improvement in general health all provide further valuable 
guides. Experience shows that in the favourable case the red 
cell count rises towards normality pari passu with the falling
white cell count. This improvement in anaemia is also closely
/
linked with the response of the spleen, the type of leukaemia
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and the stage of the disease. The treatment of chronic 
leukaemia may, however, he regarded as effective when, provided 
none of the contraindications to treatment have meanwhile arisen, 
the total white cell count falls sufficiently far to permit 
these favourable concomitant changes to take place.
The literature on the use of radioactive phosphorus for 
chronic leukaemia is now extensive hut there is still consider­
able difference of opinion as to the therapeutic problems
imposed by variations in the sensitivity to irradiation.
32P was first used in the treatment of leukaemia by Lawrence
in 1937 and since then interest has grown in the many possible
methods of dosage. Lawrence and his co-workers (1939) began
32tentatively by giving small repeated doses of P over a period
of many weeks, carefully observing the haematological response.
This approach was essential with a new therapeutic agent,
32especially since its action, once the P had been administered, 
was a prolonged one, and could not be controlled after absorp­
tion. However, with increasing experience of the response to
32he expected from injected or ingested P it became possible to 
consider different courses of treatment and methods of fraction­
ation. Kenny (1942), Low-Beer et al. (1942), Beinhard et al. 
(1946), Hall et al. (1947), and many others described various 
approaches to this problem, but all of the methods described can 
in fact be reduced to one of the following three types:-
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32Three Possible Approaches to P Dosimetry
Figure 13,
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321. A method by which the initial dose of P is followed
at intervals of a few days by further amounts 
designed to maintain the initial activity level and 
hence the initial average dosage-rate - a maintenance 
technique. (Figure 13a).
322. A method by which a small amount of P is given
initially, followed by progressively increasing 
amounts, until a desired maximum dosage-rate is 
established and then maintained as in Method 1, - 
a crescendo technique. (Figure 13b).
3. A method somewhat similar in effect to Method 2, by
32which equal amounts of P are given at rather longer 
intervals (e.g. one week) with the effect of building 
up the dosage-rate over a period - a simple fractional 
technique. (Figure 13c).
In each of the above methods the treatment was continued until 
the total white cell count had fallen to an arbitrary level 
(usually above 20,000 per c.mm.) and thereafter no further P**̂  
was given, the residual radioactivity at that time being 
expected to depress the white count to the desired minimum 
level.
The long term programme of "titrated”, regularly spaced 
32doses of P described by Osgood et al. (1955) comes into a
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different category from the three just described, and aims: at
inducing a remission and then maintaining it by judicious 
32increments of P
If only for geographic reasons, there is no doubt that
expediency must have dictated an even greater variety of
32unpublished methods of administering P , all resulting
nevertheless in the ultimate reduction of the leukocyte count
and more or less of a clinical remission of the disease.
The author's first personal responsibility for the
management of leukaemic patients began early in 1946 when he
treated chronic leukaemia by the method of splenic irradiation,
using medium voltage x-rays (250 K.V.). In April 1949 the
32first consignment of P was received from the isotope division 
of the Atomic Energy Research Establishment at Harwell, as a 
solution of sodium phosphate. Individual injections were made 
up in 5 to 10 mils of a buffered solution, sterilised by auto- 
claving, and administered intravenously in all cases.
What might be called Phase 1 in the author's search for 
a dosage system was the tentative approach similar to that 
first used by Lawrence. A base-line experience was gained by 
giving serial low doses of 2 to 3 mcs. at intervals of one to 
three or four weeks. Having learned the sort of response to 
be expected the Phase 2 method of treatment was adopted in the
107 -
32P Dosage Table for "Diminuendo1 Technique




10 20 30 40 50 60
1
70 80 90 100
30 0.43 0.86 1.29 1.71 2.14 2.57 3.0 3.43 3.86 4.29
40 0.57 1.14 1.71 2.29 2.86 3.43 4.0 4.57 5.14 5.71
50 0.71 1.43 2.14 2.86 3.57 4.29 5.0 5.71 6.43 7.14
60 0.86 1.71 2.57 3.43 4.29 5.14 6.0 6.86 7.71 8.57
70 1.0 2.0 3.0 4.0 5.0 6.0 7.0 8.0 9.0 10.0
80 1.14 2.29 3.45 4.57 5.71 6.86 8.0 9.14 10.29 11.43
90 1.29 2.57 3.86 5.14 6.43 7.71 9.0 10.3 11.6 12.9





autumn of 1949. It was argued that as the white cell count
fell from several hundred thousand cells per c.mm. to less than
100,000, so the need for sustained radiation dosage should he
reduced. Thus a table of dosage was drawn up (Table V) partly
related to body weight and partly related to the total white
cell count. It was decided that if for example a patient
weighed 70 kilogrammes he should be given an initial dose of 
327.0 mcs. of P . This dose was to be repeated each week until 
the white cell count fell to less than 100,000 cells per c.mm. 
Then the dose was to be reduced proportionately so that if the 
patient's white cell count on the treatment date had fallen to
70.000 he would then receive 7/lOths of his initial dose. If 
the following week his count was 30,000 he then received 3/lOths 
of his initial dose. This "diminuendo" treatment seemed to 
work satisfactorily, though it is now clear that in the early 
stages of treatment the dose-rate was unnecessarily high, while 
towards the end of a course - especially if the white cell 
count fell slowly from the 100,000 level - the dose-rate became 
progressively less, being less vigorously 'topped up1 each week.
About this time a further decision was made which 
yielded interesting results. It was decided to endeavour to 
depress the white cell count to very low levels, i.e. to about
2.000 white cells per c.mm. (This decision was based partly 









CUMULATIVE INTEGRAL BODY DOSE me DESTROYED
Case M 8, showing initial exponential fall of W.B.C.Opto normal range, and resistance to further P radiation
Figure 14.
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white cell count to at least 10,000 per c.mm., and partly on
the view that since a sub-lethal dose of x-rays will cause a
temporary disappearance with subsequent recurrence of a squamous
carcinoma of e.g. the skin, perhaps a more lasting effect on
leukaemia would follow a more vigorous attempt at reducing the
white cell population to near zero. This idea has, I believe
been attempted by other workers with as little success). The
effect of this approach to treatment is illustrated in Figure 14.
As the white cell count approached normal levels the weekly
increments of dose were already diminishing too much, it seemed,
to be effective. Accordingly a substantial increment was given
in an effort to depress the white cell count still further, hut
without success. It was concluded that as the leukaemic white
cell population is reduced the 'normal' leukopoietic tissue is
32more resistant to the effects of P . Very far from agreeing
with Low-Beer, that a few hundred microcuries may exert a truly
depressive effect, the author's experience led to the conclusion
that a dose of less than 2 mcs. was of little demonstrable
value in the treatment of chronic leukaemia. Several other
workers in this field (e.g. Tubiana, 1950) have expressed
agreement with this point of view.
The above experience led to the third phase of treatment,
when it was decided to abandon the "diminuendo" approach and to



















(a) Shows WBC plotted against time - non-exponential.
32(b) Shows WBC plotted against dosage from P - exponential.
32(c) Shows log WBC plotted against dosage from P
Figure 15
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the rate of 1 me. per 10 kilos) followed at weekly intervals
by half the initial dose until the white cell count fell to
about 20,000 per c.mm. Since the radiobiological half life 
32of P in leukaemic subjects is approximately 11 days, this
Phase 3 treatment led, by its 7 day increments to a gradual
build-up of dose-rate similar to type 3 in Figure 13 (c).
This dosage method was continued until the end of 1953 when the
author and his physicist collaborators (L.A.Mackenzie and B.E.
Jones) reviewed the patients treated up till that time. It
was decided to seek any possible correlation between dose, time,
fractionation, and effects on the leukocyte count. If only
because it had never been mentioned in the literature, we were
surprised to find that in the majority of cases the relationship
32between the effect on the white cell count and the dose of P
utilised was an exponential one (Easson, Jones and Mackenzie,
1954 and 1955). It may be said that this is only to be
expected, and is a common cause/effect phenomenon with biological
material. Nevertheless, the immediate value and the clinical
implications of this finding seemed to be considerable, and the
absence of any published comment on such an ’expected finding'
was the more surprising. The interesting relationship between 
32the WBC and P dosage is seen in Figure 15. Figure 15 (a) 
shows the falling white cell count plotted against time,
Figure 15 (b) shows the effects of plotting the daily white cell
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count against the radiation dose (expressed in millicuries'- 
destroyed) while Figure 15 (c) shows the straight line obtained 
by expressing this exponential semi-logarithmically.
Definition of Radiation Dose
Before considering the implications of this finding it is
important to describe the details of the analysis.
32In assessing the response to P therapy, calculation of
the integral dose received by the body must take into account the
activity that is lost by excretion as well as radioactive decay.
32Measurements of the urinary excretion of P in humans have been
made by the author (unpublished) and many other workers (e.g.
Mitchell, 195l) . From these it may be assumed that following 
32an injection of P the activity remaining in the body falls
approximately exponentially with a half-life of about 11 days.
32Thus, after a single injection of C mcs. of P the integral body 
radiation dose (i.B.D.) will build up at an exponentially 
decreasing rate, and after T days will be proportional to
fT -Xt -1CA/ e dt, where A = (0.693/H) days , and t = time elapsed
J o
after injection.
The above expression gives the I.B.D. directly in mcs.- 
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of A /  e dt was prepared and is shown in Table VI. It can be
J 0 5shown that one me.-destroyed is equivalent to 6.21 x 10 gm-rep,
or a mean dose of 9.55 rep to a standard man of 65 kilos body
weight. Thus the I.B.D. could he expressed in gm-rep, hut it
has been found more convenient for routine calculations to use
me destroyed.
Prediction Method of Dosimetry
The first implication of practical importance which 
suggested itself was the possibility of predicting the total 
dose required for any one patient by extrapolating the straight 
line obtained early in treatment. The slope of these straight 
lines, indicating differences in individual radiosensitivity 
(vide Section V) varies from patient to patient and Figures 16 
and 17 show typical examples. Much has been written about 
the need for individualisation of treatment to meet the uncer­
tainties of response to any anti-leukaemic drug, and some early 
index of individual sensititivy would clearly be of great 
value to the clinician. Furthermore, to reduce to a minimum 
any adverse effects it would seem desirable to administer as 
little of any anti-leukaemic drug as possible, consistent with 
the induction of a satisfactory clinical and haematological 
remission. That is to say, each patient should receive the 
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Showing various levels at which WBC ceased to fall
32in spite of adequate residual radioactivity from P
Figure 18.
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fact be determined as follows:-
32(a) An initial dose of P is given.
(b) Tbe fall in the white cell count is plotted for
two weekso
(c) The M.E.D. is then predicted by extrapolating the two-
week line down to a normal range.
32(d) If any further P is indicated it is given in
suitable fractions.
With x-ray therapy, still the well-established base-line
experience, some writers consider 30,000 white cells per c.mm.
as an adequate lower level, (e.g. Burchenal et al., 1954), while
others would regard a count of 10,000 or less as conducive to
longer remissions (e.g. Levitt, 1948). This latter point of
view has in fact been held at the Christie Hospital and Holt
Radium Institute for many years. Data for 30 patients treated 
3 2with P were reviewed, and it was found (Figure 18) that 
though there was a variation in the level at which the WBC 
ceases to fall (in spite of high residual radioactivity in the 
body) only a small percentage of cases failed to fall below
20,000 and about fifty per cent of cases fell to 10,000 or less. 
Thus, since the initial straight line must be extrapolated to
32some definite lower level, the author's experience with both P 
and x-ray therapy led to the decision to adopt a lower index 
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equally possible, of course, ip predict the dose for a lowest
level of, say, 15,000 or 20,000 per c.mm,
32The M.E.D. for P for this series of cases can therefore 
he defined as that minimum integral body dose required to reduce 
the leukocyte count from its value at the commencement of 
treatment down to 10,000 per c.mm.
DETAILS OF PREDICTION METHOD.
The method of predicting the M.E.D. can best be described 
in detail by considering the typical case shown in Figure 19. 
This patient received an initial injection of 6 mcs. and 14 days 
later the most appropriate straight line was drawn through the 
known points and extrapolated to a white cell level of 10,000 
per c.mm. This gave a predicted M.E.D. of 15 mcs-destroyed.
An additional amount of 5 mcs. was given at this time and the 
continuing fall in the white count permitted a more accurate 
prediction to be made at the 24th day, the value now being 13 
mcs-destroyed. Of this 13 mcs., 11 had already been given and 
the additional 2 mcs necessary were given on the 24th day.
The points obtained subsequent to the preliminary prediction (o) 
show the close agreement between the estimated and the actual 
fall in the white cell count.
The values of the I.B.D. were calculated from Table VI. 
Thus, during the 14 days after the initial injection of 6.0 mcs.
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the I.B.D. delivered was 6.0 x 0.59 = 3.5 mcs-destroyed. " The 
activity remaining on the 14th day was therefore 2.5 mcs. and 
this was raised to 7.5 mcs. by the second injection of 5 mcs.
The I.B.D. from this 7.5 mcs. from the 14th to the 24th day 
(ten days) was 7.5 x 0.47 = 3.5 mcs.-destroyed. Thus the total 
I.B.D. by the 24th day was 3.5 + 3.5 = 7.0 mcs.-destroyed. An 
alternative method of calculation is to summate the doses 
delivered by each injection separately, but for a series of 
injections the method described above is simpler.
When the predicted M.E.D. is more than 12 mcs., the 
second injection should not exceed 6 mcs. and the continuing 
fall in the white cell count permits, by successive approxi­
mations, a more accurate final prediction. In the case of a 
second course of treatment, information about the patient's 
response to the first may be a guide to the value of the initial 
injection.
It is interesting to note that the exponential relation­
ship between the white cell count and I.B.D. held (with some 
exceptions shortly to be described) for all the treatment methods 
described above - i.e. Phases 1, 2 and 3. In addition, data 
have been examined from a further six unselected courses of 
treatment carried out at other centres (Low-Beer et al., 1942; 

















Histogram showing range of M.E.D. for chronic 
myeloid and lymphatic leukaemia.
Figure 20.
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the same characteristic response, despite the use of treatment 
systems differing in detail from the author's. It is obvious, 
therefore, that this exponential relationship holds over a con­
siderable range of dosage-rates - as much as a factor of ten in
32any one patient - so that the effect of P on the leukopoietic
tissue is also independent of dose-rate over a wide range.
The histogram shown in Figure 20 demonstrates the
variation in minimum effective dosage for this series of patients.
This further underlines the fact that there can he no universally
32fixed dose approach to P therapy for leukaemia. Nevertheless, 
Figure 20 does show that an initial injection of 6 mcs. to all 
patients, regardless of differences in body weight, will depress 
the white cell count sufficiently for a satisfactory prediction 
of the M.E.D. to he made after 14 days. This quantity might in 
fact he in excess of the M.E.D. in a small percentage of cases, 
hut the experience embodied in Figure 14 suggests that such 
excess carries no risk.
Exceptions
32Of the sixty patients treated by P , twelve failed to 
show the regular exponential relationship described above. 
Exceptions to any rule deserve special analysis, and these have 
been separated in Section VI under the code letter E (l to 12).
One of these patients (E 2) had three completed courses
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32of P therapy, and thrice showed no exponential response, though
good remissions were achieved, and indeed further remissions by
32splenic x-ray therapy followed the third P treatment. Another
exception, (e 12), failed to show a regular response, no reason
for this was apparent, and her overall response to treatment
cannot be considered to have been favourable. Case E 5 also
failed to respond exponentially, though in fact there was
scarcely any response in the white cell count at all. An
excellent remission was, however, obtained in this case by splenic
x-ray therapy. A further exception was Case E 7. He responded 
32irregularly to P , he also failed to derive much benefit from
this treatment, and died 6 months later.
In none of the four patients just described was there any
apparent reason for their failure to respond like the majority.
Of the remaining eight patients in this group of twelve
exceptions there did seem to be a possible contributory feature.
Two patients, E 8 and E 9, were given substantial blood trans-
32fusions before their initial dose of P , and the absence of an 
exponential fall in the white cell count could reasonably be 
explained on the basis of a mixed population of cells in the 
peripheral blood. Cases E 4 and E 10 were at least Subacute, 
and in retrospect would have been better managed by blood trans­
fusion rather than anti-mitotic agents of any kind. Case E 3 
was also ill at the time of treatment, and developed pneumonia
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early in the course of treatment. It is probable that this
microbic infection would also produce a mixed white cell pupulation,
leukaemic and "infective", so that differing average life-spans
of white cells could account for this exceptional case. Two
more cases, E 1 and E 11, died three weeks after the start of 
32P therapy, the first of these when his white cell count was 
only just beginning to show some response. The last patient in 
this group, E 6, was another whose whole behaviour suggested a 
subacute, and consequently unfavourable phase of leukaemia.
Conclusions
Consideration of the exceptions quoted above would
suggest that a regular exponential relationship may be expected
between the falling white cell count and the integral body 
32dosage from P in the vast majority of cases (at least 55 out 
of 60), provided they are carefully selected. Thus, if this 
prediction method of dosimetry is to be employed, with the object 
of administering the Minimum Effective Dosage, care must be taken 
to avoid those patients whose initial haemoglobin level is such 
that blood transfusion is a necessary first step to treatment.
Any suggestions of a change towards a subacute phase of the 
disease - suggested by mucosal bleeding, pyrexia, splenic pain, 
increase of blast cells, rapidly falling platelet or haemoglobin 
levels, or simply poor general health - would also justify the
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avoidance of this approach to dosimetry, or indeed to any form
of antimitotic therapy. With this careful selection of
patients, accurate predictions of the Minimum Effective Dose
can be made in over 90J6 of cases.
It has been said that a non-exponential response does
not necessarily herald a poor remission, and it would be wrong
to suppose also that a regular exponential response in the
white cell count will guarantee a good remission. Five patients
who responded exponentially (Cases M5, M24, L3, L 7  and L 14)
all died within three months of treatment. In all of these
cases there were features which might well have indicated that 
32P should be avoided (See Section VT), though it is this very 
problem of the uncertainty of the leukaemic patient’s response to 
treatment that makes some early index of individual sensitivity 
so necessary.
32Most of the patients whose white cell response to P
was exponential did enjoy a satisfactory remission of their
leukaemia. Following recurrence of symptons, 15 patients have
32so far received a second course of P , and of these seven have 
had a third, and one a fourth course. From this limited group 
the response of the white cell count to second and third 
treatments is remarkably similar to the first. Though the 
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32in sensitivity with each repeated course of P . Figure 21
shows the responses of a typical patient to three successive
courses of treatment. This latter finding is surprising since
most workers in this field would expect leukaemic patients to
become increasingly refractory. The truth of this finding lies,
I believe, in the fact that leukopoietic sensitivity has not
hitherto been expressed quantitatively, and this specific cell-
sensitivity is not synonymous with the term "refractoriness".
The latter term rather connotes the combination of clinical and
haematological responses which are collectively concerned in the
induction of a remission.
It is obvious, of course, that satisfactory remissions
can be obtained in leukaemia by any of the more tentative
approaches to dosimetry, but since adopting the prediction
32method described above, the average dose of P required to 
induce a remission has been reduced by nearly 4 mcs per patient. 
Naturally, only a long term study will tell whether this method 
of treatment will give the best remissions, but it certainly does 
provide an accurate method of reducing the white cell count to 
the desired low level with the minimum of treatment. As 
already stated, it would seem reasonable to suppose that there 
is an advantage in giving no more of any potentially harmful 
drug than is therapeutically necessary. The search for optimum
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dosage must continue, and only time will tell whether the 
32M.E.D. of P , using an index point of 10,000 white cells per 
c.mm., is more or less than the optimum dose for chronic 
leukaemia.
The fact that repeated courses of treatment can he 
expected to follow a pattern similar to the first presents an 
opportunity for the comparison and measurement of the effects 
of adjuvant forms of therapy and of radiation protective 
Substances. This study has not yet been made by the author, 
though the next section of this thesis is concerned with the 
quantitative study of radio.SenSitivity made possible by this 
exponential phenomenon.
SECTION V.
Author*g Experience with RadiophoBphorus:
A Quantitative Study of Radiosensitivity.
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A QUANTITATIVE STUDY OP RADIOSENSITIVITY TO P32.
Apart from its therapeutic applications the exponential 
32relationship between P dosage and white cell response has 
several heuristic possibilities already mentioned. This 
section is concerned with a study of individual variations in 
leukopoietic radiosensitivity.
The slope of the graph, expressing the rate of fall of 
the white cell count in response to each millicurie utilised, 
is an index of the sensitivity for that patient. The slope may 
be expressed in various ways. It could, for example, be 
expressed simply in degrees, or as the tangent of the angle of 
slope. Alternatively, being exponential, the relationship 
between the initial white cell count and the count in response 
to a given dose of P32 is found from the equation CQ = CLe”^u X
where is the initial white cell count, d is the dose required 
to depress that count to the level Cg, and k is the sensitivity 
constant for that patient. A simpler expression, however, is 
the Half Value Dose, which may be defined as that integral body 
dose (ibd) which will reduce the white cell count to 50j£ of its 
pretreatment level. The Half Value Dose (HVD) is related to 
the sensitivity constant k by the equation k = 0.693/HVD, and 
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Histogram Showing Range of H.V.D.s for Chronic 
Myeloid and Lymphatic Leukaemia.
Figure 22.
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convenient method of measuring sensitivity. As with the 
Minimum Effective Dose discussed in the preceding section, the 
HVD could he expressed in gram-reps, gram-roentgens or rads, 
hut there is no advantage in so doing.
The HVD is clearly related to radiosensitivity in that
the lower the value the greater the sensitivity and vice versa.
Figure 22 shows the wide range in the sensitivity of the different
patients in this series. It is of particular interest to note
that the sensitivity of white cells in chronic lymphatic 
32leukaemia to P therapy, when compared hy this quantitative 
method, seems to he remarkably similar to those in the myeloid 
variety of the disease. Most radiotherapists familiar with 
the more conventional x-ray methods of treating leukaemia might 
have expected a significantly greater sensitivity in the 
lymphatic type. This finding prohahly indicates once more that 
a different mechanism operates with these two methods of treat­
ment, even though ionising radiation is heing employed in hoth 
cases.
The HVD is, therefore, a quantitative expression of each 
patient's white cell sensitivity, and this heing so, treated 
cases of leukaemia can he arranged in order of the radio- 
uensitivity of their leukopoietic tissue hy tabulating their 
HVDs. It then becomes possible to look for correlations between
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leukopoietic sensitivity and various clinical and haematological 
data. In fact, it now "becomes possible, on a quantitative 
basis, to seek the factor or factors on which the in vivo radio- 
sensitivity of human white cells depend.
Material
The cases analysed consist of 27 patients with chronic 
myeloid and 21 with chronic lymphatic leukaemia. To avoid
32extraneous factors which might influence their response to P 
these cases were selected in that none had been previously treated 
in any way, and this study is concerned with the first 
remission of their disease.
Having tabulated the HVDs for all patients in order of 
decreasing leukopoietic sensitivity, details were also tabulated 
(Tables VII and VIIl) of those factors believed to reflect in 
some degree the activity of the underlying disease process.
General health, degree of anaemia, immature white cells, size 
of spleen and lymph nodes, age, sex, duration of remission - all 
have been tested, but in no case has any correlation with white 
cell sensitivity been demonstrated.
Discussion and Results
That sex might influence the response to treatment of 
malignant disease had not been fully appreciated until Bussell's
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C h r o n ic  m y e l o id  l e u k a e m ia
1 2 3 4 5 6 7 8 9 10 11 12 13 14
1 F 74 100 25 150 68 14 0 0 1 44 30 4-3 0-55
2 M 64 21 20 224 66 28 1 0 1 75 55 10-9 11
3 F 64 3-0 25 185 45 43 4 1 2 34 55 21-9 1-9
4 F 62 7-5 27 80 65 23 3 0 2 72 57 10-5 2-2
5 F 45 6-5 39 70 62 2 2 2 0 7i* 67 140 2-2
6 F 54 2-0 60 280 58 40 3 0 1 42 66 19-2 2-2
7 M 61 1-5 27 130 65 33 3 1 2 46* 68 12-7 2-2
8 M 52 1 0 38 200 65 29 2 0 2 23* 52 25-5 2-3
9 F 59 3-0 32 457 68 32 2 0 2 51 46 150 2-3
. 10 F . 62 5-0 32 150 62 24 2 1 2 52 59 12-6 2-4
11 F 32 10-0 38 250 48 64 2 0 2 55 48 18-1 2-5
12 F 69 0 4 33 80 22 2 0 1 5 i yrs 49 1 00 2-6
13 F 65 0 10 76 56 56 3 2 2 32 36 17-5 2-7
14 M 50 1 0 55 300 56 66 3 0 1 160 64 27-6 2-9
15 M 72 2-5 24 340 40 50 3 1 1 39* 67 21-6 2-9
16 F 56 1 0 53 440 48 34 4 2 1 23 54 290 3-1
17 F 64 2 0 51 510 58 34 3 1 2 58* 55 22-4 3-2
18 F 61 1 0 7-5 90 80 16 3 3 1 79* 40 120 3-2
19 M 56 1 0 19 320 62 38 3 0 2 56 70 17-0 3-5
20 F 25 1 0 37 260 58 34 3 0 2 61 60 25-5 3-6
21 F 58 1-5 28 140 65 17 4 3 1 121* 54 18-9 4-5
22 F 31 1 0 38 200 68 59 3 0 2 62 51 20 0 4-5
23 F 64 2 0 11 31 63 63 3 1 2 128 51 12-5 4-6
24 M 72 1 0 12 100 26 4 1 0 4* 12-6 5-0
25 M 46 0-5 32 300 46 34 4 1 2 14* 60 27 0 5-2
26 F 41 0-2 5 460 62 28 3 1 2 27 62 22-5 5-5
27 F 12 4 0 78 590 44 38 4 3 2 23 12-6 8-4
C olum n 1. 
Colum n 2. 
Colum n 3. 
Colum n 4. 
Colum n 5. 
Colum n 6. 
Colum n 7. 
C olum n 8.
Colum n 9. 
Colum n 10.
C olum n 11. 
C olum n 12. 
Colum n 13. 
Colum n 14.
Sex o f patient 
Age
Initial percentage o f myeloblasts.
Initial percentage of all im m ature cells of granular series.
Initial W .B.C . in thousands per c.mm.
Initial haem oglobin level.
Percentage im provem ent in haem oglobin level.
Spleen size before treatm ent: 0 =  not palpable.
1 = ju s t  palpable 
2= en larged  to near umbilicus.
3 =  enlarged to iliac crest.
4 =  gross enlargem ent to right.
M axim um  dim inution o f splenom egaly during  first remission— 0 to 4.
G eneral condition after treatm ent— i.e. before second treatm ent o r death: 0 = n o t  improved, o r worse.
1 =  improved.
2 = distinctly im proved.
T im e in weeks to second treatm ent (or death— marked thus*).
Body weight in kilogrammes.
T o tal quantity  of a,P  adm inistered during first treatm ent.
Half-value dose in millicuries destroyed.
Table VII
- 136 -
C h r o n ic  l y m p h a t ic  l e u k a e m i a
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
1 M 69 L 12-5 56 66 14 1 0 1 1 2 57* 63 10 0-9
2 F 43 S 31 144 84 18 2 1 1 0 2 64 45 6-4 11
3 F 51 S 7-5 70 76 8 - 1 1 0 10* 74 12 1-3
4 M 55 s 3 0 100 66 24 0 - 1 1 2 100 56 11-5 1-4
5 M 53 BSL 0-5 500 68 34 2 1 2 2 2 74 59 14-5 1-4
6 M 66 BSL 0-5 570 59 34 2 2 2 1 1 38J 12 2 0
7 M 49 S 3-0 210 70 0 0 0 0 0 0 1* 5 20
8 M 56 BS 4-5 165 84 20 1 0 1 0 1 113. 71 20 . 2-3
9 M 67 S 3-5 100 60 28 3 2 1 0 2 156 49 12-5 2-3
10 M 62 s 1-0 96 84 22 2 2 1 0 2 107t 68 9-7 2-5
11 M 62 s 3 0 266 58 70 2 0 1 0 2 119J 57 17-1 2-7
12 M 61 SL 1 0 934 66 28 1 0 2 1 1 60J 18 2-7
13 M 46 BS 4-5 196 90 8 2 0 2 1 0 78 67 14 2-8
14 M 27 BSL 100 17 52 10 1 1 0 0 0 11* 63 9 3-3
IS F 58 S 4 0 167 68 0 2 0 2 0 0 17* 59 16-5 3-3
16 F 62 SL 0-5 680 60 36 1 0 1 1 2 38J 5 +  
X R T
4-0
17 M 52 S 4 0 178 98 6 1 0 2 1 2 79 76 20 4-7
18 M 55 BS 1-5 230 72 0 1 1 1 1 0 17* 66 17-8 6-4
19 M 71 S 3 0 260 74 10 2 1 2 1 1 112 68 20 7-2
20 M 69 BSL 3-5 300 52 32 4 0 2 0 2 180 63 40-6 7-7
21 M 67 SL 3-5 127 96 0 1 1 1 1 1 18* 70 18 1 5 0
Sex o f patient.
Age.
Presence o f im m ature  cells o f lym phoid series: B =  blast cells present.
S =  smear cells present.
L  =  large lymphocytes present.
Percentage o f polymorphs in in itia l W .B .C . (i.e. rem ainder =  lym phocyte series).
In itia l W .B .C . in  thousands per c .m m .
In itia l haemoglobin level.
Percentage im provem ent in  haemoglobin level.
Spleen size before treatm ent: 0 to 4 as in  T a b le  I .
M a x im u m  d im inution o f splenomegaly during first remission (0  to 4).
L ym p h  nodes before treatm ent: 0 =  none palpable.
1 =  small nodes.
2 =  florid enlargement.
L y m p h  nodes after treatm ent: 0 to 2, as above.
General condition after treatm ent— i.e. before second treatm ent or death. 0  to 2 as in  T a b le  I. 
T im e  in weeks to second treatm ent (o r death, m arked thus * ) .
Body weight in  kilogrammes.
LOium n io . .T o ta l quantity  o f S2P adm inistered during first treatm ent.
C olum n 16. H alf-va lu e  dose in  m illicuries destroyed.
J indicates remission continuing at tim e o f analysis.
C olum n 1. 
C olum n 2. 
C olum n 3.
C olum n 4. 
C olum n 5. 
C olum n 6. 
C olum n 7. 
C olum n 8. 
C olum n  
C olum n 10.
C olum n 11. 
C olum n 12. 
C olum n 13. 




analysis (1954) showed clearly that females had a more favourable 
prognosis, other things being equal, than did males with the 
same types of cancer. With this in mind the sex of this series
of patients has been tabulated, but it will be seen from Tables 
VII and VIII that in neither the myeloid nor the lymphatic form 
of the disease is there any correlation between sex and radio­
sensitivity of the leukopoietic marrow.
Age, so well known as a factor in the simple anaemias,
might also have been expected to have some influence on the
32sensitivity of the marrow to radiation from P , but no 
association with white cell sensitivity is demonstrated.
Immature cells appear in large numbers in the blood of 
acute leukaemic patients and it is well established that the 
irradiation of such patients makes matters worse rather than 
better. This fact has perhaps led to the belief that with 
chronic leukaemia the greater the number of immature cells in 
the peripheral blood the more sensitive the response to radiation. 
So far as available data would permit, this question has been 
tested by tabulating the percentage of blast cells and also the 
percentage of all primitive white cells in the peripheral blood 
(columns 3 and 4, Table VIl) . In the case of lymphatic 
leukaemia it was not possible to record actual numbers of 
primitive cells, but the presence of blast cells, smear cells, 
and large immature lymphocytes was noted and has been recorded
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in table VIII as "B", HS", or MLM, singly or in combination. 
Again it will be noted that there is no clear correlation 
between the radiosensitivity of the leukopoietic tissue and the 
degree of shift to the left.
The initial white cell count, being very high in some 
cases and relatively low in others, might be considered to give 
some indication of the activity of the disease and to show some 
relationship to white cell sensitivity. No correlation is 
apparent.
The anaemia of chronic leukaemia is still not adequately 
explained, but whatever its cause, its degree might reasonably 
be considered some index of the extent of the underlying 
leukaemia. The initial haemoglobin level in each case has been 
recorded and so also has the improvement in the haemoglobin 
level at its maximum during the first remission. The latter 
might be considered a good indication of the marrow's capacity 
to respond to treatment, an index of marrow depression. The 
radiosensitivity of the leukopoietic tissue shows no correlation 
to these erythropoietic data.
The size of the spleen may be of importance, providing a
reservoir of cells or a source of delay in the general 
32diffusion of P It is not easy to describe and compare the
size of the spleen, but for quantitative purposes an effort has
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been made to assign a value to each patient’s spleen. Neither 
the initial splenomegaly (Column 8) nor the degree of splenic 
resolution after treatment (Column 9) shows any clear 
correlation to white cell sensitivity.
Lymph node enlargement in chronic lymphatic leukaemia 
varies with different patients from generalised florid lymph- 
adenopathy to impalpable nodes. Tabulation of the initial 
size of the lymph nodes and also of their resolution in response 
to treatment, reveals no correlation to the lymphocyte 
Sensitivity.
The general condition of the patient is all-important.
The main object of treatment is to improve the sense of well­
being, to remove symptoms due to a high white cell count and low 
haemoglobin, and the uncomfortable size of the spleen and lymph 
nodes. It is reasonable, therefore, to look for some 
correlation between the quality of a patient’s remission and 
the radio-sensitivity of his leukopoietic marrow. No such 
relationship is apparent.
The duration of remissions (as measured between times of
treatments) is also found to bear no relation to the white cell 
32response to P
The body weight will be seen to bear no relationship to
32the HVD, nor, indeed, does the total quantity of P necessary
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to induce a remission. Since the marrow is considered the 
"target tissue" in such cases, this lack of correlation is 
interesting when considered in the light of Osgood’s confirm­
ation (1954) of earlier anatomical measurements showing the 
remarkably constant ratio between total marrow mass and body 
weight.
So far, consideration has been given only to leukopoietic 
sensitivity and potentially related factors. It is interesting 
to consider whether any correlation can be seen between the 
other data presented in Tables VII and VIII. For example, it 
is usually believed that the improvement in a leukaemic patient’s 
general condition is more dependent on the improvement in his 
haemoglobin level than on anything else, and this view is 
clearly confirmed by correlation studies on the appropriate 
columns in Tables VII and VIII. Similarly, a positive 
correlation can be seen between the degree of splenic resolution 
and the percentage improvement in haemoglobin level.
Conclusions
So far as the available haematological and clinical data 
would permit, it has been demonstrated that no correlation 
exists between the radiosensitivity of the white cell count and 
a variety of data which are commonly considered to reflect the 
activity of the leukaemic process. This study would seem to
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suggest that the leukaemic white cells, or the leukopoietic 
marrow from which they arise, respond to radioactive phosphorus 
therapy with a sensitivity which hears no relationship to the 
underlying disease process. In other words, the prognosis in 
any case, both in terms of the quality of a remission and the 
duration of survival, bears no relationship to intrinsic white 
cell sensitivity.
On what then does the sensitivity of leukopoietic tissue 
depend? The effects of oxygen on the radiosensitivity of 
various biological materials have been known since 1921 and were 
recently reviewed by Bacq and Alexander (1955). Many protec­
tive agents are also known whose presence before irradiation 
will reduce the damaging effects of ionisation. The potentiating 
effects of Synkavit have been described by Mitchell (1953) and 
are of great interest. Nevertheless, none of these agents can 
be said to explain the leukopoietic sensitivity with which we are 
here concerned. Indeed the wide variations seen in different 
animal and insect species in response to whole body irradiation 
are likewise impossible to explain by these known factors (Bacq 
and Alexander, loc. cit.).
It seems probable that differences in mean life-span of 
leukocytes might explain the differences in HVDs in this series 
of cases, and this might be worth further investigation.
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However, the next problem to arise would be to discover what 
factors influenced variations in leukocyte life-spanj The 
work of Leonard and Wilkinson (1955) suggests that the differ­
ence between the sensitivity of leukocytes to colchicine in 
myelosclerosis and in myeloid leukaemia might be related to the 
phosphatase content of the granulocytes. It was hoped that a
quantitative approach to this histochemical abnormality might
32be informative when compared with HDVs of P , but unfortunately 
the small differences in alkaline phosphatase likely to be 
found in different leukaemic patients could not be expected to 
be measurable, by present techniques, within the limits of 
experimental error.
Perhaps some of the many other known changes described 
in the section on clinical pathology (Section i) would be 
worth testing.
SECTION VI. 
Summaries of Case Histories
M 1 to 27, 
L 1 to 21, 





SUMMARIES OF CASE HISTORIES
The serial numbers of the patients described in this 
thesis have been made to conform to the numbers in Tables VTI 
and VIII. Since these tables are two of the main tables in 
this study, it seemed best to adhere to the serial numbers used 
therein. The sixty treated cases have therefore been divided 
into three groups under the code letters, M, L or E. The 27 
cases of myeloid leukaemia are first described (M 1 to M 27), 
followed by the lymphatic cases (L 1 to L 2l) . The remaining 
12 patients, as already shown, were exceptional in showing non­
exponential relationship between their falling white cell
32count and the IBD from P . These cases are described in the 
third group (E 1 to E 12).
None of these patients had received any known anti- 
leukaemic treatment before admission to the Christie Hospital, 
and unless utherwise stated, none received blood transfusion 
before or during treatment.
All blood-counting at the Christie Hospital was carried 
out by one technician for each patient, as far as possible, and 
always at approximately the same time of day - between 9 and 
11 a.m. All cell-counts and haemoglobin estimations were done 
on capillary blood obtained by finger—puncture. Haldane’s
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method was used for haemoglobin measurement, the technique 
being checked against a Medical Research Council standard every 
three months. Two hundred white cells were counted for 
differential purposes.
Case M 1.
Miss G.P. aged 74, weight 30 kilos, became rapidly weak
in May 1951. She was referred to Park Hospital in November
1951 and extensively investigated. In April 1952 her Hb was
76$ and white cell count was 28,800 per c.mm. Sternal marrow
suggested "early leukaemia". She was finally referred to the
Christie Hospital on 10.6.52 by which time the Hb was 68$ and
the WBC 150,000 per c.mm. The differential count showed 10$
myeloblasts and 25$ total primitive white cells. The spleen
and liver were not palpable, there was no lymphadenopathy, no
petechiae or ecchymoses. The sternal marrow confirmed the
hyperplasia of myeloid cells, and active erythropoiesis. On
3216.6.52 a single dose of 4.3 mcs. of P was given intra­
venously and the WBC fell exponentially with a HVD of only 0.55 
mes.-destroyed. By 2.7.52 the WBC was 8,200 and Hb 72$. The 
Hb rose to a maximum of 82$ on 6.10.52 by which date the WBC 
had also increased to 73,000 per c.mm. During this period 
the general weakness improved significantly and she gained 
several pounds in weight. However, by 22.4.53 the Hb was 56$,
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32the WBC 142,000 and a further 6.4 mcs. of P were given. The 
WBC again fell exponentially with a HVD of 0.7 mcs.-destroyed, 
the Hb rose to 70$ by 20.7.53 but the WBC by that time had again 
risen to 77,000 after being only 11,000 on 6.5.53. The spleen 
and liver remained impalpable all this time. By 24.9.53 a 
further injection of 6.3 mcs. was necessary, the WBC again falling 
exponentially with a HVD of 0.6 mcs.-destroyed. The Hb rose 
from 64$ to 88$ on 28.12.56 and the general condition improved 
remarkably. The final treatment was given on 17.8.54 (2 mcs.) 
and 31.8.54 (3 mcs.) but on this occasion the WBC fell less ex­
ponentially though with a HVD of about 0.6 mcs.-destroyed. On 
this occasion the Hb fell slowly from 60$ and suddenly collapsed 
on 3.1.55 to 18$. The WBC on this date was 125,000, the spleen 
became grossly enlarged and the patient died on 11.1.55.
32It is of interest that this patient’s four courses of P 
therapy showed HVDs of 0.55, 0.70, 0.60 and 0.60 mcs.-destroyed. 
Case M 2
Mr. J.T.H., aged 64, weight 55 kilos, developed a 
corneal ulcer in June 1952, and investigation in Burnley 
Hospital disclosed a leukaemic blood picture. He was referred 
to the Christie Hospital on 31.8.52 and by that time his Hb 
was 66$, platelets plentiful, and WBC 224,000 per c.mm., 2.1$ 
being myeloblasts and 20$ immature granulocytes of all types. 
Sternal marrow confirmed myeloid leukaemia with active
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erythropoiesis. There were no haemorrhagic features, and no
lymphadenopathy. On 2.9.52 an intravenous dose of 7,9 mcs.
32of P was given. The white cell count fell exponentially
with a HVD of 1,1 mcs.-destroyed, and on 17.9.52 a second dose
of 3,0 mcs, was given. The WBC fell to a lowest level of
9,300 by 24.9.52, the Hb on that date being 78$. The Hb rose
to a maximum of 94$ by 9.3.53, the WBC by that date having
risen to 16,700 per c.mm. The spleen was just palpable before
treatment and was impalpable by 20.10.52. The patient's general
health improved rapidly during treatment but began to deteriorate
32as did the blood picture, until further P therapy was
instituted on 29.1.54, i.e. 75 weeks after his first treatment.
The Hb had fallen to 74$ and the WBC had reached 170,000 per
c.mm. 6.0 mcs. were given on 20.1.54 and 3.0 mcs. on 26.2.54,
the HVD on this occasion being 1.2 mcs.-destroyed. Again the
Hb rose, this time to a maximum of 106$ by August 1954, though
the WBC had not fallen as "predicted" to 10,000, but had
flattened out at 27,000 per c.mm. The general condition
improved and remained so in spite of a progressive rise in the
32WBC, the Hb falling only slowly. A third course of P was 
begun on 26.10.55 with a dose of 5.0 mcs. followed by similar 
doses on 9.11.55 and 29.11.55. The HVD on this occasion was
2.6 mcs.—destroyed. At the start of treatment the Hb had been
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54^, the TOC 250,000 and platelets were scarce. A small
32transfusion was given after the last P dose and the Hb 
increased to 90jfc by February 1956. By July, however, the 
general health and blood picture began to deteriorate, and 
since the spleen was now enlarging and causing discomfort 
some tentative doses of x-rays were given to the spleen. The 
organ became almost impalpable by 29.8.56 but the Hb showed 
little response and the patient died on 3.10.56. Autopsy was 
not permitted.
Note here the increasing HVDs during the three courses 
of treatment - 1.1, 1.2 and 2.6 mcs.-destroyed.
Case M 3.
Mrs. M.E. aged 64, weight 55 kilos, developed vague
malaise towards the end of 1949. Investigation at Wigan
Infirmary in March 1950 disclosed leukaemia. On admission to
the Christie Hospital on 30.3.50 she was a pale thin woman
with enormous splenomegaly, but no hepetic or lymph node
enlargement, no petechiae, ecchymoses or mucosal bleeding.
The TOC on 11.4.50 was 185,000 per c.mm. with 3.0JG blasts and
25J6 total primitive white cells. The Hb level was 45$. A
32dose of 8.0 mcs. of P was given on 14.4.50, followed by 5.0 
mcs. on 21.4.50, by 2.7 mcs. on 28.4.50, by 0.64 mcs. on 5.5.50, 
by 0.5 mcs. on 12.5.50, by 1.0 me. on 19.5.50, another 1.0 me.
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on 26.5.50, and finally 3.1 mcs. on 31.5.50. This was an 
example of the "diminuendo" technique. The WBC fell and 
the HVD was 1.9 mcs.-destroyed, the lowest WBC being 1,600 per 
c.mm. on 15.5.50. The Hb rose during the first remission 
period to a maximum of 88J6 on 18.10.50. The WBC at that date 
was 16,000 per c.mm. During this remission the general health 
improved considerably and the spleen resolved to about 5 cms. 
below the costal margin ay 22.6.50. By November 1950 the 
general condition was deteriorating, the spleen enlarging, the 
Hb was 76j£ and the WBC 73,000. A second remission was induced 
by splenic x-ray therapy given between 7 and 21.12.50, but 
though the patient improved, further x-ray therapy was deemed 
necessary on 20.3.51. On this occasion, after a short and 
unsatisfactory remission the general health went downhill 
rapidly and the patient died on 13.8.51.
It is worth noting that though the WBC in this case was 
deliberately depressed to a very low level (l,600) by the 
first anti-leukaemia treatment, the interval to the second 
necessary treatment was only 34 weeks - certainly not superior 
to other less vigorously treated patients.
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Case M 4 .
Mrs. A.M., aged 62, weight 57 kilos, felt tired for a
year, was referred to Salford Hospital in December 1948, and
early leukaemia was diagnosed. On admission to the Christie
Hospital on 6.4.49 the general condition was fair, the spleen
was enlarged to the iliac crest, the liver was impalpable,
there were no nodes to be felt, no petechiae, ecchymoses or
mucosal bleeding, and no pyrexia. The WBC on 6.4.49 was 80,000
per c.mm. with 7.5^ blast cells and 27^ total primitive white
cells. The Hb on that date was 65^. The sternal marrow
confirmed the excessive granulopoiesis, and red-cell activity
32was considered to be poor. 3.0 mcs. of P were given on
13.4.49, again on 20.4.49 and on 27.4.49, ending with 1.5 mcs.
on 6.5.49. The WBC fell exponentially, with a HVD of 2.2 mcs.-
destroyed, to a lowest level of 3,600 on 16.8.49, and the Hb
rose to a maximum of 88^ on 18.10.49. The WBC on the latter
date was only 10,000 per c.mm. During this first remission
the general health improved considerably and the spleen was
not palpable by 18.10.49* By 31.8.50 the spleen was again
down to the umbilicus, the Hb reduced to 70j£ and the WBC up
32to 86,000. A further 5.0 mcs. of P were given on 31.8.50, 
but there was little response, and on 13.11.50splenic x-ray 
therapy was started. This was also abandoned because of 
continued deterioration and the patient died on 9.2.51.
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Case M 5.
Mrs. A.H. aged 45, weight 67 kilos, complained of 
persistent weakness after the birth of a child in 1950. She 
was investigated at Oldham Infirmary where leukaemia was 
diagnosed, and she was admitted to the Christie Hospital on
2.4.52. The general condition was fair, the spleen six cms. 
below the costal margin, but no enlargement of the liver or 
lymph nodes, no petechiae or other haemorrhagic features, and 
no pyrexia. The Hb on 19.4.52 was 62$, the WBC 70,000 per 
c.mm., 6.5$ being myeloblasts and 39$ being primitive white
32cells of various types. On 22.4.52 a dose of 7.2 mcs. of P 
was given followed by 3.5 mcs. on 29.4.52 and 6.5.52. The 
WBC fell exponentially with a HVD of 2.2 me.-destroyed and 
reached a lowest level of 8,000 on 19.5.52. The Hb showed no 
significant improvement, the spleen did not resolve, and by the 
end of May the clinical picture had deteriorated greatly. The 
spleen became grossly enlarged and painful, the WBC rose to
240,000 by 10.6.52 and the Hb was then down to 42$. Platelets 
were also scarce, and the patient died on 14.6.52.
Autopsy was carried out by Dr. Helen Bussell who reported 
several interesting features. The femoral marrow was very 
cellular, definitely leukaemic, but with minimal erythropoiesis. 
The lungs "were very curiously eodematous and very heavy, 
weighing over a kilo and standing up like casts. No tubercle
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was found, nor true consolidation, but the waxy solid oedema 
was diffusely spread through both lungs". The spleen was 
"enormous, bright red, and approximately 4.5 kilos in weight.
A large plaque of haemorrhage lay on its postero-medial aspect 
in the abdominal cavity but there was no obvious rupture of the 
organ. A certain amount of blood was also present in the 
pelvis, which had apparently oozed out of the spleen. The 
cut surface of the spleen showed a very varied picture of 
infarction, fibrosis, and oedema, in which the normal spleen
architecture was completely lost"...... "The liver weighed
3 kilos and was diffusely infiltrated. All sinusoids were
dilated much more than is likely to be an effect of heart- 
failure, I think." Microscopy revealed a widespread diffuse 
stasis with dilatation of the capillaries and arterioles of 
the lung, pleura, liver and spleen.
Case M 6.
Mrs. A.H., aged 54, weight 66 kilos, complained of 
vague abdominal discomfort for 4 years before being referred 
to the Manchester Royal Infirmary where a large spleen was 
found and leukaemia was diagnosed. On admission to the 
Christie Hospital on 8.9.52 the general condition of the 
patient was quite good, the spleen was enlarged down to the 
iliac crest and across to the midline of the abdomen, but
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there was no hepatomegaly, no nodes, petechiae, ecchymoses or
mucosal bleeding, and no pyrexia. The Hb was 58j6 and the
WBC 280,000 per c.mm., 2.0^ being blasts, but some 60^ were
primitive white cells. Platelets were plentiful. A  dose 
32of 9.5 mcs. of P was given on 15.9.52 followed by 2.0 mcs. on
29.9.52, by 2.5 mcs. on 7.10.52, and 5.2 mcs. on 24.10.52.
The WBC fell exponentially, with a HVD of 2,2 mcs.-destroyed, 
to a lowest level of 5,500 per c.mm. on 6.11.52, and the Hb 
rose to a maximum of 98J6 by 12.3.53. The WBC on the latter 
date had risen to 21,000 per c.mm. A second treatment became 
necessary by August 1953 and a single dose of 11.0 mcs. was 
given on 7.8.53. The WBC again fell exponentially with a HVD 
of 1.3 mcs.-destroyed. A good remission followed but a third 
course of treatment became necessary in March 1954. A dose 
of 6.0 mcs. was given on 23.3.54, followed by 3.8 mcs. on 
7.4.54 and 3.0 mcs. on 15.4.54. The WBC again fell exponen­
tially with a HVD on this occasion of 2.8 me s.-destroyed. The 
spleen was scarcely palpable by June 1954 and the Hb rose to 
92J&. In August, however, the general health began to fail 
rapidly and though x-ray therapy to the spleen was cautiously 
tried on 24.8.54 there was no real improvement. Erythro­
poietic collapse was seen in December 1954 and the patient 
died on 15.1.55.
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The three HVDs in this case were 2.2, 1.3 and 2.8 
mcs.-destroyed.
Case M 7.
Mr. H.M., aged 62, weight 68 kilos, developed 
’'indigestion11 in July 1952 and felt generally nnwell. He was 
admitted to Wigan Infirmary as an abdominal emergency on
13.11.52 and leukaemia was discovered. On admission to the 
Christie Hospital on 27.11.52 his general condition was quite 
good, the spleen was enlarged to the iliac crest hut his liver 
was not enlarged, nor were there any palpable nodes. There 
were no petechiae, no ecchymoses or mucosal bleeding, and no 
pyrexia. The Hb on 16.12.52 was 65^. platelets were plentiful, 
and the WBC was 130,000 per c.mm., 1.5^ being blast cells and 
27'fo were primitive cells of all types. On* 16.12.52 a dose of
9.7 mcs. was given, followed by 3.0 mcs. on 31.12.52. The 
WBC fell exponentially with a HVD of 2.2 mcs.-destroyed, to a 
lowest level of 6,000 on 12.1.53. The Hb rose to a maximum 
of 98J6 on 10.4.53 by which time the WBC had risen to 15,600 
per c.mm. The general condition improved remarkably and the 
spleen was scarcely palpable on 6.3.53. Clinical and haemato- 
logical deterioration was apparent, however, in September and 
on 14.10.53 the patient was found to have signs of cerebral 
thrombosis. He died on 2.11.53.
S.
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Autopsy was carried out by Dr. Helen Bussell and this 
confirmed an extensive area of softening in the grey matter 
and sub-cortical white matter in the left parietal lobe. The 
spleen was "very large and adherent to the parietes, and burst 
on handling, revealing a huge necrotic cavity which contained 
pints of brown fluid within a necrotic lining. The lower 
pole of the spleen was the only healthy part, and a spleniculum 
was present, attached to the lower tip of the organ”. No 
other special features were noted, but once again (vide M 5) 
the lungs were curiously heavy. The possibility of this whole 
history being due to a splenic abscess with a leukaemoid blood- 
picture was considered, but on review the leukaemic diagnosis 
was accepted.
Case M 8.
Mr. A.F., aged 52, weight 52 kilos, felt unduly fatigued 
about March 1949, and was investigated in Salford Hospital in 
November 1949, when leukaemia was discovered. He was admitted 
to the Christie Hospital on 1.3.50 when he was ill. The 
spleen was enlarged to the umbilicus, but the liver was not 
enlarged and there was no significant lymphadenopathy, no 
pyrexia, no petechiae, ecchymoses or mucosal bleeding.
Platelets were plentiful, the Hb on admission was 65^, and the 
total WBC was 200,000 per c.mm. of which 1.0^ were myeloblasts
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opand 38$ were primitive cells of various types. P therapy 
began with 5.0 mcs. on 14.3.50, followed by 4.0 mcs. on 22.3.50, 
by 5.0 mcs. on 29.3.50, by 2.0 mcs. on 5.4.50, by 1.0 on
21.4.50, by 1.1 mcs. on 28.4.50, by 0.5 mcs. on 5.5.50 and 
again on 12.5.50, by 1.0 me. on 19.5.50, and finally 4.3 mcs.
on 26.5.50. The WBC fell exponentially, with a HVD of 2.3 mcs.- 
destroyed, and reached a lowest level of 2,500 per c.mm. on
5.5.50. This was one of the patients in whom an attempt was 
made, without success, to depress the WBC to still lower levels. 
It will be noted that even a final dose of 4.3 mcs. failed to 
depress the WBC any further. The Hb rose to a maximum of 94$ 
by 9.6.50, the WBC at that date being 8,700. The spleen 
became impalpable by 26.5.50, and the patient's general health 
improved considerably. He suddenly deteriorated, however, 
during August 1950, he became pyrexial and the blood-picture 
suggested aplasia. He died on 26.8.50.
The most striking feature at autopsy was the dark 
crimson colour of the marrow at the centre of the femur. Dr. 
Helen Russell considered this was due to stasis and haemorrhage.
Case M 9.
Mrs. E.E.I., aged 59, weight 46 kilos, complained of 
lassitude in April 1952, first consulted her doctor in February 
1954, and was investigated at Blackpool Infirmary and referred
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to the Christie Hospital on 2.4.54. The spleen was enlarged 
to the umbilicus, the liver was just palpable, there were no 
enlarged lymph nodes, no pyrexia, no petechiae, ecchymoses, 
or mucosal bleeding. Platelets were plentiful, the Hb was 
68$, and the WBC was 457,000 per c.mm., 3.0$ of which were
myeloblasts and 32$ primitive cells of all types. 6.0 mcs.
32of P were given on 13.4.54, additional 5.0 and 4.0 me. doses 
being given on 27.4.54 and 7.5.54 respectively. The WBC fell 
exponentially, with a HVD of 2.3 mcs.-destroyed, the lowest 
level being 7,000 per c.mm. on 3.9.54. The Hb rose to a 
maximum of 100$ on 3.9.54, and the spleen was no longer 
palpable by 4.6.54, while the general health improved vastly. 
By February 1955 the spleen was again below the umbilicus and 
across the midline, and by April 1955 the Hb had fallen to 
52$. the WBC having risen to 195,000 per c.mm. A course of 
splenic x-ray therapy at that time produced a short remission, 
and was repeated during September 1955 and again in January 
and May 1956. On each occasion a worthwhile improvement in 
general health was achieved - rather surprisingly towards the 
end - but myocardial insufficiency complicated the terminal 
picture and the patient died on 14.9.56.
- 157 -
Case M 10.
Mrs. E.W., aged 62, weight 59 kilos, failed to "pick
up" after bronchitis in December 1951. Her lassitude was
investigated at Withington Hospital and she was admitted to the
Christie Hospital on 26.6.52. The general condition was quite
good, the spleen was moderately enlarged, as also was the liver,
but there was no significant lymphadenopathy, no pyrexia, no
petechiae, ecchymoses or mucosal bleeding. The platelets were
plentiful, the Hb level was 62$ and the WBC was 150,000 per c.mm.,
5$ being myeloblasts, and 32$ primitive cells of various types.
32P was given as follows:- 8.0 mcs. on 8.7.52, 2.1 mcs. on
22.7.52 and again on 7.8.52. The WBC fell exponentially, with
a HVD of 2.4 mcs.-destroyed, the lowest level being 8,300 on
1.9.52. The Hb rose to a maximum of 86$ on 24.11.52, the WBC
at that time being 24,000 per c.mm. The spleen became just
palpable by 24.11.52 and the patient's general condition very
greatly improved. The Hb began to fall during the spring of
321953 and a second course of P was instituted with 8.0 mcs. 
on 3.7.53 followed by 3.0 mcs. on 17.7.53. Again the WBC 
fell exponentially, with a HVD on this occasion of 2.0 mcs.- 
destroyed, from an initial 190,000 to a lowest level of 12,500 
on 27.7.53. The Hb rose during this second remission from an 
initial 60$ to a maximum 76$ on 22.9.53. Deterioration was
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sudden, however, and by 15.12.53 the Hb was 64$ and WBC 
216,000. The spleen, barely palpable on 17.11.53 was now down 
to the umbilicus. A three weeks' course of splenic x-ray 
therapy began on 8.1.54. The WBC fell to 9,500 on 4.2.54 
and the Hb rose from 60$ to 82$ on 2.3.54. The patient felt 
greatly improved, but suddenly collapsed, with splenic pain, 
purpura, etc. - signs of an acute leukaemic termination - and 
she died on 12.3.54. Autopsy was not permitted.
The HVDs in this case were 2.4 and 2.0 mcs.-destroyed.
Case M 11.
Mrs. F.M., aged 32, weight 48 kilos, felt tired and
vaguely unwell several months after the birth of her second
child (November 1950) . She consulted her doctor in August
1951 and was referred to the Christie Hospital on 10.8.51.
The general condition was good, the spleen was down to the
umbilicus, the liver was not enlarged, and she had no lymph-
adenopathy, no pyrexia, no petechiae, ecchymoses or mucosal
bleeding. Platelets were plentiful, the Hb was 48$ and the
WBC 250,000 per c.mm., 10$ being blast cells and 38$ immature
32cells of all types. P was given as follows:- 4.6 mcs. on
27.8.51, 2.0 mcs. on 3.9.51 and 2.3 mcs. on 10.9.51, 17.9.51,
25.9.51, 1.10.51 and 9.10.51. The WBC fell exponentially,
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with a HVD of 2.5 mcs.-destroyed, to a lowest level of 13,500 on
8.10.51. The Hb rose to a maximum of 112$ on 7.1.52, the WBC 
then being 16,000 per c.mm. The spleen became impalpable by
23.11.51, and the patient's general health considerably 
improved. Deterioration began in mid-1952 and a two weeks1 
course of splenic x-ray therapy was begun on 11.9.52. The 
WBC fell from 121,000 to 9,400 by 2.10.52, while the Hb rose 
from 64$ to a maximum of 103$ on 14.11.52. The general 
condition also improved during this period but the whole picture 
deteriorated again, and on 13.4.53 chemotherapy was instituted, 
using B.E.P. She had 10 mgs. daily from 15.4.53 to 17.4.53 
with some initial improvement, but after leaving hospital she 
developed pneumonia. By 30.9.53 she was again considered
in need of chemotherapy and had a further 14 days’ course, 
having 10 mgs. daily. The Hb rose from 53$ to 75$ by 12.2.54 
though the WBC was then up to 250,000. No further treatment 
was given apart from general supportive measures and the 
patient died on 13.9.54. Autopsy was not possible.
Case M 12.
Mrs. J.B., aged 69, weight 49 kilos, developed sudden 
weakness in March 1949. She refused investigation and 
remained in bed for 3 months, but finally agreed to examination 
in Bury Hospital in December, 1949. On admission to the
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Christie Hospital on 6.1.50 the general condition was only fair, 
the spleen was substantially enlarged, and the liver moderately 
so, though there was no lymphadenopathy, no pyrexia or haemorr- 
hagic features. The Hb was 80$, platelets were plentiful and 
the WBC was 33,000 with no myeloblasts but 4$ of immature white 
cells. There was a symptomless urinary infection of B. coli 
and an infective leukaemoid blood picture was considered.
However a 2$ basophilia in the peripheral blood, and also the 
large number of myeloblasts in the sternal marrow strongly 
suggested myeloid leukaemia. In addition, the large spleen
(not kidney1.) and liver added further weight to this diagnosis.
325.0 mcs. of P were given on 11.1.50 and 24.1.50 and the WBC 
fell exponentially with a HVD of 2.6 mcs.-destroyed. The 
lowest WBC level was 3,000 per c.mm. on 7.3.50 and the Hb had 
risen to 102$ by 27.9.50, the WBC then being 6,000. The 
spleen was impalpable by 2.8.50 and the patient's general 
condition has remained excellent to date. Naturally such a 
remission casts doubt in retrospect on the original diagnosis.
On 12.12.56 the Hb was 92$, the WBC 14,000, the spleen nearly 
down to the iliac crest, and the patient had what could only be 
called a polycythaemic facies. The peripheral blood showed a 
shift to the left with 10$ myelocytes but no blast cells. The 
marrow showed active granulo- and erythropoiesis. It is of
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interest that a radioiron tracer study showed a plasma clearance 
rate of only 13 minutes and an iron turnover rate of 8.9 mgs. 
per hour. This suggests very active erythropoiesis, and in the 
absence of obvious haemolysis, a polycythemic development in the 
future seems an interesting possibility.
Case M 13.
Mrs. A.H., aged 65, weight 36 kilos, was troubled by
rheumatoid arthritis for many years. An attack of diarrhoea
led to an abdominal examination in October, 1950 and a large
Spleen was found. Investigation at Leigh Infirmary confirmed
myeloid leukaemia and she was sent to the Christie Hospital on
6.11.50. The general condition was rather frail, the spleen
was enlarged to the iliac crest, the liver was not palpable,
there was no lymphadenopathy and no haemorrhagic features. The
Hb was 56$ just before treatment, platelets were plentiful and
the WBC was 76,000 per c.mm. 10$ of the WBC were primitive
32cells. An initial dose of 5.0 mcs. of P was given on 
10.11.50 followed by five weekly doses of half this quantity.
The WBC fell exponentially, with a HVD of 2.7 mcs.-destroyed, 
to a minimum level of 3,800 on 23.12.50. The Hb rose to a 
maximum of 112$ by 23.7.51. The patient then looked poly- 
cythaemic and had symptoms of visual disturbance, limb pains, 
and general suffusion which finally led to the administration
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32of 5.0 mcs. of P on 13.8.51. This was designed to reduce
her erythropoeisis. The spleen, at the iliac crest in her
initial leukaemic phase, had resolved to the umbilical level «thT
32persisted. The WBC at the time of this second dose of P
was 28,000 per c.mm. and this fell to 6,700 by 9.11.51. The
haemoglobin also fell to 100$. The problem thereafter was
that of the polycythaemic patient with increasing thrombotic
features - scotomata, dysarthria, headache, etc. In addition
32to repeated venesections, 5.0 mcs, doses of P were given on
3212.2.53, 3.7.53 and 3.3.54. The response to P was always 
short-lived and the Hb reached a highest level of 134$ in July, 
1954. Whole body x-ray therapy was tried in September, 1954 
with only a moderate response, and in April 1955, chemotherapy 
with the anti-malarial drug Daraprim was begun. For the first 
time the Hb was effectively controlled at levels between 90$ 
and 100$. However, when last reviewed on 12.2.57 the general 
condition was not good, cerebral thrombotic signs dominated the 
clinical picture, and the Hb had fallen to 75$. The platelets, 
however, were 223,000 per c.mm. and the WBC 19,600.
This remains a most interesting case and the relation­
ship between myeloid leukaemia, polycythaemia vera, and myelo­
sclerosis once more comes to mind. It may well be that this 
has been a case of polycythaemia vera from the beginning.
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Case M 14.
Mr. S.B., aged 50, weight 64 kilos, developed breath­
lessness in August 1950, was investigated at Wigan Infirmary 
and referred to the Christie Hospital on 1.1.51. The general 
condition was good, the spleen reached below the umbilicus, 
the liver was not palpable and there were no significant lymph 
nodes to he felt, nor any bleeding tendency. Platelets were 
plentiful, the Hb was 56$, and the WBC 300,000 per c.mm., 1.0$
being blasts and 55$ immature cells of all types. On 12.1.51
32a dose of 9.2 mcs. of P was given followed by 4.6 mcs. on
19.1.51, 26.1.51, 2.2.51 and 9.2.51. The WBC fell exponen­
tially, with a HVD of 2.9 mcs.-destroyed, to a lowest level of
4,700 on 22.2.51. The Hb rose to 100$ by 26.4.51 when the WBC 
was 6,900, but the highest Hb recorded during this remission 
was 122$ on 30.11.53. The spleen was impalpable by 26.4.51 
and the general condition looked excellent. The patient however 
was something of a chronic invalid, having been off work for 
many years following an accident. He seldom admitted good 
health. By 9.2.54 the Hb had dropped to 86$, the WBC had
risen to 150,000, platelets were 180,000 and the spleen was
32enlarged again almost to the umbilicus. P was given again:-
6.0 mcs. on 9.2.54, 3.0 mcs. on 3.3.54 and 4.3 mcs. on 16.3.54. 
The Hb again rose to 110$ on 29.4.54 but the WBC fell
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erratically, possibly because of intercurrent pyrexial 
episodes. The WBC remained low however, and the Hb fell 
rapidly from 88$ on 2.11.54 to 37$ on 19.11.54. It is of 
interest to note that during October 1954 this patient developed 
a patchy paresis of the right arm, affecting mainly the deltoid 
and biceps, associated with pain radiating to the fingers.
The question of a leukaemic deposit was considered but the 
general deterioration called for palliative measures only, and 
the patient died on 27.11.54. Autopsy revealed a carcinomatous 
tumour of undetermined origin densely adherent to the side of 
the upper cervical vertibrae. This was considered to be 
unassociated with his myeloid leukaemia. The femoral marrow 
in this case again showed the dark crimson colour referred to 
previously.
Case M 15.
Mr. F.T., aged 72, weight 67 kilos, developed cough and 
dyspnoea early in 1951. Twelve months later he noted dis­
comfort in the left hypochondrium and was referred to Crnmpsall 
Hospital in April 1952. Myeloid leukaemia was diagnosed and 
he was referred to the Christie Hospital on 27.5.52. In 
addition to his leukaemia he had congestive heart failure and 
his general condition was poor. The spleen was enlarged below
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the umbilicus but the liver was not felt, there was no lymph-
adenopathy, and no petechiae or mucosal bleeding. Platelets
were plentiful, but the initial Hb level was only 40$ of normal.
The WBC was 340,000 per c.mm., 2.5$ being blast cells and 24$
32total primitive white cells. 9.6 mcs. of P were given on
4.6.52, 3.8 mcs. on 18.6.52, 1.45 mcs. on 25.6.52, 2 mcs. on 
2.7.52 and finally 4.8 mcs. on 9.7.52. This was another 
example of an attempt to depress the WBC as low as possible but
it fell no lower than 18,000 on 18.8.52. The WBC nevertheless
%
fell exponentially with a HVD of 2.9 mcs.-destroyed. The Hb 
on 18.8.52 was 82$ and it rose to 90$ by 29.9.52, by which time 
the WBC had also increased to 27,000. At this time also the 
spleen was just palpable. The general condition of the patient 
did improve, but in view of his cardiac defect and general 
decrepitude this improvement was not spectacular. There was 
sudden and rapid deterioration in February, 1953, and the 
patient died on 26.2.53. Autopsy was not permitted.
Case M 16.
Mrs. A.S., aged 56, weight 54 kilos, noticed breath­
lessness and cyanosis of the lips and face in March, 1950. She 
had had a left radical mastectomy in 1947 for mammary cancer 
but had no sign of local or metastatic cancer. She was 
attending the Christie Hospital because of the breast history
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and myeloid leukaemia was diagnosed in August, 1950. Marrow 
metastases were considered as a possible cause of her leukaemic 
blood picture but finally were regarded as unlikely. The 
general condition was good, the spleen was grossly enlarged 
across the mid-line, but the liver was impalpable, there were 
no nodes and no bleeding or petechiae. Platelets were plenti­
ful and the initial Hb level was 48$. The WBC was 440,000
per c.mm. of which 1$ were blast cells and 53$ total immature 
32cells. P was given as follows:- 7.5 mcs. on 23.8.50 and
30.8.50, 4.5 mcs. on 7.9.50 and 14.9.50, 1 me. on 21.9.50 and
3.5 mcs. on 28.9.50 and 6.10.50. The WBC fell exponentially 
with a HVD of 3.1 mcs.-destroyed, the lowest level being
14,000 on 2.10.50. The Hb rose to a maximum of 82$ by 11.1.51, 
but by then the WBC had risen to 138,000. The spleen 
diminished considerably but never above the umbilicus, and 
indeed by January 1951, had again become large and uncomfortable. 
This fact and the rapid rise in WBC led to further treatment, 
in spite of the good Hb response and improved general health.
The second treatment in this case was by splenic x-ray therapy, 
begun on 31,1,51 and terminated on 13.3,51. The WBC by this 
treatment was reduced to 6,000 per c.mm. by 15,3.51 though the 
Hb did not improve above the 80-85$ level. The spleen also 
was reduced once more in size but again only to the umbilidal
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level, though it was more comfortable for the patient. The 
general condition remained good until 31.8.51 when the 
leukaemia deteriorated and the patient also developed recurrent 
skin nodules of breast cancer as well as lung metastases.
A few weeks before her death on 25.10.51 an attempt was made to 
control her malignancy with chemotherapy (T.E.M.) but no 
improvement was noted. Unfortunately an autopsy was not 
permitted.
Case M 17.
Mrs. A.W., aged 64, weight 55 kilos, felt unwell and
noted abdominal swelling in 1951. She saw her doctor regularly
but was given tonics for her lassitude without examination
until July 1952, when she was referred to Bolton Boyal
Infirmary. Leukaemia was diagnosed and she was sent to the
Christie Hospital on 26.9.52. By then she was ill with a very
large spleen and liver, and oedema of the ankles and lumbar
region. There was no lymphadenopathy, no ecchymoses, petechiae
or mucosal bleeding, the initial Hb was 58$ and platelets were
plentiful. The WBC was 510,000 of which 2$ were blast cells
and some 54$ total immature cells, mainly metamyelocytes and
32myelocytes. 7.8 mcs. of P were given on 29.9.52, a further 
3.6 mcs. on 24.10.52, 3,0 mcs. on 30.10.52, 5.0 mcs. on 7.11.52
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and 3.0 mcs. on 18.11.52. The WBC fell exponentially with a 
HVD of 3.2 mcs.-destroyed, the lowest level being 14,000 on
28.11.52, when the Hb was 78$. The Hb rose to a maxi mum of 
92$ on 19.1.53, the WBC then having risen to 53,000. The 
liver became impalpable by 19.1.53 and the spleen just palpable on 
that date. The general condition improved very considerably 
but during September, 1953, she developed haematuria and 
deterioration was apparent both clinically and haematologically. 
The haematuria was intermittent at first but the patient died 
in uraemia on 6.11.53. Autopsy was not permitted.
Case M 18.
Mrs. F.M.H., aged 61, weight 40 kilos, attempted suicide 
on 3.6.51 without success. She was considered mentally normal 
but was found to have myeloid leukaemia. Her general health 
was fair, the spleen grossly enlarged, there was generalised 
small lymphadenopathy, but no haemorrhagic features. Platelets 
were slightly reduced and the initial Hb level was 80$. The 
WBC was 90,000 per c.mm., with 1$ blast cells and 7.5$ total 
primitive cells. The bone marrow and peripheral blood in this 
case suggested a leuko-erythroblastic disease, but all clinical 
and radiographic surveys, both initially and on many occasions 
before death, failed to reveal any malignancy or to support a
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32diagnosis of myelosclerosis. 4.0 mcs. of P were given on
10.8.51, followed by 2.0 mcs. on 16.8.51, on 27.8.51 and on
11.9.51. The WBC fell exponentially with a HVD of 3.2 mcs.- 
destroyed, the lowest level being 6,800 on 19.10.51. The Hb 
rose to 96^ by 31.7.52 by which time the WBC had risen to
31,000 per c.mm. The spleen became mnch reduced in size by 
January, 1952, and the general condition vastly improved, though 
mental instability proved troublesome from time to time. The 
patient remained remarkably well but died, curiously, from a 
sudden uncontrolled haemorrhage from a varicose ulcer, on 
18.2.53. Autopsy was not permitted.
Case M 19.
Mr. J.D.N., aged 56, weight 70 kilos, complained of 
lethargy in early 1949, followed by aching in the left side of 
the abdomen. He also noted an increasing tendency to bruising 
after trivial injuries. He was referred to the Christie 
Hospital by his family doctor on 30.6.49 and chronic myeloid 
leukaemia was diagnosed. The general condition was fair, the 
spleen was considerably enlarged but the liver was not, neither 
was there any lymphadenopathy, pyrexia or mucosal bleeding. 
Platelets were plentiful and the initial Hb was 62/6. The WBC 
was 320,000 per c.mm., with Vfo blast cells and 19/6 total 
primitive white cells. The sternal marrow was hyperplastic
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and confirmed myelogenous leukaemia. On 27.7.49 a dose of 
327.0 mcs. of P was given, followed by 3.0 mcs. on 11.8.49,
4.0 mcs. on 20.8.49 and 3.0 mcs. on 1.9.49. The WBC fell 
exponentially with a HVD of 3.5 mcs.-destroyed, the lowest 
level heing 11,000 on 10.10.49. The Hb then was 82$ hut rose 
to 100$ by May, 1950, when the WBC was 16,000. The spleen 
was not palpable by March, 1950, and the patient's general 
health had improved remarkably - indeed he played cricket as
a fast howler. He felt less well in August 1950, the TOC
rose to 81,000, the Hb fell to 88$, then the spleen became
32moderately enlarged again. A second course of P was given -
5.0 mcs. on 23.8.50 and 2.5 mcs. on 7.9.50. Again the WBC
fell exponentially though on this occasion with a HVD of only
2.4 mcs.-destroyed - a significantly more sensitive response.
The lowest WBC following this treatment was 5,500 per c.mm. on
10.10.50, the Hb then being 92$. The spleen by that date was
again impalpable and the general health improved to its former
vigour. A third course of treatment became necessary by
32August, 1951, and he was given 5.0 mcs. of P on 3.8.51. It 
was decided however to continue with splenic irradiation in 
this case, mainly because the patient demanded out-patient 
treatment. Six weekly splenic treatments were given from
28.11.51 until 10.1.52 and again an excellent remission followed.
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The WBC fell to a low level of 9,000 on 24.1.52, and the Hb 
rose to a maximum of 98$ by 9.4.52. The spleen too became 
impalpable by that date and the general health was excellent. 
This was short-lived, however, and by 27.5.52 the spleen was 
gigain painful and down to the umbilicus, the general health 
was not good and the WBC rising rapidly (82,000). Chemo­
therapy was instituted on 25.6.52 using B.E.P. Maintenance 
doses were given from time to time and a good clinical and 
haematological remission was achieved. The spleen became 
smaller and more comfortable, the WBC remained below 20^000 
per c.mm. and the Hb around 95 - 100$ until April, 1953, when 
the drug was changed to Myeleran. The blood picture remained 
excellent thereafter though the patient had various complaints 
of abdominal pain of uncertain origin - apparently not splenic 
infarction. Investigations revealed a curious left-sided 
impairment of renal function, dye being poorly excreted, 
presumed to be due to pressure from the overlying spleen. 
Myeleran kept him going very well until December, 1953, when 
ecchymoses, not seen since his first treatment in 1949, 
reappeared and were then associated with thrombocytopenia.
The Hb began to drop slowly and on 19.1.54 a course of 
6-mercaptopurine was instituted, ending on 14.2.54. This 
drug, and Myeleran, were given on two further occasions without
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significant improvement and the patient died, with gross
anaemia and a huge tender spleen, on 24.6.54. Autopsy was
not permitted.
It is of interest that the HVDs for the two completed 
32courses of P were 3.5 and 2.4 mcs.-destroyed.
Case M 20.
Mrs. A.T., aged 25, weight 60 kilos, noted menstrual 
irregularity ahout December 1950, followed by lassitude in 
1951. She noted swelling in the abdomen in July 1951, was 
referred to Blackburn Infirmary in September and thence to the 
Christie Hospital on 16.10.51 as myeloid leukaemia. The 
general health was excellent, the spleen was considerably 
enlarged though the liver and lymph nodes were not enlarged, 
there were no ecchymoses, petechiae or pyrexia. Platelets 
were plentiful and the Hb level on admission was 58$. The 
WBC was 260,000 per c.mm. with 1$ blast cells and 37$ total
immature white cells. Sternal marrow confirmed the diagnosis.
325.5 mcs. of P were given on 30.10.51, 3.0 mcs. on 7.11.51,
12.11.51, 20.11.51, 27.11.51 and 4.12.51 with a final 5.0 mcs. 
on 11.12.51. The WBC fell exponentially with a HVD of 3.6 
mcs.-destroyed, the lowest level being 5,500 on 21.12.51.
The Hb at that date was 72$ but it rose to a maximum of 92$
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by 31.3.52. The spleen was no longer palpable by 28.4.52 
and the general health of the patient improved considerably.
In May, 1952, there was a short epistaxis, and in July a 
period of menorrhagia. The latter ceased after excision of 
a cervical erosion on 29.7.52. The spleen began to enlarge 
again, the WBC increased and the Hb fell so that a second 
course of treatment, by splenic x-ray therapy on this 
occasion, was given from 30.12.52 to 27.1.53. The Hb 
increased from 78$ in December 1952, to 94$ by August 1953, 
in spite of an unexpected leukopenia. The splenic radiation 
had stopped at a WBC level of 6,000 per c.mm. but the count 
continued to fall to a minimum of 1,700 on 23.2.53. This 
leukopenia persisted and was complicated by perineal infec­
tions on two occasions. By June 1953, the WBC was 12,000 
and it continued to rise until further splenic radiation became 
necessary in January 1954. The WBC then was 110,000, the Hb 
Was 74$ and the spleen, which had resolved completely during 
the leukopenic phase, had again become karge and tender. The 
WBC fell slowly in response to x-ray therapy but the Hb showed 
no corresponding rise. On 4.2.54 an increase in blast cells 
was noted in the peripheral blood, the general condition 
deteriorated, bleeding recurred from the nose and uterus, and 
in spite of chemotherapy with 6-mercaptopurine the patient died 
on 27.2.54. Autopsy was not permitted.
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Case M 21.
Mrs. D.T., aged 58, weight 54 kilos, was troubled with
gout since 1937. An exacerbation of her gout led to a medical
review in Park Hospital, Manchester, in 1951 and myeloid
leukaemia was discovered. The patient's general health, had
been deteriorating slowly though her main symptom was discomfort
in her gouty hands (See Figure 8). The general condition on
admission to the Christie Hospital was poor, the spleen was
enormous and filled most of the abdomen, though the liver and
lymph nodes were not enlarged, neither was there any bleeding
tendency or pyrexia. Platelets were plentiful and the Hb
level on admission was 65$. The WBC was 140,000 per c.mm.
with 1.5$ blast cells and 28$ immature cells of all types.
325.4 mcs. of P were given on 18.3.52 and 2.7 mcs. on 25.3.52,
1.4.52, 8.4.52, 22.4.52 and 29.4.52. The WBC fell exponen­
tially with a HVD of 4.5 mcs.-destroyed to a lowest level of 
5,600 on 3.5.52. The haemoglobin on that date was 62$ but 
it rose to a maximum of 82$ on 15.9.52, the WBC then being
30,000 per c.mm. Though the spleen became significantly 
smaller it was never above the umbilicus. The general 
condition did in fact ultimately improve but it is interesting
that this patient had an acute exacerbation of her gout during
32this first month after completing her P therapy. She was
- 175 -
confined to bed with acutely painful and swollen ankles and 
wrists, but this cleared up and she was able to lead an active 
life once more. Unfortunately this patient was admitted to 
another hospital for investigation of her gout in December 1952, 
and though some clinical data were obtained, these were 
incomplete. No further anti-leukaemic treatment was apparently 
given but the patient died on 17.7.54.
Case M 22.
Miss E.C., aged 31, weight 51 kilos, became lethargic
in 1952 and after periods of improved health she finally had
a blood examination which showed a leukaemic picture. After
investigation at Westmorland County Hospital she was referred
to the Christie Hospital on 25.3.54. The general condition
was not good and the patient looked ill. The spleen was
grossly enlarged to the iliac crest and the liver was also
considerably enlarged. There were no haermorrhagic signs and
no lymphadenopathy. The Hb on admission was 68$, platelets
were plentiful, and the WBC was 200,000 per c.mm., 1.0$ being
32blasts and 38$ total primitive cells. 6.0 mcs. of P were 
given on 26.3.54, followed by 4o0 mcs. on 15.4.54, and 5.0 mcs. 
on 27.4.54 and 4.5.54. The WBC fell exponentially, with a HVD 
of 4.5 mcs.-destroyed, reaching its lowest level of 10,000 per 
c.mm. on 10.7.54. The Hb at that date had risen to its highest
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level of 127$ and the spleen was no longer palpable. The 
general health of the patient improved considerably and rapidly 
and was well-maintained until the summer of 1955. By June, 
1955, the Bb had dropped to 80$ and the WBC had risen to
Q O141,000. On 27.6,55 a dose of 6.0 mcs. of P was given 
followed by 3.0 mcs. on 12.7.55. The TOC again fell exponen­
tially though, with a HVD of 1.4 mcs.-destroyed, much more 
sensitively than on the first occasion. The TOC flattened 
out at a fairly high level (30,000) but the Hb rose to 100$ 
on 10.9.55. The general health again improved sufficiently 
to return to work as a school teacher, but she was re-admitted 
to hospital on 24.1.56 gravely ill. Pyrexia and epistaxis 
suggested an acute leukaemic phase and the patient died on 
8.2.56.
Autopsy showed pneumonia and a large recent infarction 
in the spleen. The bone marrow of the femur, sternum and 
vertebrae did not indicate aplasia but showed active leuko- 
and erythropoiesis. The plasma clearance-rate of radio iron 
on 26.1.56 had been rapid (20 minutes half-clearance time) 
but the patient was too ill to pursue detailed study.
The HVDs were 4.5 and 1.4 mcs,-destroyed.
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Case M 23.
Mrs. S.P., aged 68, weight 51 kilos, first developed 
epistaxis in 1950. This recurred from time to time, and in 
March 1952, she noted a painful and tender swelling in the 
abdomen. Investigation at Wigan Infirmary disclosed leukaemia 
and she was admitted to the Christie Hospital on 21.8.52. The 
general condition was good, the spleen was enlarged well below 
the umbilicus, but the liver and lymph nodes were impalpable. 
There were no petechiae, ecchymoses or pyrexia. Platelets were 
plentiful and the Hb on admission was 63$. The initial WBC 
was only 31,000 per c.mm, but with 2.0$ of myeloblasts and 11$ 
of immature white cells of all types. The sternal marrow was 
hyperplastic with a shift to the left in leukopoiesis, and
32active erythropoiesis. On 26.8.52 a dose of 7.3 mcs. of P 
was given followed by 5.25 mcs. on 16.9.52. The WBC fell 
exponentially, with a HVD of 4.6 mcs.-destroyed, to a minimum 
level of 5,200 on 6.10.52. The haemoglobin then was 80$ but 
it rose to a maximum of 126$ on 6.8.53, the WBC at that date 
being 18,000 per c.mm. The spleen became just palpable by 
February, 1953, and the general health improved considerably. 
This excellent remission lasted until February 1955, and even 
then the Hb was still 92$ and the WBC only 50,000, though the 
spleen was down to the pubis and most uncomfortable. Splenic
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x-ray therapy was given from 8.2.55 to 28.2.55 in an effort to 
reduce the size of the organ. As often happens, the spleen 
showed little diminution in size yet much of the local discomfort 
and tenderness disappeared. The greatly enlarged spleen has 
persisted to date and though the patient is still alive she is 
now becoming progressively anaemic. Radio-iron studies have 
shown a rapid plasma clearance-rate and iron turnover, and 
since the sternal marrow has shown active erythropoietic and 
leukopoietic activity these findings suggest a haemolytic phase. 
Some response to steroids may be expected though the general 
- condition of the patient justifies no optimism.
Case M 24.
Mr. J.W.C., aged 72, developed dyspnoea in April 1949, 
and investigation at Rochdale Infirmary revealed myeloid 
leukaemia. He was admitted to the Christie Hospital on
31.5.49, when the general condition of the patient was poor, 
the spleen was moderately enlarged, but the liver and lymph 
nodes were not palpable. There were no ecchymoses, petechiae, 
or pyrexia, but the scarcity of platelets and the very low 
haemoglobin level of 26$ suggested a terminal leukaemia. This 
was one of the first leukaemic patients treated in this series 
and his poor response would not nowadays be surprising. The
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WBC on admission was 100,000 per c.mm., with l.o$ blasts and
12$ primitive cells of all types. A dose of 7.5 mcs. of P32
was given on 1.6.49, followed by 2.3 mcs. on 8.6.49 and 3.0 mcs.
on 13.6.49. Though the WBC fell exponentially, with a HVD of
5.0 mcs.-destroyed, the Hb did not improve. After the last 
32P dose a small blood transfusion was given but the patient 
suddenly deteriorated and died on 30.6.49. Autopsy showed 
once again the curious bright red and haemorrhagic marrow 
(sternal) described in several other cases. In addition 
Dr. Helen Russell commented on the heavy oedematous lungs.
Case M 25
Mr. W.M., aged 46, weight 60 kilos, developed undue
lassitude about December 1951, followed by abdominal swelling
which was investigated at Chorley Hospital in February 1952.
Leukaemia was discovered and the patient was admitted to the
Christie Hospital on 19.2.52. The general condition was poor,
having deteriorated rapidly, the spleen was grossly enlarged
into the right lower abdomen, and the liver too was grossly
enlarged. There was no pyrexia or mucosal bleeding. The
initial Hb level was 46$, the WBC 300,000 per c.mm., blast
cells amounting to only 0.5$, with some 32$ immature cells of
32all types. 6.0 mcs. of P were given on 26.2.52, followed 
by 3.0 mcs. each on 4.3.52, 11.3.52, 18.3.52, 25.3.52,
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2.4.52, 8.4.52, and 22.4.52. The WBC fell slowly bint 
exponentially, with a HVD of 5.2 mcs.-destroyed, the lowest 
level being 15,000 per c.mm. on 24.4.52. The Hb at that date 
was 77$ and it rose to a maximum of 80$ by 1.5.52, the WBC then 
being up to 32,000. At the end of that month the patient 
suddenly deteriorated with an acute myeloblastic leukaemia and 
died on 4.6.52. Unfortunately, autopsy was not permitted.
Case M 26.
Mrs. M.F. , aged 41, weight 62 kilos, developed 
abdominal swelling, lassitude, loss of weight, and sweating in 
April 1949. Investigation at Wigan Infirmary revealed myeloid 
leukaemia and she was admitted to the Christie Hospital on
11.10.49. The general condition was quite good, the spleen was 
substantially enlarged but the liver and lymph nodes were not 
palpable. There was no bleeding tendency and no pyrexia, 
platelets were plentiful, and the initial Hb level was 62$.
The WBC on admission was 460,000 per c.mm., 0.2$ being blast
cells, and all primitive cells amounting to only 5$ of the
• 32total. 6.0 mcs. of P were given on 13.10.49, followed by
4.0 mcs. on 21.10.49 and 2.11.49, and 3.0 mcs. each on 5.11.49,
17.11.49, 28.12.49 and 25.1.50. The WBC fell slowly but 
exponentially, with a HVD of 5.5 mcs.-destroyed, to a minimum 
level of 36,000 per c.mm. on 28.11.49. The Hb at that date
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was 78$ but it rose to a maximum of 90$ by 25.1.50, the WBC
then being 102,000 per c.mm. The spleen became reduced to a
few cms. below the costal margin, and the general health of the
patient improved considerably. By April 1950 the WBC had
risen to 160,000 and the Hb had dropped to 80$; the spleen
was again moderately enlarged, and though the general health
remained good a further course of radiotherapy was begun on
3221.4.50 when 3.0 mcs. of P were given. A similar dose was 
given on 28.4.50 but with such a slowly falling count further 
treatment was continued by splenic x-ray therapy, starting on
8.5.50. The WBC fell to a minimum of 4,900 on 27.6.50, when 
the Hb was 91$, the spleen not palpable, and the general health 
excellent. The Hb rose to 98$ by 14.9.50 but the spleen became 
large and tender and the WBC rose to 160,000 by the end of 1950. 
Further splenic irradiation was given from 20.2.51 to 24.3.51, 
and again the spleen disappeared behind the costal margin by
10.5.51 and the Hb on that date was 106$. Deterioration during 
the next few months called for chemotherapy with a mustard 
derivative, from 29.8.51 to 7.9.51. The WBC was controlled 
but the Hb showed little improvement, and though chemotherapy 
was repeated in November there was no real response, Small 
doses of splenic irradiation were tried again in view of previous 
responsiveness to this treatment but the patient died on
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12.12.51.
Autopsy confirmed widespread myelogenous leukomic 
infiltration, but in addition the femeral marrow showed areas 
of fibrous tissue replacement, i.e. myelofibrosis, and the 
sternal marrow showed lesser similar changes. The spleen 
showed large infarcted areas but also areas of active 
haemopoiesis.
Case M 27.
Miss J.B., aged 12, developed symptomless abdominal
swelling noted by her Mother rather than by the patient, in
May 1950. Investigation in Accrington Hospital revealed
myelogenous leukaemia and she was admitted to the Christie
Hospital on 5.9.50. The general condition was fairly good,
the spleen nearly filled the abdomen, and the liver also was
moderately enlarged. There was no bleeding tendency or
pyrexia, platelets were plentiful, and the initial Hb level
was 44$. The WBC on admission was 590,000 per c.mm., 4,0$
being blast cells and 78$ immature cells of all stages. On
328.9.50 the first dose of 4.25 mcs. of P was given, followed
by similar doses on 14.9.50 and 21.9.50. The WBC fell very
32slowly, and it was decided to avoid further P in this case
and switch instead to splenic x-ray therapy. The latter began
on 29.9.50 and ended on 6.10.50. The initial fall in the WBC
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32in response to P alone was sufficient to establish that the
response was exponential with a HVD of 8.4 mcs.-destroyed.
32The WBC fell in response to P and x-ray therapy to a minimum 
level of 6,200 per c.mm. by 16.10.50, the Hb then being 64J6.
By 21.11.50 the Hb was 82j£ but the WBC had already risen to
24,000. The spleen never resolved as far as the umbilicus 
but the general health showed a distinct improvement. Re­
treatment was necessary by February 1951, and splenic 
irradiation from 13.2.51 to 9.3.51 led to considerable improve­
ment again. The spleen was barely palpable by April 1951, 
and by July the Hb was 108^. By December 1951, though the 
general condition remained excellent, the spleen was again 
huge and the WBC 300,000 per c.mm. From 14.12.51 to 2.1.52 
another course of splenic x-ray therapy reduced the size of the 
spleen to a more comfortable level, it also reduced the WBC to
11,000 by 7.1.52, but as so often happens at this stage, it 
failed to improve the red cell count. By June, general 
deterioration had set in, and though B.E.P. was tried from
19.6.52 onwards, a myeloblastic phase ended in death on 7.8.52. 
Autopsy was not permitted.
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Case L 1.
Mr. W. McC., aged 69, weight 63 kilos, noted lamps in
the neck in December 1950. Investigation in Warrington
Infirmary revealed chronic lymphatic leukaemia and he was
referred to the Christie Hospital on 5.3.51. On admission he
was slightly cyanosed and had inflammatory changes in the right
lower lobe of his lung. The spleen was just palpable, the
liver was not palpable but there were lymph nodes enlarged though
small in all areas. The Hb was 66$, platelets were plentiful
and there were no haemorrhagic features. The WBC was 56,000
per c.mm. with many large immature lymphocytes. A dose of 
3210.0 mcs. of P was given on 13.3.51 and the WBC fell exponen­
tially, with a HVD of 0.9 mcs,-destroyed to a minimum level of 
3,500 per c.mm. on 25.4.51. The Hb on that date was 72$ but 
it rose to a main mum level of 80$ an 15.6.51 when the WBC was
16.000 per c.mm. The spleen became impalpable by May 1951, 
and the general condition improved considerably though slowly, 
the opacity in the right base being completely cleared by June
1951. The blood picture deteriorated rapidly during January
1952, and the patient was re-admitted on 22.1.52 with symptoms 
and signs of coronary thrombosis. He had in fact a history 
of coronary thrombosis in 1946. He improved with bed rest 
arifl sedation and was allowed home on 3.3.52. The Hb then was
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68$ with 58,000 white cells, 48,000 of which were lymphoblasts. 
It was decided to avoid any positive anti-leukaemic treatment 
for the time being but the patient died suddenly in another 
hospital on 11,4,52.
Case L 2.
Mrs. F.R., aged 43, weight 45 kilos, developed malaise 
and lassitude when aged 40 and had a rather premature meno­
pause. In June 1953, she noticed a lump in the left axilla 
and was referred to Oldham Royal Infirmary where blood 
examination revealed lymphatic leukaemia. She was admitted to 
the Christie Hospital on 15.7.53 when her Hb was 84$, platelets 
plentiful, and there were no haemorrhagic signs. The spleen 
was moderately enlarged, the liver was not palpable, but lymph 
nodes in all areas were slightly enlarged. The WBC was
144,000, 97$ being lymphocytes with many smear cells. On
3217.7.53 a single dose of 6.4 mcs. of P was given and proved 
adequate. The WBC fell exponentially with a HVD of 1.1 mcs.- 
destroyed to a minimum level of 9,600 per c.mm. on 14.8.53.
The Hb on that date was 90$ but it rose to 102$ by 11.3.54 by 
which time the WBC had risen to 52,000 per c.mm. The spleen 
resolved significantly but incompletely, but the lymph nodes 
became quite impalpable by 24.12.53. The general condition 
of the patient was greatly improved but in October 1954, she
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deteriorated quite rapidly. The Hb was still at 96^, but the
WBC had risen to 102,000, In spite of the good Hb level and
moderate WBC the patient’s symptoms of anorexia, lassitude,
dyspnoea, splenic discomfort, and occasional ecchymoses led to
32a further treatment with 6.0 mcs, of P on 14,10.54. The 
WBC again fell exponentially with a HVD of 1.2 mcs.-destroyed, 
reaching a lowest level of 6,400 on 24.11,54. The Hb on the 
latter date had dropped to 80J& - not a good finding, but 
curiously enough the patient’s general health had improved 
very considerably. By February, 1955, the spleen was 
impalpable and the Hb reached lQOjI by June 1955. Though she 
has had one or two bouts of pulmonary infection the patient 
remains active and well with no disturbing symptoms. On 
24.4.57 her Hb was 9 6 and the WBC 64,000, the liver was not 
palpable, the spleen enlarged 3 cms. below the costal margin. 
Only one node was palpable, a small one in the left axilla. 
There were no petechiae or ecchymoses, and the appetite was 
excellent.
The two HVDs in this case were again remarkably 
similar — 1.1 and 1.2 mcs.-destroyed.
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Case L 3.
Mrs.E.S., aged 51, weight 74 kilos, developed herpes
zoster in the cervical region in June 1948, and thereafter
discovered enlarged nodes in the neck. These subsided, but
investigation in Oldham Boyal Infirmary showed a blood picture
suggesting early lymphatic leukaemia. No treatment was
indicated at that time, but by June 1950, she had 50,000 white
cells per c.mm., 77j£ being lymphocytes. On admission to the
Christie Hospital in August 1950, the WBC was 70,000 with 92.5)1
lymphocytes, many being smear types. The spleen extended
nearly to the umbilicus, the liver was not felt but lymph nodes
in all areas were palpable though not greatly enlarged. The Hb
level was 76)6, platelets were plentiful, and no haemorrhagic
32signs were seen. An initial dose of 7.0 mcs. of P was given 
on 23.8.50 followed by 2,0 mcs. on 30.8.50 and 1.0 me. on
7.9.50, 14.9.50 and 21.9.50. The WBC fell exponentially with 
a HVD of 1.3 mcs.-destroyed. The Hb rose only 8% to 84JS on
2.10.50 when the WBC was 3,000 per c.mm. The lymph nodes showed 
no significant resolution, and particularly disappointing was 
the fact that ascites, present on admission, not only persisted 
but increased considerably. The general condition did not 
improve, the Hb and WBC both collapsed during October and the 
patient died on 28.10.50. The ascites in this case was an 
unusual feature, but unfortunately no autopsy was permitted.
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Case L 4
Mr. J.H.D., aged 55, weight 56 kilos, noticed a 
swelling in the left neck in January 1951. Investigation at 
Manchester Royal Infirmary revealed chronic lymphatic leukaemia 
and he was referred to the Christie Hospital on 26.2.51. At 
that time the WBC was 33,000 and the Hb 86)6. The patient 
felt well and no treatment was indicated. He was seen at 
short intervals until October by which time the Hb had fallen 
to 66)6 and the WBC had risen to 100,000 per c.mm. 97)6 of the 
white cells were lymphocytes with many smear types, platelets
were plentiful, and the spleen and liver were not palpable.
32On 30.10.51 a dose of 5.5 mcs. of P was given followed by
3.0 mcs. on 7.11.51 and 12.11.51. The WBC fell exponentially 
with a HVD of 1.4 mcs.-destroyed, to a minimum level of 2,700 
on 20.11.51. The Hb on the latter date was 62)6 but rose 
slowly to a maximum of 90)6 on 27.10.52. The WBC by that time 
was 17,500 per c.mm. The lymph nodes showed little resolution, 
but the general condition of the patient improved considerably. 
By October 1953, the first remission had clearly terminated 
both clinically and haematologically, the Hb being 55)6, the 
WBC 120,000 per c.mm. and the general condition quite poor. 
Recent "influenza1’ had left him feeling ill. At this stage 
chemotherapy was employed out of interest, and not because of 
any contra-indication to radiation therapy. One of the
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nitrogen mustard derivatives (C.B.9859) was given on 3,10.53 
and produced a rapid drop of the WBC to about 1,000 cells per 
c.mm. by 14.10.53! The Hb also fell and 4 pints of blood 
were transfused during 20 and 21.10.53. The Hb then rose 
from 46)6 to 67)6 and continued to rise to 86)6 on 19.1.54. The 
lymph nodes had also shown a dramatic resolution and were 
scarcely palpable within 10 days of the chemotherapy. The 
platelets also dropped to between 40,000 and 50,000, but the 
patient's general health undoubtedly improved during the 4 
months following this rather frightening chemotherapy. By 
April, 1954, further chemotherapy was indicated, T.E.M. being 
used on this occasion. Again worthwhile improvement followed, 
though a pneumonic attack in August 1954 spoiled the clinical 
value of this remission. By December 1954, the Hb was down 
again to 45)6, the WBC 120,000 and platelets also reduced. 
Tentative doses of x-rays to the spleen were initiated on
2.12.54 with little real improvement. This was continued on 
a weekly out-patient basis from 29.3.55, but though the spleen 
became less uncomfortable for a time, the patient finally 
deteriorated and died on 12.10.55. The WBC was rising 




Mr. W.H.B., aged 53, weight 59 kilos, noted swollen 
glands in the neck three years before being referred to 
Blackburn Infirmary where chronic lymphatic leukaemia was 
diagnosed. On admission to the Christie Hospital in February 
1953, the Hb was 68)6, platelets were plentiful and there were 
no haemorrhagic findings. The spleen was moderately enlarged, 
and lymph nodes were grossly enlarged in the neck, axillae and 
groin. The WBC was 500,000 per c.mm., with scarcely any poly­
morphs, but many smear cells, large lymphocytes, and lympho-
32blasts. On 27.2.53 a dose of 8.46 mcs. of P was given, 
followed by 3.0 mcs. on 13.3.53 and 23.3.53. The WBC fell 
exponentially, with a HVD of 1.4 mcs.-destroyed, to a minimum 
level of 5,200 on 31.3.53. The Hb at that date was 70)6 but 
it rose slowly to a maximum level of 102)6 in February, 1954, 
the WBC then being 108,000 per c.mm. In May 1954, this patient 
developed an attack of herpes zoster over the right shoulder 
region (See Figure 6) and this was followed by a widespread 
papular eruption (not vesicular) on the trunk. Biopsy of one 
of these papules showed ’rather widespread but patchy infil­
tration of the sub-epithelial layers by lymphocytes, with an
occasional clump of histiocytes”. By July 1954, the WBC was
32200,000 and the Hb 72)6. A single dose of 6.0 mcs. of P was
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given on 29.7.54 and again the WBC fell exponentially with a
HVD of 0.9 mcs.-destroyed to a lowest level of 13,000 per
c.mm. by 6.9.54. The Hb on that date was 83)6, but this rose
steadily to 98)6 by 28.9.54. The general condition also
improved, the spleen and lymph nodes however showed little
response. By February 1955, the Hb had fallen again to 68)6
and the WBC was 285,000 per c.mm. A single dose of 5.0 mcs.
32of P was given on 25.2.55 and again the WBC fell exponentially 
with a HVD of 1.1 mcs.-destroyed to a lowest level of 8,000 by 
5.4.55. The Hb then was 70)6 but it rose to 88)6 in August 
1955. However recurrent pulmonary infections led to pro­
gressive deterioration and by February 1956, the Hb had fallen 
to 40)6 and the WBC was up to 304,000. Tentative doses of 
x-rays to the spleen were given between 16.2.56 and 24.2.56, 
but in spite of blood transfusions and general supportive 
measures the patient died on 5.7.56. Autopsy was not permitted.
Note again the limited variation in the HVDs for thr'ee 
32courses of P - 1.4, 0.9 and 1.1 mcs.-destroyed.
Case L 6
Mr. H.R., aged 66, developed pleurisy in July 1954, 
and swollen glands in the right neck in September 1954. He 
was admitted to the Christie Hospital on 19.10.54 and investi­
gation revealed chronic lymphatic leukaemia. The spleen was
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moderately enlarged, the liver was not palpable but lymph nodes 
were large and florid in the right neck, axillae and groins, 
and both tonsils were considerably enlarged. The Hb was 68)6, 
platelets were reduced but no haemorrhagic features were 
noted. The WBC was 570,000 per c.mm., nearly all lymphocytes,
with smear cells, large immature lymphocytes and lymphoblasts.
32On 29.10.54 a dose of 6.0 mcs. of P was given followed by a 
further 6.0 mcs. on 15.11.54. The WBC fell exponentially, 
with a HVD of 2.0 mcs.-destroyed, to a minimum of 19,000 per 
c.mm. on 21.12.54. The Hb on that date was 78)6 and it rose 
steadily to a maximum of 93)6 on 29.3.56, the WBC then being 
up to 40,000 per c.mm. The general condition of the patient 
improved, but the spleen showed no response, and the lymph 
nodes, especially the mass in the right neck, showed only 
moderate resolution. It is of interest that though additional 
resolution of the neck nodes did occur after x-ray therapy on
1.2.55 there was incomplete resolution even after 2,000r in 
4 days through a field 10 x 12 cms. This dosage produced 
patchy moist desquamation, and might well have produced total 
if temporary resolution of squamous cell carcinoma, much less 
lymphosarcoma. The nodes of chronic lymphatic leukaemia are 
truly limited in their radio-sensitivity. By February 1956, 
further treatment was necessary. The Hb had fallen to 64)6
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and the WBC had risen to 180,000 per c.mm. On 13.2.56 a dose 
32of 4.7 mcs. of P was given, followed by 3.1 mcs. on 28.2.56.
The WBC again fell exponentially, with a HVD of 1.5 mcs.-
destroyed, to a mininrom level of 19,500 per c.mm. on 14.3.56.
The Hb at that date was 68$ hut it rose slowly to a maximum
of 72$ by July 1956. The spleen and nodes showed no response,
and though there was real subjective improvement until
November, there was rapid deterioration in December 1956. On
3218.12.56 a single dose of 5.0 mcs. of P was given and yet 
again the WBC fell exponentially with a HVD of 0.8 mcs.- 
destroyed from an initial level of 154,000 to a lowest level of
19,700 per c.mm. on 4.1.57. The general condition, however, 
did not improve and the Hb fell steadily from a pre-treatment 
level of 52$ to 28$ on 19.2.57. This might have been expected 
from the finding on 14.12.56 that the time for 50$ plasma 
clearance of Fe59 was 141 minutes. (Marrow samples were at 
that time unsatisfactory). The patient is now moribund (June, 
1957).




Mr. J.T.M., aged 49, weight 48 kilos, developed a 
generalised erythematous rash during December 1954. This 
became an exfoliative dermatitis and while in the North 
Lonsdale Hospital blood examination disclosed chronic lymphatic 
leukaemia, with 210,000 white cells, 96$ of which were lympho­
cytes. The Hb level was 70$, platelets were reduced, the 
spleen was not palpable but the liver was just palpable. No
lymph nodes were felt and there were no petechiae, ecchymoses
32or other haemorrhagic features. 5.0 mcs. of P were given 
on 27.1.55 and during the following 4 days blood counts showed 
an exponential fall in the WBC with a HVD of 2.0 mcs.- 
destroyed. The skin showed a rapid improvement during these 
first four days, but the patient suddenly collapsed and died 
on 1.2.55. At autopsy the leukaemia was confirmed, blood 
smears looked like acute lymphoblastic leukaemia, but the bone 
marrow was quite extraordinary. Dr. J.A. Shrigley reported 
•"large areas of marrow are replaced by proliferating fibro­
blasts, reticulum cells, and intense eosinophilic leucodytic 
infiltration". The case was discussed with Dr. M.C.G. Israels 




Mr. H.B.S., aged 56, weight 71 kilos, gave a history
of recurrent pyrexial attacks with pulmonary infections during
ten years prior to his leukaemia diagnosis. In 1949 he
became distinctly more weak than hitherto and was finally
referred to a physician in November 1950, and thence to the
Christie Hospital on 8.11.50 as chronic lymphatic leukaemia.
The spleen was moderately enlarged, the liver was not palpable,
nodes were slightly enlarged in all areas, there were no
haemorrhagic signs, and the general health was only fair. The
Hb was 84$, platelets were reduced, and the WBC was 165,000
per c.mm., 95.5$ being lymphocytes, with many smear types and
moderate numbers of lymphoblasts. On 17.11.50 a dose of 10.0 
32mcs. of P was given, followed by 5.0 mcs. on 24.11.50 and
1.12.50. The WBC fell exponentially, with a HVD of 2.3 mcs.- 
destroyed, to a minimum level of 4,500 per c.mm. on 13.12.50. 
The Hb on that date was 82$ but it rose to a maximum of 102$ 
by February 1951, by which time the WBC had also climbed to 
21,000. The patient’s general health improved during this 
remission, though he was troubled from time to time by a 
variety of vague symptoms - headaches, pains in the chest, 
diarrhoea, etc. - and was investigated extensively to exclude 
coronary thrombosis. He nevertheless maintained an active
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business life until January 1953 by which time his Hb had
fallen to 80^ and the WBC was 132,000 per c.mm. A dose of 
3210.0 mcs. of P was given on 22.1.53 followed by 3.0 mcs. on
5.3.53. The WBC fell again exponentially, with a HVD of 2,5
mcs.-destroyed, reaching 6,100 per c.mm. on 18.2.53. The Hb
on the latter date was only 72̂ 6 but it rose to 90̂ 6 by
September 1953. The spleen became impalpable by 5.3.53, but
the nodes behaved curiously in that where they were only just
palpable before treatment they became distinctly larger in all
32areas about five days after the first injection of P and
became almost impalpable again about six weeks after treatment.
A single exposure of 600r x-rays to both sides of the neck
on 24.9.53 (10 x 8 cm. fields, at 250 Kv.) produced no
resolution whatever. By November 1953 the Hb had again fallen
to 78^, the WBC was 72,000, platelets reduced, and the general
condition of the patient was poor. On 13.11.53 a dose of 
326.5 mcs. of P was given, but after an apparent response of
the WBC and the Hb during December 1953, he deteriorated
rapidly with marrow exhaustion and auto-antibodies. The
patient died on 12.2.54, but autopsy was not permitted.
32The HVDs for the two completed courses of P were
2.3 and 2.5 mcs.-destroyed.
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Case L 9
Mr. J.W.D., aged 67, weight 49 kilos, had at least 
four attacks of bronchitis and pneumonia between 1946 and 
1952. During an attack in February 1952 an enlarged spleen 
was found, and investigation at the Northern Hospital, 
Manchester, disclosed chronic lymphatic leukaemia. The 
spleen was grossly enlarged, the liver edge was four cms. 
below the right costal margin, lymph nodes were only slightly 
enlarged in the groins, and there were no haemorrhagic find­
ings. The Hb was 60$, platelets moderately reduced, and the
WBC was 100,000 per c.mm., with nearly 97$ lymphocytes, many
32being smear types. On 1.4.52 a dose of 5.0 mcs. of P was 
given, followed by 2.5 mcs. each on 8.4.52, 16.4.52 and
22.4.52. The WBC fell exponentially, with a HVD of 2.3 mcs.- 
destroyed, to a lowest level of 5,200 by 1.5.52. The Hb at 
that date was 66$ and it rose to a maximum level of 88$ by
25.8.52, by which time the WBC was only 7,800 per c.mm. The 
liver became impalpable by 9.6.52 and the spleen was reduced 
to the umbilical level by the same date. The patient's 
general health improved considerably, but the whole picture 
began to deteriorate about November 1954, when the Hb had 
fallen to 66$, the WBC being up to 74,000 per c.mm. The 
patient, however, insisted that he felt fit in spite of the
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haematological deterioration. He removed to the south of 
England during 1955 and Dr. Jan de Winter has since reported 
that the patient has shown worthwhile response to x-ray 
therapy until January 1957 when at last his health was showing 
signs of terminal deterioration.
Case L 10
Mr. V.D., aged 62, weight 68 kilos, complained of 
lassitude and loss of weight for two years. Backache in 
May 1953 led to a medical investigation at the North Lonsdale 
Hospital where chronic lymphatic leukaemia was found. On 
admission to the Christie Hospital on 22.5.53 the spleen was 
enlarged to the umbilicus, the liver edge was enlarged 3 cms. 
below the costal margin, but only two nodes were palpable in 
the left groin. There were no haemorrhagic signs, the Hb 
was 84$ and platelets were moderately reduced. The WBC was
96.000 per c.mm., 99$ being lymphocytes with many smear cells.
329.7 mcs. of P were given on 3.6.53, and the WBC fell 
exponentially, with a HVD of 2.5 mcs.-destroyed, to a minimum 
level of 12,400 on 23.6.53. The Hb on that date was 78$ but 
it rose to a maximum of 106$ by 8.1.54 when the WBC was up to
23.000 per c.mm. The spleen showed significant resolution 
within two months of treatment, but the nodes in the groin 
resolved more slowly. The general condition of the patient
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also improved considerably within two months of treatment, and.
this remission lasted for two years. A second treatment of 
325.0 mcs. of P was given on 16.8.55, the indications for thi#
being clinical rather than haematological. The Hb was 82$
and the WBC only 38,000. The spleen, however, was enlarging,
the general health was poorer, and the patient had had several
pyrexial attacks of pneumonitis. There was a rapid improve-
32ment in general well-being after this P , and although the
WBC fell no lower than 18,500, the Hb rose to 93$ by 23.11,55.
The WBC on the latter date was 23,000 per c.mm. It should be
noted that the WBC had again fallen exponentially with a HVD
on this occasion of 4.0 mcs.-destroyed. This patient was last
seen for review on 26.4.57 when his general health remained
very good apart from old-standing arthritis. The spleen was
still at the umbilicus but was not uncomfortable. The liver
was not palpable and there were no Substantial lymph nodes to
be felt. The Hb was 80$ and the WBC 8,800 per c.mm.
32The HVBs for his two courses of P were 2.5 and 4.0 
mcs.-destroyed.
Case L 11
Mr. J.S., aged 62, weight 57 kilos, complained of 
increasing lassitude and susceptibility to infections for 18 
months before investigation at Barrow Hospital disclosed chronio
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lymphatic leukaemia. On admission to the Christie Hospital
on 23.3.53 the liver was just palpable, the spleen was
moderately enlarged, and lymph nodes were also moderately
enlarged in the left neck and both axillae. There were no
haemorrhagic signs, the Hb was 58$, platelets were Somewhat
reduced, and the WBC was 266,000 per c.mm. with 97$ lymphocytes
32and many smear cells. On 14.4.53 a dose of 8.1 mcs. of P 
was given, followed by 4.5 mcs., 1.5 mcs., and 3.0 mcs. 
respectively on 28.4.53, 5.5.53, and 6.5.53. The WBC fell 
exponentially, with a HVD of 2.7 mcs.-destroyed, but the Hb 
did not improve, and indeed in June the Hb fell to 46$ and the
WBC to 6,200 per c.mm. The patient felt weak and was re­
admitted to hospital where he was given two pints of packed 
red cells. His improvement was immediate, and as so often 
happens, the Hb improvement was out of all proportion to the 
quantity of transfused blood. By September the Hb was 105$ 
and by February 1954 was recorded at 128$, the WBC then being
23,000 per c.mm. The general condition had also improved 
enormously from the time of the small transfusion, the spleen 
was not palpable, and there were no nodes or haemorrhagic 
signs. In July, 1955, he deteriorated again, the Hb fell to
80$ and the WBC rose to 41,000. A single dose of 6.0 mcs.
was given on 4.8.55 and the WBC fell exponentially, with a HVD
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of 2.0 mes.-destroyed, to a lowest level of 7,000 per c.mm. by
28.10.55. The haemoglobin rose to 100$ by December, 1955,
and the patient felt "absolutely splendid”. By December,
1956, he was again in need of treatment and had 5.3 mcs. o f 
32P on 28.12.56 followed by 2.0 mcs. on 11.1.57. The WBC fell 
from 66,000 to 11,000 on 8.2.57 and the Hb rose from 82$ to 
105$ by the same date. The HVD on this occasion was 2.6 mcs.- 
destroyed. When last reviewed on 8.3.57 this remission was 
being well maintained.
32The HVDs for these three courses of P were 2f7, 2.0 
and 2.6 mcs.-destroyed.
Case L 12
Mr. W.F.H., aged 61, developed an acute respiratory
infection in August, 1953. He had a further pneumonic episode
in April, 1954, was referred to Oldham Royal Infirmary and
thence to the Christie Hospital on 9.6.54. The general
condition was good, the spleen just palpable, and lymph nodes
in the neck, axillae and groins were florid. There was no
pyrexia, no petechiae, ecchymoses or mucosal bleeding. The
Hb was 66$, platelets were scarce, and the WBC was 934,000 per
c.mm., with large lymphocytes and smear cells in small numbers.
32The first course of P consisted of 3 doses each of 6.0 mcs. 
on 17.6.54, 1.7.54 and 20.7.54. The WBC fell exponentially,
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with a HVD of 2.7 mcs., the lowest level being 14,500 on 12.8.54.
The Hb rose to a maximum of 94$ on 14.4.54, the WBC at that
date having climbed to 197,000 per c.mm. The spleen was not
palpable by 28.10.54 and the large lymph nodes had become
considerably smaller by September, 1954. The general condition
also improved significantly, but began to deteriorate again by
32November, 1955. A second course of P began on 1.12.55 with
5.0 mcs. followed by 3.0 mcs. on 23.12.55. The WBC again fell 
exponentially but on this occasion more sensitively, the HVD 
being 0.9 mcs.-destroyed. The Hb at the start of this second 
course was only 60$, the WBC 500,000 and platelets 150,000 
per c.mm. An Fe59 study indicated poor erythropoiesis and 
confirmed the sternal marrow findings of scanty nucleated red
■ji.cells. The Hb did, however, appear to improve, as did the 
general condition, until 20.1.56 when purpura and mucosal 
bleeding heralded the fatal termination on 27.1.56. At autopsy 
the most striking feature was the generalised small haemorrhages 
in most organs, and a massive intracranial haemorrhage which 
Irad destroyed both internal capsules and most of the left 
posterior occipital lobe.




Mr. A.S.M., aged 46, weight 67 kilos, first complained
of a lump in the left axilla about March, 1953. He felt well,
but on examination at Park Hospital, Manchester, chronic
lymphatic leukaemia was discovered and he was referred to the
Christie Hospital on 29.6.53. At that time the Spleen waa
enlarged to the umbilicus, the liver was not palpable, but he
had large florid nodes in both axillae and neck as well as
bilateral hilar nodes. There was a congenital absence of
the right pectoralis major muscle. The initial Hb level was
90$, the WBC 196,000 with smear and blast cells in small
32numbers. An initial dose of 9.6 mcs. of P was given on
10.7.53 and the WBC fell exponentially with a HVD of 2.8 mcs.- 
destroyed. A second injection of 4.5 mcs. was given on
24.7.53 and the WBC fell to a lowest level of 12,000 on 10.8.53.
The Hb rose to a maximum of 98$ on 1.2.54. The WBC on the
latter date was 53,000 per c.mm. It is interesting to note
32that after the first P injection the patient complained of 
transient discomfort in his enlarged lymph nodes and there was 
some discernible increase in their size. The nodes did, 
however, become significantly smaller after treatment and the 
spleen was not palpable by 7.12.53. By January, 1955, the Hb 
had fallen to 83$, the WBC had risen to 253,000, the spleen was 
just palpable, but the lymphadenopathy was again florid.
- 204 -
32A second course of P therapy "began with 5.0 mcs. on 13.1.55,
repeated on 27.1.55, and with 3.0 mcs. on 10.2.55. Again
the WBC fell exponentially with a HVD of 2.8 mcs.-destroyed.
The WBC fell to a lowest level of 21,000 on 19.3.55, the
highest recorded Hb being 94$ on 23.5.55. The WBC on the
latter date was 49,000 per c.mm. The spleen on this occasion
never became quite impalpable and the liver was also palpable.
Deterioration became obvious during January, 1956 - falling
Hb, rising WBC, scarce platelets, increasing size of nodes
32and spleen. A further course of P began with 4.5 mcs, on 
2.3.56, followed by 5.0 mcs. on 23.3.56. The WBC responded 
again exponentially, and again with a HVD of 2.8 mcs.- 
deStroyed, falling to 18,000 per c.mm. by 11.4.56. The Hb 
rose from 74$ to 86$ on 16.4.56, the WBC then being 20,000.
The spleen was not palpable on 9.7.56 but the nodes remained 
unresponsive.
This remission continues in June 1957.
  32The remarkably constant HVDs for three courses of P
should be noted - 2.8, 2.8 and 2.8 mcs.-destroyed.
Case L 14
Mr. W.T.J., aged 27, weight 63 kilos, complained of 
pain in the left thigh for two years, but investigations were 
uninformative until November 1949, when he was found to have a
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leukaemic blood picture. He was referred from Wrexham
Hospital to the Christie Hospital on 30.11.49. The spleen
then was just palpable, the liver was not palpable nor were
there any enlarged lymph nodes. There were no haemorrhagic
signs but platelets were scarce (90,000 per c.min.), the Hb
was 52$ and the WBC only 17,000 with many smear cells, large
32lymphocytes, and lymphoblasts. A dose of 5.0 mcs. of P
was given on 30.12.49 followed by a further 4.0 mcs. on 11.1.50.
The WBC fell exponentially, with a HVD of 3.3 mcs.-destroyed,
the lowest level being 5,000 per c.mm. on 19.1.50. The Hb on
that date was 60$ and it never increased above 62$. The
Spleen did not resolve and the general condition never really
improved. Diarrhoea with blood in the stools, shortly after
his treatment, raised the suspicion that the whole clinical
picture might have been Brucellosis, but all serological tests
were negative, as also was sigmoidoscopy. The patient became
acutely ill in March 1950, with pyrexia, bleeding from the gums
and rectum, with tenderness of the spleen, no lymphadenopathy
but rapidly progressive anaemia. He died on 17.3,50. This
32was one of the first patients treated at this centre with P 
and in retrospect one cannot but think it was unwise to have 
treated such a dubious and probably acute leukaemia. Autopsy, 
unfortunately, was not permitted.
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Case L 15
Miss S.S., aged 58, weight 59 kilos, complained Si
lack of energy for 2 years and lumps in both axillae for 15
months before being referred to the Manchester Jewish
Hospital where chronic lymphatic leukaemia was diagnosed.
On admission to the Christie Hospital on 25.12.52 the spleen
was moderately enlarged, the liver was not palpable but
lymph nodes were grossly enlarged in all areas. There were
no haemorrhagic signs, platelets were moderately reduced,
the Hb was 68$ and the WBC was 167,000 per c.mm., 96$ being
lymphocytes with many smear cells. On 31.12.52 a dose of 
328.46 mcs. of P was given, followed by 4.0 mcs. on 15.1.53 
and 22.1.53. The WBC fell exponentially, with a HVD of
3.3 mcs.-destroyed, but it fell steadily to a minimum of
4,000 on 24.3.53 and the Hb also fell steadily to 24$ on 
the Same date. The peripheral blood and sternal marrow 
all suggested aplasia, though the complete failure of 4 pints 
of whole blood and 4 pints of packed red cells to prevent 
the progressive fall in the Hb level suggested a haemolytic 




Miss D.R., aged 62, developed left-sided hemiplegia 
due to cerebral thrombosis in 1949. She was also troubled 
by rheumatoid arthritis, but in January 1954, she had acute 
broncho-pneumonia and was found in Oldham Royal Infirmary to 
have chronic lymphatic leukaemia. The Hb then was 86$ and 
the WBC 267,000 per c.mm. She was kept under observation 
until December 1954, when she was referred to the Christie 
Hospital for treatment. On admission the general health was 
fairly good, the spleen was just palpable, the liver impalpable, 
but lymph nodes were generally enlarged. There were no 
haemorrhagic features, but the Hb was down to 60$, platelets 
were scarce and the WBC was 680,000, all but 0.5$ being lympho­
cytes, including many smear cells and large lymphocytes. On
329.12.54 a dose of 5.0 mcs. of P was given and this produced 
a slow exponential response in the WBC with a HVD of 4.0 mcs.- 
destroyed. On 28.12.54 the predicted Minimum Effective Dose 
was in the region of 25 mcs. and in view of this slow response 
the treatment method was changed to splenic x-ray therapy. The 
WBC fell to a minimum of 9,900 on 3.2.55, the Hb then being 67$. 
The Hb continued to a maximum of 96$ by May, 1955, the WBC by 
then being 45,000 per c.mm. The spleen became impalpable by 
March 1955, but the lymph nodes showed no significant resolution. 
The general health improved enormously, but in November 1955,
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further splenic irradiation became necessary after a fall of 
Hb to 68j£ and a rise in WBC to 280,000 per c.mm. Again the 
general health improved, the WBC fell and the Hb rose to a 
maximum of 82^ in March 1956. By July 1956 deterioration was 
rapidly increasing and another course of splenic x-ray therapy 
was begun on 19.7.56 and supplemented by a small blood trans­
fusion. The platelets were now down to 50,000 and petechial 
haemorrhages appeared in showers. The patient removed to 
the Southport area in September 1956, and in January 1957 was 
reported to be just holding her own after blood transfusions 
and cortisone.
Case L 17
Mr. A.E.J., aged 52, weight 76 kilos, noticed swollen
glands in his neck in July 1953, he was investigated at Wigan
Infirmary, and referred to the Christie Hospital on 19.11.53.
The general condition was good, the spleen just palpable, and
he had florid enlargement of cervical, axillary, and mesenteric
nodes. The liver was not enlarged, he was apyrexial, with no
petechiae, ecchymoses, or mucosal bleeding. The Hb was 98j£,
platelets slightly reduced, and the TOC was 178,000 with some
32smear cells. 5.7 mcs. of P were given on 1.12.53, 7.0 mcs. 
on 15.12.53 and 7.3 mcs. on 6.1.54. The WBC fell exponentially, 
with a HVD of 4.7 mcs.-destroyed, to a lowest level of 12,700
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per c.mm, on 22.2.54. The Hb on the latter date was 104$,
the highest level recorded during the first remission. The
general condition improved considerably, the spleen was
impalpable by 17.6.54, and the nodes had become significantly
smaller. By May, 1955, the general condition had deteriorated,
the Hb had fallen to 65$, the WBC was 300,000 and blast cells
32were making their appearance. A second course of P was 
given as follows:- 5.0 mcs. on 26.5.55, 6.4 mcs. on 9.6.55,
7.0 mcs. on 24.6.55 and 8.0 mcs. on 8.7.55. The WBC again 
fell exponentially, the HVD on this occasion being 5.2 mcs.- 
destroyed. The general condition undoubtedly improved, and 
the lymph nodes again became much smaller. The Hb however, 
did not significantly improve and by October 1955, he was again 
ill, with gross splenic enlargement, hepatomegaly, and florid 
lymph nodes. The rapid collapse of erythropoiesis was 
associated with a rapid Fe59 clearance rate which suggested 
haemolysis, though Coomb's test was negative. Deterioration 
continued in spite of supportive measures, (avoiding anti­
mitotic agents) and the patient died on 3.3.56.




Mr. B.N., aged 55, weight 66 kilos, noted swelling 
of his neck glands in September 1952, saw his family doctor in 
May 1953, and was referred to Accrington Hospital in August 
1953, when chronic lymphatic leukaemia was found. On admission 
to the Christie Hospital in September 1953, the spleen was just 
palpable, the liver impalpable, lymph nodes slightly enlarged 
in all areas but there were no haemorrhagic signs. The Hb 
was 72$, platelets moderate in number, and the WBC was 230,000
per c.mm., 98.5$ being lymphocytes, with smear and blast cells.
32On 11.9.53 a dose of 9.4 mcs. of P was given, followed by
8.4 mcs. on 29.9.53. The WBC fell exponentially with a HVD 
of 6.4 mcs,-destroyed, but as the WBC fell so also did the 
haemoglobin and platelet levels and the general health 
deteriorated. The patient was troubled by septic lesions of 
the arms and face and he died with aplasia and pyrexia on
30.12.53. Unfortunately autopsy was not permitted.
Case L. 19
Mr. A.E.L.F., aged 71, weight 68 kilos, developed 
herpes zoster in December 1952, and while in Crumpsall Hospital 
was found to have chronic lymphatic leukaemia. On admission 
to the Christie Hospital on 3.3.53, his spleen was moderately 
enlarged, the liver was impalpable, but lymph nodes were florid
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in axillae and groins. There were no haemorrhagic features,
the Hb level was 7d$, platelets were plentiful, and the WBC
was 260,000 per c.mm., 97$ being lymphocytes, with many smear
32forms. On 13.3.53 a dose of 9.7 mcs. of P was given,
followed by 4.85 mcs. on 31.3.53 and 5.5 mcs. on 10.4.53.
Though the WBC fell exponentially with a HVD of 7,2 mcs. - 
destroyed, this was clearly a radio-resistant case and the WBC 
fell slowly to a minimum of 40,000 per c.mm. on 24.4.53. The 
spleen and lymph nodes showed significant resolution and the 
general health also improved greatly. The Hb however 
increased only by 10$, reaching 84$ by January 1954, the WBC 
by that time being up to 182,000 per c.mm. The Hb level
remained in the 70 - 80$ range, however, for many months, and
the patient remained active and free of symptoms until April 
1955. The WBC was then 225,000 and the Hb 74$, but the spleen 
was uncomfortable and the patient felt generally unwell. On
16.5.55 a dose of 7.5 mcs. was given (approximately the HVD of
32the first course of P ). By 2.6.55 it was obvious that the
same slow exponential fall in the WBC was taking place. Tor
this reason splenic x-ray therapy was instituted on that date,
and the WBC was depressed down to a minimum level of 8,600 by
3229.6.55 - a much more rapid effect than with P . The spleen 
became impalpable and the Hb rose to 90$ by 27.9.55, but the
- 211 -
WBC was also already rising rapidly and this remission was 
short-lived. On 24.1.56 a course of C.B. 1348 was started and 
the Hb rose slowly from 63$ to between 75 and 80$. When last 
reviewed on 16.4.57 the general health was good apart from 
dyspnoea (aged 751) . The lung fields were clear clinically 
and radiographically. Nodes were palpable only in the axillae, 
the spleen was enlarged to the umbilicus and the liver was just 
palpable. There were no haemorrhagic signs and the Hb was 76$, 
platelets were only 82,000 and the WBC 164,000 per c.mm. The 
low platelet count is the main deterrent to further treatment, 
but fortunately the patient is comfortable and happy.
Case L 20
Mr. G.R.A., aged 69, weight 63 kilos, noted lumps in 
the neck for 17 months and increasing fatigue for 9 months 
before admission to Withington Hospital in March 1950. Chronic 
lymphatic leukaemia was diagnosed and the patient admitted to 
the Christie Hospital on 26.4.50. On admission the spleen was 
grossly enlarged into the pelvis and across the mid-line, the 
liver was enlarged about 4.0 cms. below the costal margin, 
there were florid nodes in all areas, oedema of the ankles, but 
no haemorrhagic signs. The Hb was 52$, platelets were 
moderately reduced, and the WBC was 300,000 per c.mm. with 97.5$
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lymphocytes including smear cells, large lymphocytes and
32lymphoblasts. On 3.5.50 a dose of 8.0 mcs. of P was given
followed by 7.0 mcs. on 10.5.50, by 5.0 mcs. on 17.5.50, by
7.0 mcs. on 24.5.50, by 5.2 mcs. on 31.5.50, a further 7,0 mcs.
on 7.6.50, and finally 1.4 mcs. on 17.6.50. This large dose 
32of P reduced the WBC, Hb and platelet counts, though the WBC 
did fall quite exponentially with a HVD of 7.7 mcs.-destroyed. 
On 21.6.50 the Hb was down to 29$, the WBC was 50,000 and 
platelets were scarce. There were petechiae on the lower 
limbs. Pour pints of packed cells were given and the improve­
ment, though slow at first, continued until March 1952, when 
the Hb was 84$, the WBC was 6,500 and there was no palpable 
spleen, liver or lymph nodes. This astounding change from 
grave illness to near normality may have been assisted also by 
multi-vitamin therapy. In October 1952, he was described by 
me as "unrecognisable from his original state". He had 
continued to gain weight, was very fit, had no oedema, the Hb 
was still 84$, the WBC 6,900 with no palpable spleen, liver 
or nodes. In June 1953, he began to deteriorate and by 
September the Hb was 56$, the WBC 118,000, the spleen was again
below the umbilicus, the liver 5.0 cms. enlarged, and lymph
32nodes were again palpable. A  second course of P was begun 
on 16.10.53 with 9.6 mcs. repeating the same dose on 30.10.53.
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Unfortunately there was no improvement on this occasion. The 
WBC and Hh fell progressively in spite of transfusions, vitamins, 
etc. There was evidence of auto-haemolysis terminally, and 
the patient died on 19.12.53.
Case L 21
Mr. I.S., aged 67, weight 70 kilos, developed a sore
throat in October 1952, and was Seen at Blackpool Victoria
Hospital on account of enlarged tonsils. Examination disclosed
chronic lymphatic leukaemia, but his Hb level was 98$, the
total WBC only 49,000, and since his general health was good no
active treatment was advised. He was referred to the Christie
Hospital on 8.1.54 by which time he had many slightly enlarged
lymph nodes in all areas, the spleen was just palpable but
the liver was not enlarged and there were no haembrrhagic signs.
The Hb was 96$, platelets moderately reduced, and the WBC was
127,000 per c.mm., 96.5$ being lymphocytes, including smear cells
and immature lymphocytes. The patient felt rather unwell and
32it was decided to treat with P - perhaps a little unwisely,
32in retrospect. On 19.1.54 a dose of 6.0 mcs. of P was given 
followed by another 6.0 mcs. on 9.2.54 and again on 23.2.54.
The WBC fell very slowly but exponentially with a HVD of 15.0 
mcs.-destroyed (the most resistant case I have seen). So slow
was this response that splenic x-ray therapy was instituted on
12.3.54. However, after only 2 small exposures it was decided 
not to pursue radiation therapy any further. In April 1954, 
the patient was feeling well and the Hb was up again to 95^ 
while the WBC was 62,000 per c.mm. On 21.5.54 he was reviewed 
and found to be unchanged, but he died suddenly at his home on
25.5.54 and autopsy was not carried out. The presumptive cause 
of death was coronary thrombosis.
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Case E 1
Mr* G.L., aged 49, weight 56 kilos, complained of
increasing swelling of the abdomen for nine months before
consulting his doctor in September 1949. He had no other
symptoms, and was referred to the Christie Hospital on 3.10.49.
The spleen was grossly enlarged into the left iliac fossa and
across the midline. There were no enlarged lymph nodes,
the liver was impalpable, there were no petechiae or other
haemorrhagic features, and no pyrexia. The general health was
poor, however, the Hb was 85$, platelets were plentiful, the
WBC was 70,000 per c.mm., 10$ being primitive cells of the
myeloid series, and 1.0$ myeloblasts. He was regarded as a
case of chronic myeloid leukaemia, and on 13.10.49 a dose of 
326.0 mcs. of P was given, followed by 4.0 mcs. on 21.10.49.
The WBC had only just begun to show a significant depression 
(60,000) when the patient developed considerable splenic pain, 
collapsed and died on 5.11.49. Autopsy by Dr. R.M. Taylor 
confirmed the myeloid hyperplasia in the femoral marrow, with 
active erythropoiesis and normal megakaryocyte production.
The marrow was described, however, as ’’almost plum-coloured’’. 
The spleen showed considerable congestion, and areas of old and 
one large recent infarction. The lungs were also congested 
and there was an area of haemorrhage in the left lower lobe.
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The brain too was extremely congested. $he adrenals were 
small and flat, and there was considerable haemorrhagie 
exudate in the peritoneal cavity. There was gross congestion 
of the entire intestinal tract, with small sub-mucosal 
haemorrhages, but no sub-serosal haemorrhages were found. Both 
kidneys were extremely congested. The significant histological 
features, apart from leukaemic infiltration of various organs, 
was the extensive interstitial oedema in the lungs, heart, 
lymph nodes, spleen, and kidneys. There was also portal 
cirrhosis of the liver, and signs of tubular damage in the 
kidneys. The post-morten blood urea level was 490 mgms. per 
100 mils.
Case E 2
Mr. E.Ho, aged 71, weight 66 kilos, complained of 
abdominal discomfort, headaches and lassitude, from January 
1952, but consulted his doctor only in July 1952. Investi­
gation at Wrexham Hospital disclosed chronic myeloid leukaemia, 
and he was admitted to the Christie Hospital on 5.8.52. The 
general condition of the patient was quite good, the spleen was 
enlarged to the umbilicus, the liver was impalpable, there was 
no lymphadenopathy, and no haemorrhagie signs or pyrexia. The 
Hb was 56$, platelets were plentiful, and the WBC was 300,000
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per c.mm., 3.0^ "being myeloblasts, and 44J6 immature myeloid
cells of all types. On 6,8.52 an initial dose of 10.0 me. of 
32P was given, followed by 3.0 mcs. on 26.8.52 and 5.75 mcs.
on 10.9.52. The WBC fell erratically, with no regular
32exponential relationship to P dosage, reaching its lowest
level of 7,800 per c.mm. by 17.9.52. The spleen was impalpable
by 6.10,52 and the Hb rose to a maximum of 105^ by 14.1.53.
The general condition improved remarkably and he gained 14 kilos
in weight. By April 1953, however, rapid deterioration had
occurred. The spleen was again down to the umbilicus, and was
tender and painful. The Hb fell to 56̂ 6 and the WBC rose to
32348.000 per c.mm. On 12.5.53 a dose of 10.0 mcs. of P was
given, and 3.0 mcs. on 26.5.53. Again there was an irregular
and fluctuating fall in the WBC when plotted against integral
32body dosage from the P • Nevertheless the WBC fell to
11.000 by 5.6.53, and the Hb rose to 88^ by 30.9.53. Though
the spleen had resolved behind the costal margin, the WBC by
the latter date had risen rapidly to 270,000 per c.mm. On
3216.10.53 a single dose of 10.0 mcs. of P was given and yet 
a third time there was no exponential fall in the WBC, though 
it did fall to 8,800 by 2.11,53 and the Hb rose to from 68JG 
on 12.10.53 to a maximum of 94j£ on 29.1.54. The WBC on the 
latter date was already up to 112,000 and although the general
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health had improved during this fourth remission further 
treatment was called for in March 1954. Splenic x-ray 
therapy hegan on 3.3.54 and continued for four weeks. The 
WBC fell to a minimum of 6,000 by 6.4.54, the spleen again 
became impalpable, the general condition improved remarkably, 
and the Hb rose from 58$ to 84$. A sixth course of treatment, 
again by splenic irradiation began on 18.11.54, a seventh 
course a year later on 22.11.55, and his most recent treatment 
on 26.2.57. During 1955 the patient was found to have 
diabetes mellitus, easily controlled by diet.
This case clearly indicates that worthwhile, if short-
32lived remissions can be produced by P even when the relation­
ship between the falling WBC and integral body dosage is not 
an exponential one. The reason for this is not apparent.
Case E 3
Mrs. M.E.T., aged 57, weight 45 kilos, felt off colour 
for many months, then developed persistent diarrhoea, and 
consulted her doctor in September 1952. Investigation at 
Wigan Infirmary disclosed chronic myeloid leukaemia, and after 
transfusion with packed cells she was transferred to the Christie 
Hospital on 7.10,52. The patient was then pale and ill-looking, 
with considerable enlargement of both the spleen and the liver, 
lymph nodes were not palpable and there were no haemorrhagie
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signs or pyrexia. The Hb was 32$, platelets were plentiful,
and the WBC was 146,000 per c.mm., 15$ being blasts and 30$
total primitive white cells. This patient was considered a
rather sub-acute case of myeloid leukaemia, having regard to
her relatively short illness, low haemoglobin level and
significant number of myeloblasts. However, a dose of 7.95 
32mcs. of P was given on 14.10.52, followed by 3.0 mcs, on
30.10.52. The WBC did not fall exponentially, though it did
fall to a minimum of 7,100 by 25.11.52. During the first 
week of November 1952 the patient complained of pain in the 
chest and dyspnoea, and had pneumonic signs which cleared up 
on antibiotics. This pneumonic episode may have influenced 
the relationship of the WBC to integral dosage, possibly by 
producing a mixed population of white cells - those of 
"leukaemic origin” and those of ”inflammatory origin” - with 
perhaps different life spans. The spleen showed significant 
but incomplete resolution and the Hb rose from 32 to 50$ before 
transfusion on 11.12.52. The patient’s general health did 
not improve, however, and she died in another hospital on
2.1.53. Autopsy was not carried out.
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Cas e E 4
Mr. R.E.D., aged 28, weight 68 kilos, developed
epigastric pain, headaches and giddiness during August 1952.
Investigation in Wrexham Infirmary revealed myeloid leukaemia
and he was referred to the Christie Hospital on 8.10.52.
He was pale and ill, had generalised small lymph nodes, the
Spleen was enlarged nearly to the umbilicus, the liver was not
palpable, and there were no haemorrhagie features or pyrexia.
The Hb was 46$, platelets were reduced, and the WBC was
74,000 per c.mm., 1.4$ being myeloblasts, and 30$ total primitive
white cells. The rapid onset of the illness and the gross
anaemia suggested a somewhat subacute rather than a truly chronic
32myeloid leukaemia, but P therapy was instituted on 24.10.52
with a doSe of 10.0 mcs. This was followed by 5.0 mcs. on
18.11.52, but the WBC fell in an irregular non-exponential 
manner, and the Hb showed no response. A small transfusion of 
2 pints of whole blood was given on 28.11.52 with significant 
improvement in the general condition. The spleen became 
impalpable on 9.12.52, there were no haemorrhagie signs or 
pyrexia, and on 10.12.52 the Hb was 68$. By February, 1953, 
the Hb had collapsed to 34$, the WBC was 10,800 and the general 
condition poor. In spite of transfusions, cytamen, and other 
supportive measures in another hospital, the patient developed
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cerebral symptoms and died on 5.3.53. Antopsy was not 
permitted.
Case E 5
Miss M.J., aged 62, weight 42 kilos, found lumps in
her neck about 1950. In 1952 she stopped working because of
anginal pain and in January 1954, had an attack of coronary
thrombosis. Investigation at the Manchester Jewish Hospital
disclosed chronic lymphatic leukaemia. On admission to the
Christie Hospital on 24.5.54 the patient’s general condition
was fair, there was generalised small lymphadenopathy, the
spleen was just palpable, the liver impalpable, there were no
haemorrhagie signs, but the patient looked dehydrated. The
latter improved rapidly in hospital and on 1.6.54 a dose of 
326.0 mcs. of P was given. The WBC showed no response whatever 
and remained between 320,000 and 370,000 per c.mm. There was 
some basal congestion at this time and the patient had coryza 
and some cough. This may have influenced her WBC, though I 
doubt this. The Hb had also remained stationary at 60$. On
29.6.54 splenic x-ray therapy was started and the WBC fell, but 
very slowly, to 20,000 on 5.8.54, and then rapidly to 3,200 by
13.9.54. At this latter date the platelets had also dropped 
to 70,000 per c.mm. and there were several large ecchymoses.
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These disappeared, the general condition improved remarkably, 
the spleen became impalpable in September 1954, the Hb was 
86$ by November 1954, and apart from recurrent cardiac 
difficulties this remission lasted until August 1955. The 
leukaemic infiltration of the lungs raised the question of 
tuberculosis during 1955. This was excluded, however, by 
several negative cultures and guinea pig inoculation. The 
WBC rose to 84,000 and the Hb fell to 63$ with general 
malaise. Splenic irradiation began again on 18.8.55, ending 
on 20.9.55. There was no real improvement, however, and the 
patient died with terminal haemorrhages into the skin, on
3.10.55.
Case E 6
Mr. H.B., aged 53, developed a submandibular swelling 
in 1947 but was reassured by his family doctor and the lump 
disappeared during an attack of pneumonia. In 1948 more 
glands appeared in the neck and he was investigated at 
Manchester Royal Infirmary early in 1949. On admission to the 
Christie Hospital on 23.9.49 the general condition was fair, 
there was florid enlargement of lymph nodes in all areas, 
including the hila and mediastinum. The spleen was enlarged
5.0 cms. below the costal margin, the liver was not palpable, 
but there were palpable mesenteric nodes in the abdomen.
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There were no haemorrhagie signs or pyrexia. The Hb was 76$,
platelets were reduced, and the WBC was 149,000 with many
32smear cells. 8.0 mcs. of P were given on 27.9.49, followed
by 3.0 mcs. on 2.11.49. The WBC by the latter date had already
fallen to 11,000 per c.mm., but not in an exponential fashion.
The Hb had not improved, and though the spleen was a little
smaller, the large nodes were still troublesome. Accordingly,
single exposures of 500r were given to both sides of the neck
and to both groins and axillae between 2.11.49 and 7.11.49.
By January 1950, the spleen was no longer palpable, the nodes
were somewhat smaller but still enlarged, the Hb was 78$ and
the WBC 7,900 per c.mm. By September 1950, further treatment
was necessary because of clinical deterioration and a WBC up
to 2.10',000 and Hb down to 68$. On 12.9.50 a dose of 5.0 mcs.
32of P was given but the whole blood picture collapsed and 
sternal marrow on 3.10.50 showed little sign of any haemo- 
poietic activity. The patient died on 18.10.50.
Case E 7
Mr. W.R., aged 54, complained of lassitude, 
occasional vomiting, anorexia and loss of weight for 12 months. 
He had lumps on both sides of the neck for 4 weeks before he 
finally consulted his doctor, was referred to the Manchester
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Royal Infirmary, and chronic lymphatic leukaemia was diagnosed 
in April 1952. He was admitted to the Christie Hospital on
1.5.52 when his general health was only fair, he had large
florid nodes in all areas, the spleen and liver were just
palpable, there were no petechiae or other haemorrhagie signs,
and no pyrexia. The Hb was 56$, platelets were plentiful,
and the WBC was 265,000 per c.mm. with a substantial number of
32smear cells. On 13.5.52 a dose of 9.5 mcs. of P was given, 
and the WBC fell rapidly, but not exponentially, to a low level 
of 5,000 per c.mm. by 9.6.52. Though the lymph nodes also 
regressed significantly the Hb showed no improvement and 
remained at the 50 - 55$ level during June and July, 1952.
The patient was re-admitted to hospital on 11.8.52 with a Hb 
of only 20$ and in spite of blood transfusion she died on
4.11.52. Autopsy was not permitted.
Case E 8
Mr. J.T.M., aged 64, (a French polisher - of 
aetiological significance?) 'collapsed1 in June, 1952, and 
was admitted to Blackburn Infirmary where lymphatic leukaemia 
was diagnosed. On admission to the Christie Hospital on
30.7.52 the Hb was only 34$, the WBC 155,000 with lymphoblasts 
and smear cells, the spleen just palpable, enlarged nodes in 
all areas, but no harmorrhagic signs. He was regarded as a
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32sub-acute case of leukaemia and before P was given he was
transfused, with difficulty. On 5.8.52 a dose of 9.2 mcs. of 
32P was given and the WBC fell irregularly and rapidly to 
3,500 per c.mm. on 28.8.52. The Hb also fell rapidly to 18^ 
and did not respond to transfusion. The patient died on
14.9.52. In retrospect, this case should not, of course, 
have been treated by a radiation method.
Autopsy by Dr. J.A. Shrigley showed considerable 
lymphocytic infiltration of the bone marrow as well as the 
kidneys, lungs and lymph nodes. Otherwise no special features 
were noted.
Ca s e E 9
Mr. F.B., aged 37, felt unusually tired in October, 
1951, and during the autumn of 1952 developed dyspnoea on 
effort. He was treated by his doctor, unsuccessfully, as 
pernicious anaemia, but was finally investigated in Blackpool 
Infirmary in November, 1952, when lymphatic leukaemia was 
discovered. On admission to the Christie Hospital on 9.12.52 
his Hb was 82^ but he had had 10 pints of blood transfused 
during the previous few weeks. The WBC was only 35,500 per 
c.mm. with many primitive white cells. The spleen and liver 
were just palpable and there was a generalised small
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lymphadenopathy. Because of the satisfactory clinical and
haematological condition active treatment was withheld, hut the
whole picture deteriorated rapidly early in January, 1953.
The patient had epistaxis, the WBC rose to 60,000 and the Hb
fell to 40$ - all suggesting a subacute leukaemia. The patient
32was transfused again and on 15.1.53 a dose of 11.5 mcs. of P 
was given. The blood picture became aplastic, with the 
haemoglobin at about 20$, the WBC reaching 750 per c.mm. on
11.2.53. Packed-cell transfusions improved the patient 
enormously, but though he was kept going with repeated trans­
fusions, he died with marrow failure on 23.4.53. This again 
was a patient for whom it would have been better to avoid 
radiation therapy, though probably any anti-mitotic agent would 
have been equally ineffective.
Case E 10
Mr. C.W.F., aged 65, developed sudden dyspnoea in 
August, 1953, after a short period of lassitude. He was 
admitted urgently to Burnley Hospital and acute lymphatic 
leukaemia was diagnosed. On admission to the Christie Hospital 
on 20.8.53 his general health was not good, there were general­
ised small lymph nodes, the spleen was just palpable but
the liver was not so, the Hb was only 34$, and the WBC 130,000
32with many lymphoblasts. 9.3 mcs. of P were given on 3.9.53,
- 227 -
followed by 3.0 mcs. on 18.9.53 and 4.0 mcs. on 25.9.53. The 
WBC fell irregularly to a low level of 8,300 by 2.10,53, but 
the Hb also fell in spite of transfusions. The patient became 
pyrexial, developed purpura, gross anaemia, thrombocytopenia, 
and died on 5.10.53.
Autopsy, by Dr. Helen Russell, confirmed lymphatic
leukaemia, with much haemorrhage into many of the organs,
including the brain. The marrow of the sternum and lumbar
vertebrae was again a curious, purple-pink colour. Microscopy
Showed typical lymphatic leukaemic marrow with suppression of
the red and granular series. There was also, throughout many
of the organs examined, a notable capillary dilatation which
32Dr. Russell believes to be an effect of P . Incidentally, 
the patient had a congenital horse-shoe kidney.
Case E 11
Mr. R.M.P., aged 67, noted increasing lethargy for 
three years but did not respond to symptomatic treatment by 
his doctor. Investigation in Bury Hospital finally disclosed 
lymphatic leukaemia in October 1954, and on admission to the 
Christie Hospital on 19.11.54 the general condition was quite 
good. There was generalised lymphadenopathy, the spleen was 
moderately enlarged, the liver was impalpable, there were no 
haemorrhagie signs, and no pyrexia. The Hb was 69$, platelets
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were scarce, and the WBC was 263,000 per c.mm. On 23,11.54 a
32single dose of 6.0 mcs. of P was given. The WBC fell, not 
exponentially, and never below 70,000 because the Hb, having 
remained static, suddenly collapsed to 30$ on 13.12.54 and the 
patient died on 16.12.54.
Autopsy, by Dr. Helen Russell, disclosed an unusually 
extensive lymphocytic infiltration of all the organs examined, 
including even the tongue. Dr. Russell again commented on 
the unusual red colour of the bone marrow to the naked eye, 
and this was associated microscopically with capillary 
congestion. Groups of nucleated red cells were also seen in.
many areas. Again comment was made of the oedematous
capillary congestion of the lower lobes of the lung, and the 
interStial oedema of the liver.
Case E 12
Mrs. L.C.A., aged 50, weight 63 kilos, developed 
tonsillitis in April 1948, and noted swollen lymph nodes in the 
neck. The nodes persisted and biopsy in Ancoats Hospital, 
Manchester, on 19.1.49 was reported as lymphosarcoma. However, 
on admission to the Christie Hospital on 2.2.49 it was found 
that, though the total WBC was only 11,400 per c.mm., 9,500 of 
these were lymphocytes. The sternal and iliac marrow also 
showed a considerable preponderance of lymphocytes. The
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spleen and liver were not palpable. Lymph nodes were 
enlarged in all areas, bnt there were no haemorrhagie 
features, the Hb was 80$ and platelets were plentiful.
Single x-ray exposures of 400r each were given to the 
nodes in the neck, axillae and groins, but the nodes showed 
little resolution. The patient remained well until 
February 1951, when the liver was enlarged 4 cms. and the 
spleen 6 cms. below the costal margin. The WBC on 19.2.51 
was 46,000 and 42,000 of these were lymphocytes. The Hb 
was still 84$ and no anti-leukaemic treatment was given.
In May, 1951, the patient developed some proptosis and diplopia 
on lateral deviation of the eyes. I 131 tracer studies 
excluded thyrotoxicosis and a small dose of 400r to the right 
orbit on 31.5.51 was followed by a ten days' course of x-ray 
therapy to substantial lymph node masses in the upper abdomen 
during September, 1951. The WBC at that time was 102,000, 
with a Hb level of 80$. This settled to a WBC of 4,800 by 
29.10.51, the Hb remaining static. The patient remained well 
but, by September 1953, the WBC had risen to 340,000 per c.mm.
and the Hb had fallen to 40$. The spleen was not palpable.
32On 9.9.53 a dose of 8.0 mcs. of P was given followed by 5.0 
mcs. on 24.9.53. The WBC fell, but not exponentially, to a
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low level of 6,000 per c.mm. by 5.10.53, but the Hb had also 
fallen rapidly to 26$. In spite of repeated transfusions the 
general condition deteriorated and the Hb did not rise above 45$. 
By April, 1954, the patient was intolerant to closely cross- 
matched blood. She left hospital on 29.4.54 with a Hb of 14$ 
and was considered beyond further help. However, when seen 
again on 13.7.54 the Hb was 80$ - a remarkable improvement, 
clinically and haematologically, which seemed to be attributable 
to raw liver which the patient had been eating in large 
quantities. A spontaneous cessation of auto-haemolysis is 
another possible explanation. Unfortunately this improvement 
did not last, in spite of continued liver therapy, massive 
doses of Vitamin B 12 and cortisone. She died on 12.12.54 
but autopsy was not permitted.
GENERAL CONCLUSIONS
1. In spite of more than a century of continuous study, 
the initiating, the sustaining, and the compensatory 
mechanisms at work in leukaemia are still not understood.
A vast literature daily becomes more vast, and increasingly 
complex and subtle methodologies are being brought to bear on 
this many-facetted problem. A glance at one of the most 
recent publications on leukaemia (Rebuck, Bethell and Monto, 
1957) underlines this point by describing, e.g. new approaches 
to the study of cell-structure by electron and phase-contrast 
microscopy; antigenic, environmental, and genetic studies; 
new leukopheretic techniques in the study of leukopoiesis; 
and ever more detailed biochemical probings into the intra­
cellular metabolism of leukaemic and normal cells. All of 
this scientific subtlety, however, does not diminish the need 
for more bed-side observation and thought by the clinician.
2. With prevention of leukaemia in mind, the author is
of the opinion that further aetiological studies are of urgent 
importance. As with other forms of malignant disease, new 
carcinogenic agents are constantly being discovered, and one 
of the great challenges of our time lies in the knowledge 
that many causative agents remain only to be unmasked.
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3. So far as the management of the leukaemias is concerned, 
therapeutic eclecticism would seem to he the ideal. There is 
an obvious advantage for the patient to he managed in a hospital 
ox institute where the entire armamentarium is available, the 
appropriate weapon being chosen according to individual 
requirements. An unforeseen hut natural result of the intro­
duction of chemotherapy has been that physicians throughout
the country are now eager to treat their leukaemic patients by 
themselves. With a relatively rare disease, this means that 
no one worker or group of workers is now able to observe these 
patients in large numbers, and the opportunity to study and 
assess newer drugs is becoming increasingly limited. This is 
unfortunate, but perhaps organized therapeutic trials will 
overcome this difficulty.
324. The author's experience with P therapy for chronic
leukaemia has demonstrated that remissions can be induced 
which are in every way comparable with those achieved with 
x-ray or chemo-therapy. The concept of the mini mum effective 
dose for each individual patient is a new and practical 
approach to leukaemia therapy, and its theoretical advantages 
are also significant. This is now the routine treatment for 
suitable cases at the Christie Hospital in Manchester.
\
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5. The reason for individual differences in the radio- 
sensitivity of leukaemie white cells is as elusive as the 
rest of the basic problems of leukaemia. Experiments with 
tissue cultures in vitro can demonstrate changes in radio- 
sensitivity dependent e. g. on the oxygen saturation of the 
culture medium, and many other sensitising and protective 
chemical agents are known. But this knowledge does not appear 
to explain the in vivo differences in sensitivity in humans.
6. What of the future? Bierman (1957) has rightly re­
emphasised the error of focussing too much attention on the 
leukocytes in leukaemia, and he has called for a broader 
outlook on the disease than heretofore. Nevertheless, the
exponential relationship between the falling white cell count
32and the integral dosage from P provides a unique opportunity,
without detriment to the patient, to study and possibly to
measure the effects of sensitising, protective, and adjuvant
drugs. The author is particularly interested in the
possibility also of measuring the life-spans of leukaemia white
cells, and relating them, if possible, to the Half Value Dose 
32of P . Unfortunately, as, remarked above, untreated leukaemia 
is being seen less frequently at this centre.
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It seems to be an innate human urge 11 to reduce the 
diverse to the identical1', to seek a unifying comprehensive 
hypothesis, but the known facts about leukaemia still defy 
such a manipulation. At the moment we are like Plato's 
philosophers in their subterranean cave, aware only of the 
shadows, unable to explain or even to relate them, but 
conscious that by a "toilsome ascent up the steep slope" we 




qoThis thesis is concerned with the response to P 
of chronic leukaemia in humans.
Section I outlines the historical hasis of classification of 
the leukaemias, preference being given for a simple working 
system. The common clinical syndromes are described, followed 
by a brief account of the main clinical pathological features. 
Aetiology is also considered here, including incidence, the 
relationship of leukaemia to other diseases, and the 
aetiological importance of various external factors, chemical 
and physical.
Section II is concerned with the principles of management of 
leukaemic patients, and outlines the evolution of modern 
therapeutic practice.
Section III discusses the pharmacology of radioactive phosphorus, 
the anti-leukaemic agent with which this thesis is primarily 
concerned. The biochemical and the physical features are 
described, its absorption, distribution, and excretion, and 
finally the biological effects which follow its administration.
Section IV describes the author’s experience in treating 60
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32patients with P at the Christie Hospital and Holt Radium 
Institute in Manchester, England. The evolution of a dosage 
system is discussed, and it is shown that in more than 9QJ6 of 
selected cases of chronic leukaemia an exponential relation­
ship exists between the falling white cell count and the
32Integral Body Dosage from P . The logarithms of the WBC
plotted against the cumulative IBD (most conveniently
expressed in millicuries-destroyed) gives a straight line
graph. Such a straight line can he extrapolated at an early
stage in treatment and permits a prediction to he made of the
Minimum Effective Dose for each patient. This method of
treatment has provided satisfactory remissions both clinically
and haematologically.
This exponential relationship has held in all hut 12
of the 60 treated patients, hut in 7 of these there were
obvious reasons for this non-exponential behaviour.
Following recurrence of symptoms, 16 patients have
32received a second course of P , seven of these have had a 
third, and 1 a fourth course. The pattern of response has
been remarkably similar to the first, but with a curious 
tendency to increasing sensitivity.
Section Y describes one of several possible applications of
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the exponential fall in the WBC - a quantitative study of 
white cell sensitivity. The HVD is a quantitative expression 
of leukopoietic sensitivity for each individual. Twenty seven 
caSes of chronic myeloid and twenty one of chronic lymphatic 
leukaemia were tabulated in order of their white cell sensi­
tivity, and various haematological and clinical data were 
similarly tabulated, but with none of these has any clear 
correlation been demonstrated.
Section VI provides summaries of the case histories of the
32sixty patients treated by P .
It is concluded that in addition to and in spite of
much detailed and complex research, there is need for more
clinical study of leukaemia, and especially for aetiological
investigation. Management of patients is advocated in centres
possessing all modern therapeutic techniques, and regret is
expressed at the dilution of experience that has followed the
introduction of chemotherapy. Therapeutic trials might be
organised on a national scale to offset this loss of clinical
32material. The prediction method of P dosimetry is advocated 
when this isotopic treatment is appropriate. Much more work 
is seen to be necessary if even small questions are to be 
answered in this vast problem.
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